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Summary 
Breast cancer is the leading cause of cancer amongst women in the westernized world. It is 
a heterogeneous disease ranging from premalignant hyperproliferation to invasive and 
metastatic carcinomas. Disease progression is poorly understood but is likely due to the 
accumulation of genetic alterations leading to widespread changes in gene expression, 
ultimately affecting cell biology and often increasing growth capacity and survival 
advantage. Consistent with this, recent studies have shown that different breast tumour 
subclasses display distinct gene expression profiles. In addition to genetic alterations, there 
is increasing evidence for gross epigenetic alterations in tumour cells, both at the levels of 
DNA methylation and histone marks.  
Epigenetic alterations target and modulate several important genes in breast cancer, 
contributing, not only for its initiation, but also for its development and response to 
therapies. One of the key genes in breast biology and cancer, which expression and 
molecular function is strongly regulated by epigenetic modifications, is the ligand-activated 
transcription factor oestrogen-receptor  (ER), the primary mediator of the ovarian-
produced steroid hormone oestrogen action in breast mammary cells. Breast cancer 
development and progression is, in fact, closely associated with the presence or absence of 
ER being an important prognostic and predictor indicator in this disease. Consequently, 
the leading drugs used for endocrine therapy of breast cancer, namely anti-oestrogens such 
as tamoxifen or fulvestrant, block ER activity. Despite the efficacy of these target agents 
during short/medium time regimens, the use of endocrine therapy is limited by the onset of 
drug resistance, normally mediated by epigenetic alterations, in which most patients, who 
initially respond favourable to endocrine therapy, eventually recur.  
In the present thesis we present an immunohistochemical approach involving two ER-
signalling pathways-related transcription factors, FOXA1 and GATA-3, in order to assess 
whether their expression could be useful as prognostic markers in breast cancer patients. 
We demonstrated that patients harbouring FOXA1-positive tumours show a better disease-
free survival in a 5 years follow-up time and that FOXA1 expression associates with good 
prognosis clinicopathological features. More importantly, and for the first time, we 
established that this forkhead-box transcription factor has a power for recurrence risk 
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stratification among the poor prognostic ER-negative breast cancer patients, 
demonstrating the clinical importance of this biomarker in breast cancer prognosis. We still 
demonstrated that GATA-3 does not constitute a strong predictor for breast cancer disease-
free survival nor a good prognostic marker, but was shown to be a robust luminal 
differentiation marker. Taken together, the expression assessment of FOXA1 and GATA-3 
can provide important clinical information, not only regarding the favourable prognostic 
outcome, but can also constitute an important tool to define and assess the luminal A 
subtype in breast cancer and, eventually, response to endocrine therapy.  
ER-negative breast cancers are resistant to endocrine therapies and have a worse 
prognosis than ER-positive breast cancers. DNA methylation and chromatin remodelling 
are two epigenetic mechanisms that have been linked with a generation of an aggressive 
ER-negative phenotype in breast cancer. Endocrine therapies have been reported to 
interfere with the expression of ER-repressed genes, ultimately leading to the ER-
negative phenotype of breast cancer, but most importantly, with the induction of breast 
cancer cell aggressiveness and invasiveness in specific cell contexts. We have been focussed 
on studying CDH3/P-cadherin gene expression, as an ER-repressed gene in breast cancer; 
enlightening a mechanism for its regulation in a breast cancer cell model. The mechanism by 
which ER-signalling inhibition led to P-cadherin overexpression was completely unknown 
until now. Herein, we described a chromatin remodelling (H3K4me2) at CDH3 gene 
regulatory region which, being induced by ICI 182,780 treatment, can modulate CDH3 
promoter activity and the expression of a pro-invasive protein in breast cancer, as P-
cadherin. Moreover, this study allowed the identification of a new transcription factor, 
C/EBP that is able to regulate CDH3 activity in breast cancer cell lines and which 
expression associates with P-cadherin in breast cancer patient samples.  
Overall, the work summarized in this thesis discusses molecular characteristics that may 
influence the risk for ER-negative breast cancer patients to recur, also suggesting two new 
markers which, in addition to ER assessment, might be useful for predict breast cancer 
outcome in patients non-responsive to endocrine therapies. Moreover, we demonstrated a 
chromatin remodelling event provoked by the pure anti-oestrogen ICI 182,780, which is able 
to increase CDH3 promoter activity and therefore, the expression of the pro-invasive protein 
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P-cadherin in breast cancer cells, contributing to the elucidation of how breast cancer cells 
may acquire aggressive properties after loss of oestrogen signalling 
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Resumo 
O cancro da mama constitui a neoplasia mais frequente entre as mulheres dos países 
ocidentalizados. A elevada heterogeneidade da doença permite variações fenotípicas que 
vão desde a hiper-proliferação pré-maligna ao carcinoma invasivo e metastático. Apesar das 
vias de progressão da doença ainda não se encontrarem totalmente caracterizadas, a causa 
mais comum e provável será a acumulação de alterações genéticas, as quais, produzem 
alterações na expressão de vários genes e afectam a biologia da célula, conferindo 
capacidades de crescimento e de sobrevivência. De facto, tem-se verificado, em estudos 
recentes, que diferentes sub-grupos de cancro da mama exibem perfis distintos de 
expressão genética. Associadas a estas alterações genéticas, as modificações epigenéticas 
ocorridas nas células tumorais, essencialmente ao nível do padrão de metilação do ADN e 
da acetilação/metilação da cromatina, têm sido alvo de crescente interesse na compreensão 
do processo da carcinogénese. 
As alterações epigenéticas controlam uma série de genes importantes no cancro da mama, 
contribuindo não só para a sua iniciação, mas também para o seu desenvolvimento e 
resposta terapêutica. Um dos genes centrais na biologia da glândula mamária e na sua 
carcinogénese é o receptor de estrogénio (RE), um factor de transcrição que constitui a 
principal ferramenta que permite a acção da hormona esteróide – estrogénio, sobre as 
células mamárias. O desenvolvimento e progressão do cancro da mama estão por isso 
fortemente associados à presença ou ausência de expressão do RE, constituindo este, um 
importante factor de prognóstico e preditivo da resposta terapêutica endócrina nesta 
neoplasia. Consequentemente, as principais drogas usadas para terapia endócrina de cancro 
da mama, nomeadamente as anti-estrogénicas, como o Tamoxifeno e o Fulvestrant, visam 
bloquear a actividade do RE. Não obstante a eficácia da utilização destes fármacos, o uso 
da terapia endócrina tem vindo a demonstrar algumas limitações, uma vez que a maioria 
dos doentes que inicialmente respondem a esta terapia, vêem tardiamente a desenvolver 
resistência endócrina, eventualmente com recidiva, provocada normalmente por alterações 
epigenéticas não específicas. 
 Num contexto de genes associados à via de sinalização mediada pelo RE, estudou-se por 
imunohistoquímica a expressão de dois factores de transcrição, FOXA1 e GATA-3, no sentido 
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de avaliar a sua importância como factores de prognóstico em pacientes com cancro da 
mama. Demonstrou-se que pacientes com tumores positivos para FOXA1 apresentam uma 
melhor tempo-livre de doença num período de estudo de 5 anos e que a expressão de 
FOXA1 está associada a perfis clínico-patológicos de bom prognóstico. Demonstrou-se ainda 
que a expressão de FOXA1, num sub-grupo de tumores RE-negativos, permite a 
estratificação do risco de recorrência durante o mesmo período de estudo, realçando assim 
a importância clínica deste factor de transcrição no prognóstico do cancro da mama. 
Relativamente à expressão da proteína GATA-3, observou-se que este factor de transcrição 
não constitui nem um factor de prognóstico robusto, nem um indicador de melhor tempo-
livre de doença, revelando, no entanto, ser um importante e consistente marcador de 
diferenciação luminal. Assim, a avaliação da expressão de FOXA1 e GATA-3 poderá ser útil, 
não só sob o ponto de vista da prática clínico-patológica, no sentido de fornecer uma 
importante informação relativamente ao prognóstico da doente, mas também como uma 
ferramenta essencial para definir o subtipo luminal A em cancro da mama.  
Os tumores mamários RE-negativos são resistentes a terapias endócrinas e apresentam 
pior prognóstico relativamente a tumores RE-positivos. A metilação do ADN e a 
remodelação da cromatina são dois mecanismos epigenéticos que têm sido relacionados 
com a aquisição de um fenótipo mais agressivo de cancro da mama. Tem sido descrito que 
as terapias endócrinas podem modelar a expressão de genes reprimidos pelo RE, 
conduzindo o tumor à aquisição progressiva de um fenótipo RE-negativo, com 
consequente indução de invasão celular em ensaios in vitro. O gene CDH3/P-caderina é, no 
modelo de cancro da mama, um gene reprimido pelo RE, embora o mecanismo pelo qual a 
inibição da sinalização mediada pelo REe resultantesobre-expressão de P-caderina, fosse 
ainda desconhecido. Demonstrou-se assim que o tratamento de linhas celulares de cancro 
da mama RE-positivas com o antagonista de RE, ICI 182,780, leva a uma remodelação da 
cromatina ao nível do promotor do gene CDH3, através de uma proeminente marca 
activadora H3K4me2, a qual se sugere ser causal da indução da expressão da proteína pró-
invasiva P-caderina. Este estudo permitiu ainda identificar um novo factor de transcrição 
com capacidade de regular a actividade do promotor CDH3 em linhas celulares, e cuja 
expressão se associa com a P-caderina em tumores de pacientes com cancro da mama. 
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Em conclusão, o trabalho constante desta tese explora características moleculares que 
podem influenciar o risco de recidiva de doentes com cancro da mama hormono-negativos 
e onde a avaliação de dois novos marcadores, conjuntamente com a determinação da 
expressão de RE, pode ser importante na avaliação do prognóstico de doentes com 
neoplasia mamária não-responsiva às terapias endócrinas. Demonstrou-se ainda que 
determinadas alterações da cromatina, induzidas pelo ICI 182,780, são responsáveis pela 
activação do promotor CDH3 e consequente expressão de P-caderina em células de cancro 
da mama. Este estudo permite assim elucidar um mecanismo pelo qual células de cancro da 
mama adquirem propriedades agressivas após perda de sinalização mediada pelo RE. 
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Objectives and Thesis Layout 
 
The role of transcriptions factors, as key entities for the most fundamental cell 
functions, has becoming studied as important tools to be used in clinical pathology. 
Modulation of transcription factor activity, through genetic or epigenetic processes, 
constitutes the tip of the spear of the cellular gene expression and cellular biology. In breast 
cancer, where those genetic and epigenetic mechanisms are someway disrupted, 
transcription factor expression naturally represents important markers of tumour behaviour 
with pathological value. Moreover, they drive crucial human oncogenic pathways, being 
used as targets for therapeutic interference in cancer development, progression and in 
treatment-response prediction.  
The general aim of the work reported in this thesis is to investigate and discuss how 
molecular (genetic or epigenetic) determinants may affect breast cancer risk and patient 
outcome, with a very special emphasis in poor prognosis ER-negative tumours, as well as, 
in ER-positive cell lines where ER-signalling was abrogated by anti-oestrogens treatment. 
In doing so, this thesis is organized in individual chapters, each aiming to fulfil a specific goal 
in the quest to accomplish the general objective of this dissertation, as presented below. 
Chapter 1 presents a general introduction that reviews the most current knowledge 
on breast cancer, aiming to introduce the reader for the research topics presented 
throughout the following chapters. It briefly summarizes the classification, epidemiology, 
and treatment of breast carcinomas, while devoting particular attention to the main genetic 
and epigenetic mechanisms which regulate gene expression in breast cancer. Moreover, a 
robust explanatory section concerning the role of P-cadherin in mammary tumours is 
stressed, since the regulation of this gene constitutes a major object of our research. 
Chapter 2 focus on the relevance of the expression of FOXA1 and GATA-3 in breast 
cancer and their special prognostic significance in hormone receptor-negative tumours. 
Herein, we explored the usefulness of assessing the expression of these two transcription 
factors to stratify subsets of patients that can have better outcome, among the ER-
negative/poor prognosis breast cancer group.  
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Chapter 3 encloses a study which major aim was to explore the molecular 
mechanism linking the ER-signalling pathway and P-cadherin-regulated expression in 
breast cancer cells, as previously shown in the past by our group. The mechanism by which 
ER-signalling inhibition led to P-cadherin overexpression was completely unknown until 
now. This chapter shows how chromatin remodelling of CDH3 gene promoter by anti-
oestrogens can modulate the expression of a pro-invasive protein in breast cancer, as P-
cadherin. This study still permitted to identify, for the first time, a new transcription factor – 
C/EBP that is able to regulate P-cadherin expression. 
Chapter 4 attempts to bring together the findings from Chapters 2 and 3, and 
thoroughly discuss them in the milieu of other relevant published data. Brief suggestions for 
future directions to complement our research are presented, together with a few general 
concluding remarks.  
Finally, an appendix section was included, enclosing additional studies performed 
during the PhD time course. 
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1. GENERAL INTRODUCTION 
 
1.1 – BREAST CANCER EPIDEMIOLOGY AND RISK FACTORS 
 
At the newborn twenty-first century, cancer remains the major public health 
problem worldwide, accounting approximately for one in four deaths in developed countries 
(1-2). In 2008, in Europe, excluding non-melanoma skin cancers, there were an estimated 
3.2 million incident cases of cancer diagnosed, with approximately 1.7 million cancer deaths 
(3-4). Breast cancer is by far the most common form of cancer diagnosed in women in both 
developing and developed countries of the world and it is the cause of death in 
approximately 20-30% of all females who die from cancer in these countries. In fact, one in 
ten of all new cancers diagnosed worldwide each year is a cancer of the female breast (5-6). 
Today, breast cancer affects nearly 430.000 female, being ranked the leading cause of 
cancer deaths (129.000 in 2008) in European women (3-4) (Figure 1). According with the 
data from the Portuguese League Against Cancer (www.ligacontracancro.pt), breast cancer 
is also the first cause of death by cancer in Portuguese women. Although the estimates age-
standardised incident rates (103.5/100.000) are above the European standard 
(94.3/100.000), the Portuguese breast cancer mortality rate (21/100.000) is slightly lower 
than the European ratio (26/100.000) (3).  
 
Figure 1. Estimated incidence of breast cancer throughout Europe in 1990 and in 2006. Without exceptions, breast cancer 
incidence has increased in all European countries in the time interval studied (16 years). However, breast cancer mortality 
rates in Europe have fallen dramatically since 1989. [Adapted from Cancer Research UK; Globocan 2002; Black et al., 1997 
(7); Ferlay J et al., 2007 (3)]. 
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In Portugal, one in each ten Portuguese women develops this disease during its life, 
with about 4.500 new cases/year and with 1.500 deaths/year, making breast cancer an 
important health problem for the Portuguese population. Unfortunately, while favourable 
trends in the reduction of breast cancer mortality has been established for most of the 
countries in European Union, Portugal, Spain and Greece represent a notable exception, 
with an increased risk of dying from breast cancer of 11%, 15% and 7%, respectively (8).  
Breast cancer presents a multifactor etiology, leading to a variety of genetic changes 
that ultimately result in variable biological behaviours among different patients (9). As it 
happens for most of the human malignancies, where the interaction between 
environmental factors and genetic profiles dictates the susceptibility for the initiation of the 
disease, remarkable epidemiologic, clinical and genetic studies have been made in order to 
define social and biological traits, which can improve the identification of breast cancer risk 
groups among women (10-11) . There are marked differences in the incidence of breast 
cancer in different places, the predominant impression being that the disease is more 
common among Caucasians living in the colder climates and more highly industrialized 
countries of the Western hemisphere (6). The observed differences in breast cancer 
incidence rates among countries may reflect demographic variations in modifiable risk 
factors (9, 12). In fact, the Western diet is associated with both earlier age at menarche and 
post-menopausal obesity, but other factors such as the sedentary lifestyle and alcohol 
consumption, also contributes to increased breast cancer risk (11-13). In other hand, 
childbearing and breastfeeding reduces risk, with greater protection for early first birth and 
a larger number of births (13). The post-menopausal obesity, the late menopause (after the 
age of 55 years) and the early menarche (before than 12 of age) are important risk factors, 
since they increase the breast exposure to elevated levels of oestrogen. Indeed, hormonal 
influence due to the lifetime exposure of the mammary gland epithelium to endogenous sex 
hormones has been described as the most well-established risk factor in breast cancer, 
having a major role in a variety of other female cancers, namely vaginal and endometrial 
carcinomas, since oestrogens have effects on cell proliferation and DNA damage, as well as 
in the promotion of cancer growth (6, 9, 14-15). Clinical and experimental data have 
indicated that exposure to oestrogens is one of the leading causes of sporadic female breast 
cancer and, in 2002, oestrogen was declared to be a known human carcinogen by the 
1. General Introduction 
5 
National Toxicology Program of the National Cancer Institute in USA (6). Several studies 
have explored the effect of endogenous serum concentrations of hormones and breast 
cancer risk. Post-menopausal women, who present high serum levels of sex hormone 
binding globulins (SHBGs) and elevated levels of serum estradiol, show an increased risk for 
breast cancer development. Similarly, it has been shown that this risk is also increased in 
women that present high blood and tissue levels of oestrogen and progesterone (12). 
Moreover, other hormones, such as insulin-like growth factor-1 (IGF-1), have been 
suggested to potentiate the risk of breast cancer (16). However, nowadays, women face an 
exogenous source of oestrogens, which are provided by the widespread usage of oral 
contraceptives and hormonal replacement therapy (HRT), this last being associated with 
increased risk of breast cancer, especially when comparing its use during short and long 
periods of time (13, 17).   
Other well-established risk factors for breast cancer is the existence of family 
inherited germline mutations in breast cancer susceptibility genes, like BRCA1 and BRCA2, 
the most common implicated high-penetrance genes in hereditary breast cancer (6, 18). 
Approximately 5%-10% of all breast cancer cases result from the presence of mutations on 
these inherited susceptibility genes within the family history, being the existence of one or 
more first-degree relatives an established criterion for increased risk of developing the 
disease (19). Male breast cancer is rare and represents approximately 1% of all cancers in 
men, causing around 0,1% of male deaths per year. The risk of breast cancer in males 
carrying BRCA2 mutations, though small, is probably greater than in men carrying BRCA1 
mutations and it may account for 4-14% of all cases (6, 20). A history of prior breast 
biopsies, especially if revealing benign proliferative disease, also increases the risk of 
invasive carcinoma (21). 
 
1.2 – PATHOLOGY AND HISTOLOGICAL CLASSIFICATION IN BREAST CANCER 
The adult female mammary gland consists of a branching tree-like network of ducts, 
lined by a double layer of epithelial and myoepithelial cells, surrounded by fibroblasts 
embedded in an extracellular matrix or stroma, mainly composed by a dense fibrous 
connective tissue, admixed with adipose tissue, and harbouring vascularity. Besides the 
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structural support that stroma provides to the mammary gland, it is thought that it can play 
an important role in the dynamic induction of the breast gland structure morphogenesis and 
differentiation (22-23) (Figure 2). 
 
Figure 2. (A) Schematic cross-section of a mature female breast showing the main anatomical structures. Macroscopic 
diagram of breast structures. [Adapted from Ali S et al., 2002 (24)]; (B) and (C) Low magnification (100x) of normal breast 
gland tissue, where a complex net of mammary ducts are surrounded by connective tissue and a microscopic high 
magnification (400x) of segmental breast duct, showing a clear separation of epithelial and myoepithelial cells, which are 
immunostained for a myoepithelial marker (P-cadherin). 
 
In a premature development state, lobules exist as alveolar buds, turning into 
secretory mature structures (acini or alveoli), after menarche, as a response to the ovary 
release of female hormones, oestrogen and progesterone. These secretory units open into 
the intralobular terminal duct, which, histologically, presents essentially two layers: an inner 
layer constituted by a continuous surface of a luminal secretory epithelial cells, and an outer 
discontinuous layer of prominent basal or myoepithelial cells with large and clear cytoplasm 
and with contractile properties (25). Due to the contained myofilaments, these cells assist in 
milk ejection during lactation and provide structural support to the lobules (21). A 
committed stem cell in the terminal duct is postulated to give rise to both luminal and 
myoepithelial cells (26). While myoepithelial cells are characterized by expressing P-
cadherin, -smooth muscle actin (-SMA) and a distinct subset of basal epithelial 
cytokeratins, luminal epithelial cells can be distinguished by the expression of nuclear 
receptors for steroid hormones oestrogen and progesterone (ER and PgR), as well as, a 
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subset of epithelial cytokeratins, such as CK8, CK18, and CK19 (27). More than 90% of the 
steroid-induced epithelial cell proliferation observed in the non-pregnant gland occurs in 
the luminal cell type (27). 
Frequently, it is at the level of the terminal ductal-lobular unit (TDLU), which, not 
only constitutes the functional structure of the breast for milk production, but also is highly 
responsive to hormonal stimulus occurred during development and maturation processes 
occurring during pregnancy and lactation (22), that many of the known epithelial benign and 
malignant lesions are observed (28).  
The current histological classification of the World Health Organization (WHO) of 
breast tumours is highly extensive and includes malignant and benign neoplasias of 
epithelial origin, besides the neoplasias with myoepithelial, mesenchymal and fibroepithelial 
origin (12). Nearly 95% of breast diseases seem to have a common origin in luminal 
epithelial cells from the TDLU (12, 29), and can be divided in three major lesions: benign 
lesions, in situ and invasive carcinomas. Although the biologic progression of breast cancer is 
not yet completely established, essentially in respect to ductal carcinomas, a high number of 
clinico-pathological and molecular studies seem to point towards a progression from 
intraductal lesions with atypia or in situ carcinomas (12). 
A wide variety of benign alterations in ducts and lobules are observed in the breast 
(26). Benign lesions are usually defined as well-differentiated, with similar morphology of 
that of its origin and with well demarcated areas of expansion slow growth. According to the 
subsequent risk of developing breast cancer, these lesions have been divided into non-
proliferative breast changes, proliferative breast diseases and atypical hyperplasia (21, 26, 
29).  
In situ carcinomas represent malignant lesions that were originally classified as 
ductal or lobular, based on the resemblance of the involved spaces to normal ducts or 
lobules. However, it is now recognized that varied patterns of growths in situ are not related 
to the site or cell of origin, but rather reflect differences in tumour cell biology, such as 
whether the tumour cells express the cell adhesion protein E-cadherin or not. By current 
convention, “lobular” refers to carcinomas of a specific type, and “ductal” is used more 
generally for adenocarcinomas that have no other designation (21). Independently of the 
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special designation, both lesions share considerable epithelia proliferation rates associated 
with malignant cellular features, such as neoplastic proliferation, but without invasion of the 
natural physical barrier formed by the basement membrane of the duct or lobule. In ductal 
carcinomas in situ (DCIS), myoepithelial cells are preserved, although they may be 
diminished in number (21). With the advent of mammographic screening, the diagnosis of 
DCIS rapidly increased from fewer than 5% of all carcinomas to 30% of carcinomas in well-
screened populations. In fact, among cancers detected mammographically, almost half are 
DCIS (30) (Figure 3). 
 
Figure 3. Haematoxylin-eosin staining of breast carcinomas cross-sections. (A) Ductal carcinoma in situ (DCIS), arrow 
(200x); (B) Invasive ductal carcinoma (IDC-NOS) (200x). 
 
In contrast with DCIS, invasive breast carcinomas constitute a group of malignant 
epithelial tumours characterized by invasion of adjacent tissues and a marked tendency to 
metastasize to distant sites. The most frequent histological type of the invasive ductal 
carcinoma (ductal carcinoma NOS – Not Otherwise Specified) represents around 70 to 80% 
of all invasive breast cancers. It is a heterogeneous group of tumours that do not exhibit 
distinct morphological characteristics to be classified in a more specific way, as invasive 
lobular carcinomas, tubular carcinomas and mucinous carcinomas. The invasive lobular 
carcinoma, which constitutes the second more frequent histological type, represents 5 to 
15% of breast invasive carcinomas and is associated with lobular carcinoma in situ in 90% of 
the cases. The other types of breast carcinomas, presenting specific morphological 
characteristics in at least 90% of the tumour mass, are considered special histological types. 
Breast carcinomas of special type include invasive tubular, mucinous, cribriform and 
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micropapilar carcinomas, metaplastic carcinoma and medullary carcinoma, among others 
(12, 21). 
 
1.3 - PROGNOSTIC FACTORS AND THERAPEUTIC STRATEGIES IN BREAST CANCER 
The outcome for women with breast cancer varies widely. Many women have a 
normal life expectancy, whereas others have only a 10% chance of being alive in 5 years 
after diagnosis. With the exception of women presenting distant metastasis or with 
inflammatory carcinoma, which are both poor prognosis features, patient prognosis is 
determined by the pathologic examination of the primary carcinoma and of the axillary 
lymph nodes. Prognostic information is, therefore, important in counselling patients about 
the likely outcome of their disease and choosing appropriate treatment (21). The 
pathological examination includes cytological and histological assessment of some classical 
anatomo-pathologic parameters, which give valuable prognostic and predictive information. 
The major prognostic factors are the histological type (invasive versus in situ disease), 
axillary lymph nodes status and tumour size (10). In the absence of distant metastasis, 
which represents the major threat to breast cancer patient outcome, the axillary lymph 
node status is the most important prognostic factor for invasive carcinoma. With no nodal 
involvement, the 10-year disease-free survival rate is close to 70-80%, falling to 35 to 40% 
with one to three positive nodes, and 10-15% when more than 10 nodes are positive. Also, 
the size of the metastasis within the nodes are of proven prognostic importance (21). 
Tumour size is another powerful independent prognostic marker, with larger size associated 
with a worse outcome. The prognostic and predictive importance of tumour size is of 
greatest relevance in node-negative breast cancer patients, since this is the subgroup that 
should be treated if other prognostic markers suggest clinical aggressiveness (12). Women 
with node-negative carcinomas, with <1 cm in size, have a 10-year survival rate of 90%, 
whereas survival drops to 77% for cancers >2 cm (21). The histological grade, histological 
subtype, lymph vascular invasion, proliferative rate, DNA content and the response to 
neoadjuvant therapy (an alternative approach in which the patient is systemically treated 
before surgery), are also considered as minor prognostic and predictive factors of breast 
cancer (21). 
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Traditional therapeutic strategies for breast cancer include surgery, chemotherapy, 
and radiotherapy. The primary goal of breast cancer surgery is to remove the cancer lesion 
itself, as well as the regional axillary lymph nodes, in order to assess the extent of disease 
spreading and, therefore, helping in the further decision of therapy regimens. Actually, new 
options such as sentinel lymph node biopsy, where one to three key lymph nodes are 
removed and tested before any others are excised, are reducing the need for full axillary 
lymph node resection, particularly in women with early-stage disease (9). Systemic adjuvant 
therapies, like chemotherapy and radiotherapy, given to patients that complete their 
surgery, is designed to eradicate clinically undetectable microscopic deposits of cancer cells 
that may have spread from the primary tumour, usually result in decreased recurrences and 
improved patient survival (9-10). 
Besides these therapeutic strategies, isolated or in association with the referred 
prognostic factors, there is a number of other factors that, being also predictive of outcome, 
potentially direct therapies against particular molecular targets, like nuclear hormone 
receptors, growth factors and their tyrosine-kinase receptors (31).  
 
1.3.1 – Hormonal Receptors: ER and PgR 
Breast cancer is usually a hormone-dependent tumour. More than 100 years ago, 
George Beatson showed that ovariectomy in pre-menopausal women resulted in metastatic 
breast cancer remission and improved prognosis (32). Discovery of the involvement of the 
ovarian hormone oestrogen in stimulating breast cancer growth paved the way for the 
development of therapies that inhibit oestrogen synthesis or block its receptor (33). 
Oestrogens may affect carcinogenesis by acting either as initiators, causing direct DNA 
damage by hydroxylated oestrogen metabolites, or as promoters, inducing growth and 
survival of initially transformed cells (34-35). Through the binding with high affinity to 
oestrogen receptor (ER), oestrogens can regulate the growth of breast cancer, influencing 
gene expression (Figure 4A) and cellular phenotypic changes, defining ER expression in 
breast cancer as critical for tumour progression (36). In other hand, the absence of ER 
expression within a mammary tumour impairs the usage of an ER-target therapy to treat 
breast cancer. While in vivo studies, using human breast epithelium implanted into athymic 
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nude mice, have shown that epithelial proliferation is induced by oestrogens in a dose-
dependent manner, progesterone, either alone or in combination with oestrogen, had no 
effect on epithelial proliferation (37). However, in contrast with these findings, it has been 
demonstrated that patients following an oestrogen-HRT regimen show a lower risk of 
developing breast cancer when compared with the ones that follow a combined 
administration of oestrogen plus progestins (38). Current assays use immunohistochemistry 
to detect nuclear steroid hormone receptors, a finding that is commonly correlated with a 
low breast cancer histological grade, better patient outcome and is an important predictor 
of response to hormonal therapy (21, 39). Eighty percent of carcinomas that are ER and 
progesterone receptor (PgR) positive respond to hormone manipulation, whereas only 
about 40% of those with either ER or PgR alone are able to respond. ER-positive tumours are 
also less like to respond to chemotherapy. Conversely, cancers that fail to express one of 
these markers have less than 10% likelihood to respond to hormonal therapy but are more 
likely to respond to chemotherapy agents (21).  
There are two subtypes of ER: ER and ER. These two receptor subtypes vary in 
structure, and their encoding genes are on different chromosomes (40). Though, ER is 
highly homologous to ER in its DNA- and ligand binding domains, being equally activated 
by 17-estradiol (E2), and inhibited by anti-oestrogens (24, 40). However, although all 
studies agree that ER is expressed in breast cancer cells, its involvement in breast 
carcinogenesis is highly controversial. It has been suggested that a change of ER/ER ratio 
during tumour development is more relevant than the absolute levels of ER or ER, a 
hypothesis supported by the finding that, in ER-positive breast cancers, the mean ratio 
ER/ER is higher than in normal tissue (41-42). 
Since most breast carcinomas are, at least initially, hormone responsive, systemic 
endocrine therapy is an established strategy for adjuvant breast cancer treatment (43). 
Current endocrine therapies of breast cancer are based on three main known mechanisms 
of action, all of them targeting the ER signaling pathway (39, 44): 1) antagonizing ER 
function by competitive binding (selective oestrogen receptor modulators – SERMs and pure 
antiestrogens); 2) downregulating ER (pure antiestrogens); and 3) reducing levels of 
synthesized estrogen (aromatase inhibitors). 
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Extensive research on the function and structural conformation of ER, together with 
the known protective effects of oestrogens in various tissues, have allowed the elucidation 
of the agonist/antagonist activity of different ligands, ultimately leading with the 
development of new classes of SERMs, drugs that act like E2 agonists in certain tissues, such 
as bone, cardiovascular system, brain and lipid metabolism, but antagonizing oestrogen 
action in others, like breast and ovaries (24, 39, 44-46). Tamoxifen, the first prototypic SERM 
(9), was originally developed as an oral contraceptive (47), but the potential of its anti-
oestrogenic action was recognized and it has now become the first-line endocrine agent for 
breast cancer treatment. Tamoxifen can reduce the risk of breast cancer in women at high 
risk for developing the disease and is beneficial in pre- and post-menopausal women whose 
tumours are ER-positive (24, 44, 48), being responsible by 26% of reduction in the annual 
recurrence rate and by 14% reduction in the death rate by breast cancer (9). Unfortunately, 
the treatment with tamoxifen is not effective for more than 5 years, since development of 
resistance is a very common event (49). The biologic activity of tamoxifen ranges from full 
oestrogen agonist to partial and full antagonist, depending on the species studied and the 
target tissue assessed. Therefore, although tamoxifen causes tumour regression in some 
women with metastatic disease (48), this range of activity may account for some of the 
undesirable effects of tamoxifen, such as increased endometrial proliferation and a slightly 
increased risk of endometrial carcinoma (50). A SERM, like Tamoxifen, has the possibility to 
bind to either ER or ER, but due to differences in the transactivating functions (AF), the 
SERM-ER complexes can be altered, resulting in increased or decreased oestrogenicity 
(Figure 4B). It is known that the ligand programs the ER conformation, so that coactivators 
or corepressors can bind to the external surface of a SERM-ER complex and, therefore, 
activating or repressing transcriptional activation of oestrogen target genes (51-53). 
Advances have been made during the past decade, providing the development of new 
SERMs, such Raloxifene, which has lower toxicity, decreases breast cancer incidence and has 
no oestrogen-like action on the uterus (54). 
Whether a synthetic drug acts as an oestrogen or anti-oestrogen on a specific gene 
may be dictated by the particular ensemble of the ER subtype, by the receptor interacting 
proteins or other transcription factors, or by specific elements within the promoter of 
oestrogen-regulated genes. Alterations in these other factors may also play a role in the 
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resistance to hormonal therapies. Ablative endocrine therapies, such as aromatase 
inhibitors, have recently been shown to be superior to tamoxifen and are being 
incorporated into first line therapy of advanced disease (10, 55). Aromatase inhibitors 
inhibit the tumour growth by lowering the systemic oestrogen concentration, due to the 
blockage of peripheral production of oestrogen in adipose tissue and in the tumour itself 
(Figure 4C). Most importantly, aromatase inhibitors are effective even in postmenopausal 
women with low oestrogen concentrations – probably due to the tumour ability of the 
tumour to become hypersensitive to oestrogen, after prolonged oestrogen deprivation (55). 
Clinically interesting, a report showed that aromatase inhibitors achieved a higher response 
rate than tamoxifen in ER-positive breast cancer patients (56), especially when these 
tumours also express high levels of the oncogene HER2, which is known to increase 
tamoxifen resistance (57). A recent study also demonstrated that overall survival was 
prolonged for patients who switched from tamoxifen to aromatase inhibitors therapy (49), 
and that these compounds showed superiority over tamoxifen in the neoadjuvant setting, 
even challenging chemotherapy with regard to response in selected group of patients (58-
59). 
Despite the potential to exploit the selective agonist pharmacology of SERMs, the 
elimination of partial agonist also has been regarded as a highly desirable goal, in order to 
improve clinical efficacy. In the last decade, the development of a specific or “pure” 
antioestrogen with high affinity for ER and without any agonist effects was initiated with the 
purpose to provide increased benefits over tamoxifen in the treatment of patients with 
oestrogen dependent disease. The search for such drug revealed a compound with the 
appropriate effect, known as ICI 182,780 (ICI) (50, 60-61). This compound, commercially 
known as Faslodex® or Fulvestrant, is a steroidal pure antioestrogen with a similar binding 
affinity for ER, when compared to that of estradiol, and much greater than that of tamoxifen 
(60-61). Partial tamoxifen agonistic effects have been attributed to the fact that one of the 
activation domains (N-terminal AF-1) of ER remains active in the tamoxifen-ER complex (62) 
(Figure 4B). In contrast, ICI, due to multiple changes in the relative orientation of the major 
ligand-dependent ER transcriptional activation domain AF-2, attenuates the ability of ER to 
activate or inhibit transcription in a ligand-dependent or independent manner in vivo, 
contributing to the oestrogen action blockade (63) (Figure 4D). These changes include 
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impaired dimerization, increased turnover, and disrupted nuclear localization (50, 53, 62, 
64-65), leading not only to ER malfunctioning, but also to its reduced cellular levels and half-
life, impairing the transcription of ER-regulated genes (60). The molecular basis for this 
increased turnover is not completely clear, but is accompanied by a block in nucleo-
cytoplasmic shuttling. In the presence of ICI, nuclear ER re-shuttling does not occur and 
degradation takes place (66). 
 
Figure 4. Molecular effects of oestradiol and anti-oestrogen compounds. Shown are the molecular effects of (A) oestradiol, 
(B) the selective oestrogen receptor modulator (SERM) tamoxifen, (C) the aromatase inhibitors and (D) the steroidal pure 
antioestrogen fulvestrant on ER signalling. As shown in panel A, oestradiol binding to ER leads to loss of heat shock 
proteins (HSPs), dimerization and phosphorylation of receptors, with conformational change leading to coactivator 
activation at both AF1 and AF2 sites; a full agonist effect is seen. In panel B, SERM (tamoxifen) binding to ER leads to loss of 
HSPs, dimerization and phosphorylation of receptors, but with different specific conformational changes, leading to 
coactivator activation at AF1 only, and not at AF2 sites; therefore, a partial agonist effect is seen. In panel C, aromatase 
inhibitors compete with androgen for the aromatase enzyme binding site, preventing the conversion of androgen to 
oestrogen in post-menopausal woman. In panel D, fulvestrant binding to ER leads to loss of HSPs, but impair receptor 
dimerization due to altered conformational changes. Thus, receptor degradation is enhanced with no activation at AF1 or 
AF2 sites; no agonist effect is seen. [Adapted from Jonhston SR, 2005 (69) and Morris & Wakeling, 2002 (61)]. 
 
Clinically, fulvestrant is the subject of much ongoing research, which utilises 
knowledge of its novel mechanism and pharmacokinetic profile, in order to optimise clinical 
efficacy and explore new roles, including first line use in advanced breast cancer or in 
combination with existing agents (63, 67). It has been reported that fulvestrant is an 
effective and well-tolerated drug for treatment of metastatic oestrogen-sensitive breast 
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cancer (67), as it has been suggested as a suitable therapeutic option in extensively pre-
treated patients with HER2 and hormone receptor-positive advanced breast cancer (65). 
Most importantly, it has been reported that it offers potential advantages over other 
oestrogen target therapies, since no uterine pathologies, such as increase of uterine volume 
or endometrial growth, have been observed after 3 months of fulvestrant treatment in 
postmenopausal women with metastatic breast cancer, previously exposed to tamoxifen 
and aromatase inhibitors (68).  
Endocrine therapy resistance is one of the main challenges in the treatment of ER-
positive breast cancer patients (69). Resistance mechanisms to these therapies appear to be 
related to a cross-talk between ER and growth factor-signalling cascades that regulate cell 
survival, cell death and differentiation (70-71).  Some studies have demonstrated that the 
PgR-negative status of ER-positive tumours may reflect altered growth factor receptor 
signalling, giving some explanation to the lower response rates to tamoxifen of these 
carcinomas when compared to cancers typed PgR-positive (72). It has been hypothesized 
that endocrine therapy response depends on HER2 expression. Despite the still conflicting 
conclusion about this, such studies are bringing forward a new window of opportunity that 
relays on the association of endocrine therapies with specific inhibitors of important 
signalling pathways, like PI3K or MAPK, as a strategy to overcome endocrine resistance in 
ER-positive breast cancer (69). A recent study in endocrine resistant breast cancer cell lines 
showed that PI3K/Akt or MAPK pathways inhibition was sufficient to reverse both tamoxifen 
or fulvestrant resistance (69). Furthermore, regardless the ER status, a decreased 
activation of PI3K/Akt, increased ERK, and IGF-1R pathways inactivation have been reported 
as cellular responses to antioestrogen treatment (71), highlighting a new and promising 
prospect to delay the onset of anti-hormonal resistance, thereby significantly improving 
patient’s survival.  
  
1.3.2 – ErbB2/HER2 
The protein encoded by ERBB2 gene (or HER2/neu) is a transmembrane tyrosine 
kinase receptor with extensive homology to the epidermal growth factor receptor (EGFR), 
although without ligand-binding domain. At the cellular level, HER2 is transactivated by 
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EGFR upon binding of its ligand EGF, resulting in the formation of EGFR/HER2 heterodimers. 
However, formation of other heterodimers, such as HER2/HER3 and HER2/HER4, are also 
likely to occur. This heterodimerization between HER2 and the other receptors of the family 
allows the participation of HER2 in signal transduction, frequently leading not only to a loss 
of G1-S checkpoint, but also to the disruption of the delicate balance between cell survival 
and death signals (6, 73). It has been estimated that 15-30% of breast cancers overexpresses 
HER2 gene (6). Patients with primary HER2-positive disease have a higher risk of recurrence 
and death; however, the main importance of HER2 is as a predictor of response to agents 
that target this transmembrane protein (21, 74). The approval, in 1998, of monoclonal 
antibodies targeting the extracellular domain of the HER2 protein, such as trastuzumab, 
broadened the scope of targeted therapy and marked the first of many steps towards 
improved understanding of breast cancer biology (6). One of trastuzumab’s mechanisms of 
action is via antibody-dependent cellular toxicity; the activation of natural killer cells 
initiates lysis of cancer cells that are bound to the therapeutic antibody. Most importantly, 
trastuzumab inhibits the PI3K pathway, which is activated by overexpression of HER2, 
reducing PTEN phosphorylation and increasing AKT dephosphorylation and, therefore, 
increasing cell death (74-76).  
The wide range of function mechanisms of trastuzumab give rise to various 
mechanisms of resistance due to the cross-talk of HER2 with other extracellular domains of 
HER proteins, resulting in incomplete inhibition and lateral activation of proliferative 
pathways (77-78). This motivated the development of receptor tyrosine-kinase inhibitors 
(RTKi); small molecules, such as lapatinib, that compete for binding sites on intracellular 
portions of HER1 (EGFR) and HER2, targeting the downstream ERK1-2 pathways, which 
regulate cell proliferation, and the PI3K/AKT pathway, that regulates cell survival (79).  
 
1.4 - GENE EXPRESSION PROFILES OF BREAST CANCER 
Human breast carcinomas represent a heterogeneous group of tumours, which are 
diverse in their natural history, their outcome, and their responsiveness to treatment. In 
fact, patients with identical tumour types and stage of disease can present different 
responses to therapy and different overall outcomes. This problem challenges the current 
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classification system and stem from the inability to take into account biological prognostic 
determinants (80-82). More recent developed techniques, that examine the DNA, RNA, and 
proteins of carcinomas in a global way, have provided a framework for new molecular 
classifications of invasive carcinomas (NOS) (21). With a high throughput and parallel 
analysis of thousands of genes, the advent of microarray technology and gene expression 
profiling has allowed the linkage of molecular expression profiles to clinical patient’s 
outcomes and responses to therapy, generating a tool to better tailor treatment strategies 
to specific subgroups of patients, whose tumours have particular molecular aberrations (83). 
Microarray-based gene expression profiling led to a working model for a breast cancer 
molecular taxonomy, where clusters of genes, with coherent expression patterns, could be 
related to specific features of biological variation among tumour samples; for example, 
variations in proliferation rates and activation of specific signal transduction pathways (84). 
Another important implication is that genetic profiling may lead to the identification of new 
therapeutic targets (10, 27). Recent cDNA and tissue microarrays studies have showed that 
breast tumours can be classified into specific molecular subtypes, distinguished by 
differences in their gene expression patterns, providing a distinctive portrait for each 
tumour and the basis for an improved breast cancer molecular taxonomy (27, 82, 85-86). As 
expected, the majority of the studies generally separate the tumours into those that are 
clinically described as ER-positive and those that are ER-negative. Thus, using unsupervised 
clustering, they could already distinguish to some extent between “good prognosis” and 
“poor prognosis” tumours. The breast cancer molecular classification distinguishes three 
major subtypes: the ER-positive/luminal-like subtype, a gene expression cluster 
characteristic of the luminal cells and anchored by a cluster of transcription factors that 
include ER; the ER-negative/basal-like subtype, comprising tumours that express basal cell 
markers; and the HER2-overexpressing subtype, usually associated with gene amplification 
of the HER2 proto-oncogene (Figure 5). These studies have largely contributed to 
understanding the complex behaviour of certain types of breast cancer. 
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1.4.1 – ER-Positive / Luminal-Like Tumours 
The ER-positive/luminal-like molecular subtype, which represents the largest group of 
invasive tumours (NOS), consists in all tumours characterized by relatively high expression of 
genes that are known to be expressed by luminal epithelial cells (87). The “good prognosis 
signature” of this subtype is dominated by dozens of genes under the control of ER and 
other ER-associated genes, such the one which codifies for the oestrogen-regulated protein 
LIV-1, the transcription factors hepatocyte nuclear factor-3 HNF3A (or FOXA1), trefoil 
factor 3 (TFF3), X-box-binding protein (XBP1), and GATA-binding protein 3 (GATA-3) (87) 
(Figure 5). These cancers, mostly occurring in postmenopausal women, are generally HER2-
negative (luminal A), well- or moderately differentiated, slow growing and well-responsive 
to endocrine treatments. Conversely, only a small percentage of luminal-like tumours 
usually respond to standard chemotherapy (21). 
 
1.4.2 – ER-Negative / Basal-Like Tumours  
ER-negative/basal-like breast tumours represent one of the most intriguing subtypes, since 
comprises a small proportion of cancers which exhibit a basal/myoepithelial phenotype, 
defined by immunohistochemical positivity for myoepithelial markers (molecules normally 
seen in the basal/myoepithelial compartment of the normal breast) (88-89). Hence, these 
tumours, that failed to express ER and most of the other genes that are usually co-expressed 
with it (27), express basal keratins, p63, P-cadherin, laminin and integrin-4 (90-91) (Figure 
5). By strict definition basal-like cancers are a subgroup of ER-PgR-HER2 “triple negative” 
carcinomas (92-93). This cluster also encompasses the expression of many genes involved in 
cell cycle, invasion, metastasis and angiogenesis (81), which might explain the association of 
these tumours with a poor prognosis signature, with high proliferative and metastatic 
potential, high grade tumours and short patient survival (21). Basal-like cancers are of 
particular interest because of their distinct genetic features (21). When these breast 
carcinoma immunoprofiles were compared to familial and sporadic origin, we could observe 
that basal tumours were mostly associated with familial cases (90). Actually, it has been 
described that tumours from BRCA1-mutated carriers share an immunohistochemical profile 
very similar to that from sporadic basal-type carcinomas (high-grade, ER-negative, PgR-
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negative, HER2-negative), a finding recently confirmed by the analysis of the referred basal 
molecular markers (CK14 and CK17, P-cadherin, p63, and EGFR) expression (94-95). These 
results led to the assumption that this genotype strongly predisposes to the basal-like 
tumour subtype. Based on these results, Foulkes et al. have hypothesized that the wild-type 
BRCA1 key function is to act as a stem-cell regulator, besides promoting the differentiation 
towards glandular epithelium in the normal breast. In BRCA1 mutated tumours, this 
transition has failed or was not completed, and basal-cell phenotype gene expression was 
retained (96-98). In a recent study by Lim and colleagues, it was observed that the 
expression of certain basal markers such as CK14 in BRCA1-associated tumors was also 
consistent with luminal progenitor cells having an altered differentiation program. This 
group showed that the delineation of specific epithelial cell types within the human 
mammary hierarchy, unexpectedly revealed an aberrant luminal progenitor cell population 
in BRCA1 mutation carriers, suggesting it may serve as a cellular target for oncogenic events 
(99).  
 
Figure 5. Hierarchical clustering of 115 tumour tissues and 7 non-malignant tissues using the “intrinsic” gene set. (A) Gene 
cluster showing the ERBB2 oncogene and other coexpressed genes. (B) Gene cluster associated with luminal subtype B. (C) 
Gene cluster associated with the basal-like subtype. (D) A gene cluster relevant for the normal breast-like group. (E) Cluster 
of genes including the oestrogen receptor (ESR1), highly expressed in luminal subtype A tumours. [Adapted from Sorlie T et 
al., 2003 (100)]. 
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1.4.3 – ER-Negative / HER2-Overexpressing Tumours  
HER2-overexpressing subtype comprises ER-negative carcinomas that overexpress 
HER2/neu protein (Figure 5). In more than 90% of HER2-positive cancers, overexpression is 
due to amplification of a DNA segment including the gene ERBB2 and several others in the 
same 17q21-22 amplicon, such as GRB7 and MLN64, which dominate the gene signature of 
this group (27, 86-87, 101). In rare cases, HER2/neu protein overexpression may occur as a 
result of mechanisms other than gene amplification (102). These cancers are usually poorly 
differentiated, with high proliferation rates and associated with a high frequency of brain 
metastasis (21). 
 
1.4.4 - Other Expression Profiles 
Over the last years, successive extended data sets allowed the separation of the ER-
positive/luminal-like tumours into two distinct subgroups: luminal A and luminal B. While 
luminal A tumours are those anchored by the high expression of ER-associated genes, the 
smaller group of tumours, designated as luminal B, showed low to moderate expression of 
the luminal-specific genes including the ER cluster, but with a high expression of a novel set 
of genes whose coordinated function is still unknown. Expression of this cluster of genes is a 
feature that is shared with the basal-like and HER2-positive subtypes and associated with 
poor outcome (84, 87).  
Some authors suggest the existence of another group of tumours, which may 
represent between 6-10% of NOS cancers, where the gene expression pattern is typified by 
the high expression of genes characteristic of basal epithelial cells and also from non-
epithelial cell types, but with low expression of luminal epithelial genes. These tumours 
have been clustered into a subtype name “normal-like tumours” but, until now, it is unclear 
whether these tumours represent poorly sampled tumour tissues or a really distinct and 
clinically important group (21, 87).  A recent study from Weigelt et al., where an agreement 
analysis has been done between three microarray-based single sample predictors for the 
whole classification system, and also for the five molecular subtypes individually in each 
cohort, proposed that normal-like tumours could be an artefact derived from analysis of 
tumour specimens with a high proportion of normal tissue contamination (83).   
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Described recently, a potential new breast cancer molecular subtype, termed as 
“claudin-low”, was identified and characterized by the low expression of genes involved in 
tight junctions and cell-cell adhesion, including claudins 3, 4 and 7, occludin and E-cadherin. 
These human tumours were also characterized by the expression of many epithelial-to-
mesenchymal-transition (EMT)-associated genes, a comparatively high expression of 
lymphocyte and endothelial markers and a CD44+/CD24-/low-cancer stem cell signature (103-
104).  
 
1.5 - REGULATION OF GENE EXPRESSION IN BREAST CANCER 
 It is convenient to distinguish between genetic and epigenetic mechanisms that 
regulate gene expression; the former is based directly on the information encoded in the 
DNA sequence, while the latter, on those processes necessary for the manifestation of this 
information (105). In other words, epigenetics refers to information inheritance based on 
gene expression levels, while genetics refers to the information transmitted on the basis of 
gene sequence itself (106). However, genetic and epigenetic phenomena are almost 
indefinable interlinked and interdependent, contributing for an integrated approach which 
helps in the true appreciation of how the genome operates, in both health and diseases, 
such as cancer. Regulation of gene expression through binding of transcription factors to 
target DNA sequences illustrates particularly well the blending of genetics and epigenetics 
to deliver spatio-temporal gene expression patterns that are not predictable by considering 
either component alone (107-108). In fact, transcription factors, chromatin and chromatin-
modifying enzymes are key components in a complex network through which the genome 
interacts with its environment. For many transcription factors, binding motifs are found 
adjacent to the promoter regions of a large proportion of genes, requiring mechanisms that 
confer binding specificity in any given cell type. These include association of the factor with 
other proteins and chromatin packing at the binding sequences, in order to inhibit or 
facilitate the binding. The functional consequences of transcription factor binding are 
frequently dependent on protein modifying enzymes, particularly those that alter lysine 
methylation at selected histone residues (108). A classical example of this targeting of 
transcription factors to selected sites is the well known MYC transcription factor involved in 
breast cancer. Evidence that MYC binding occurs in chromatin regions, enriched in specific 
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histone modifications (109), raised numerous questions concerning 1) if the enriched 
modifications simply reflect a generally “open” and accessible chromatin conformation, 
allowing the binding, or 2) if specific modifications serve as recognition signals bound by 
guide proteins directly linked to MYC itself and, thereby, targeting it to regions enriched in 
such signals. In one way or another, in breast development, as well as in breast 
carcinogenesis, the imbalance and deregulation of the mechanisms related with known 
important signalling pathways (e.g. PI3K, MAPK or ER signalling) are indubitably linked with 
the prior control of transcription factor modulation and associated epigenetic events.  
 
1.5.1 - Transcription Factors 
 The actions of major transcription factor families are selective at several levels to 
govern the expression of sub-transcriptomes that are phenotypically related. The flexibility 
of transcriptional control includes the exact choice of the target sequence, the timing, the 
amplitude and magnitude of transcription and the integration with other transcriptional 
programs and signal transduction events. In breast cancer, the dexterity of targeting and 
regulation is blunted and, instead, transcription factors become limited to specific sub-
transcriptomes, for example, those associated with blockage of programmed cell death and 
progression through the cell cycle, invasiveness potential and, ultimately, stimulation of cell 
migration (108).  
 
  1.5.1.1 - Steroid Hormone Receptors (SHR) 
 Perhaps the clearest examples of loss of transcriptional plasticity and the evolution of 
an unresponsive transcriptome in malignancy are found among the members of the nuclear 
receptor superfamily. These transcription factors dimerize and form a single network to 
regulate self-renewal and homeostasis in a number of epithelial systems, where breast is 
highlighted (108). Nuclear/steroid hormone receptors are members of the abovementioned 
family of nuclear receptors. They are ligand-activated transcription factors and sensors for 
growth factor-initiated signalling pathways, controlling the expression of target genes in 
hormonally regulated tissues (110-111). Steroid hormones control proliferation and survival 
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of breast epithelial cells. This activity has been so far attributed to the interaction of steroids 
with their cognate receptors and the consequent regulation of gene transcription (112) 
(Figure 6).  
 
Figure 6. Steroid Hormone Receptors (SHR) act as hormone dependent nuclear transcription factors. Upon entering the cell 
by passive diffusion, the hormone (H) binds the receptor, which is subsequently released from heat shock proteins, and 
translocates to the nucleus. There, the receptor dimerizes, binds specific sequences in the DNA, called Hormone 
Responsive Elements or HREs, and recruits a number of coregulators that facilitate gene transcription. (1) hormone 
binding, (2) chaperone release, (3) nuclear translocation, (4) receptor dimerization, (5) DNA binding, (6) putative 
membrane-bound receptors, (7) coregulator recruitment, (8) transcription, (9) proteasomal degradation, (10) modulation 
by cellular signalling pathways [Adapted from Griekspoon, A et al., 2007 (116)]. 
  
 Oestrogens are probably the best studied steroid hormones which, acting through 
specific hormone receptors – ER, assume an important role as regulators of breast cancer 
growth. In fact, oestrogens have been found to control several key G1 phase cell cycle 
regulators, such as cyclin D1, MYC, CDK2, CDK4 and CDK inhibitors (6, 113). Target cell 
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response to oestrogens is dictated by the presence or absence of ER. In the absence of 
steroid hormone, monomeric inactive ER lies in the cell nucleus bound to heat-shock 
proteins (114), which are a requisite not only for the proper protein folding and assembly of 
competent stable heterocomplexes to ligand binding, but also to connect ER to protein 
trafficking systems (111). Due to its steroidal nature, oestrogens are able to diffuse passively 
through the plasma and nuclear membranes and to bind to its receptor (114). Upon 
oestrogen binding to the ER ligand-binding domain (LBD), a series of molecular 
modifications occur, including conformational changes (activation), phosphorylations, 
dissociation from the chaperone proteins and ER dimerizarion (115).  Stimulation of target 
gene expression in response to oestrogen is thought to be mediated by two distinct 
pathways: the “genomic” or the “non-genomic” (114) (Figure 6).  
 The genomic pathway of ER action, also called nuclear-initiated steroid signalling 
(NISS), involves two different mechanisms: 1) a classical pathway, where the activated ER 
dimer binds to discrete DNA sequences, termed oestrogen responsive elements – EREs, 
which are located in regulatory DNA promoter regions of oestrogen-regulated genes, 
directly interacting with coactivator proteins (e.g. AIB1 and GRIP1) and components of the 
RNA polymerase II transcription initiation complex, and resulting in enhanced transcription 
of genes, such as complement 3 and PS2 (114, 117-118); and 2) a non-classical pathway, 
which do not require the direct binding of ER to DNA (119-120). In fact, ER can influence the 
transcription of genes lacking ERE sequences and regulated by other transcription factors 
that bind to alternative regulatory DNA sequences. The promoter elements involved in this 
response include AP-1 sites, cyclic AMP-response elements (CREs) and Sp1 sites, which 
directly bind Jun/Fos (121), c-Jun/ATF-2 (122) and Sp1 (123), respectively. ER interacts with 
these transcription factors, stabilizing their direct binding to DNA, and thus enhancing the 
transcription of target genes such as cyclin D1 or IGF-R1 (124-125). It can also occur that 
some ER-target genes, like VEGF gene, have both ERE and non-classical sites in their 
regulatory region. VEGF transcription can be induced by oestrogen, due to a variant ERE or 
through Sp1 sites, according to the cellular context (126-127). Moreover, some 
transcriptional-induction synergies can be achieved by ERE half-sites and other regulatory 
elements within a promoter region, as is the case of PgR gene, which displays combinations 
of half ERE upstream of Sp1 binding sites; ER can induce PgR expression by directly binding 
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to the half-site and by indirectly binding with proteins bound to Sp1 sites (128). Regardless if 
the induction is via ERE, or indirectly via non-classical sites, the oestrogen recruitment is 
able to induce gene transcription only if the important ER regions AF1 and AF2, responsible 
for transcriptional activity, are activated. It is important to highlight that if either AF1 or AF2 
is dominant, oestrogen behaves as an agonist on gene transcription (114). AF2 activation is 
totally dependent on the ligand. The binding of oestrogen to ER induces the LBD 
rearrangement, uncovering AF2 region, serving as a binding surface for proteins that will act 
as coactivators, such as nuclear-receptor coactivators (NCoA 1,2 or 3), also known as steroid 
receptor coactivators (SRC) and translation initiation factor 2 (TIF2) (129). Binding of these 
molecules to AF2 region form large complexes that recruit histone-acethyltransferases 
(HAT), enzymes that cause the chromatin decompactation required for gene transcription. 
In contrast, corespressor proteins also can bind to AF2 region, such as nuclear-receptor 
corespressor 1 and 2 (NCoR), reducing ER-driven transcription by histone deacetylases 
(HDACs) recruitment to the promoter sites. This leads to chromatin condensation and 
decreased rate of transcriptional initiation (130-131). In contrast with AF2, AF1 activity is 
ligand independent. In the absence of oestrogen, AF1 is activated by phosphorylation, 
following the activation of MAPK and PI3K/AKT pathways. These different kinase pathways 
are triggered by growth factors receptors, such as EGFR or IGF-R1 (132).  
 In addition to the above described nuclear effects, there are ER functions that can 
occur very quickly in the cell (within seconds or minutes) and are initially independent of 
gene transcription. This rapid non-genomic mechanism of action is mediated by the 
membrane associated ER, by the so called membrane-initiated steroid signalling (MISS) 
pathway (133). At the membrane, ER associates with caveolin rafts and, upon oestrogen 
binding, interact directly with adaptor proteins, like SRC, p85 subunit of PI3K and G-proteins, 
resulting in the activation of growth factor receptors, such as EGFR, IGFR, HER2, and 
cytoplasmatic kinases like MAPKs, PI3K, AKT and mTOR (134-136). In turn, cytoplasmatic 
kinases can phosphorylate ER and its coregulators, resulting in the activation of nuclear ER-
driven transcription (137). It is suggested thought, that the ER non-genomic and genomic 
activities are complementary and even synergistic (114). 
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 1.5.1.2 - Forkhead-Box Proteins (FOX)  
Forkhead box (Fox) proteins are a family of evolutionarily conserved transcription 
factors, defined by a common DNA-binding domain termed the Forkhead box or winged-
helix domain (138). Despite the highly conserved Forkhead box DBD, Fox protein regulation 
and function vary significantly between sub-families, arising in part from sequence 
variations outside the DBD. In fact, based on forkhead box domain, the forkhead genes are 
grouped into 19 subclasses of FOX genes (139).  
Fox protein family members are important for a wide spectrum of biological 
processes, including metabolism, development, differentiation, proliferation, apoptosis and 
invasion (138). Although the first mammalian forkhead type proteins to be identified were 
the FOXA class of factors, forkhead O transcription factors (FOXO) is one of the largest and 
more important subgroups of forkhead family members (138-139). Nevertheless, several 
Fox subfamilies such as FOXO, FOXM, FOXP, FOXC and FOXA have been linked to 
tumorigenesis and progression of several cancers, working as crucial regulatory proteins, 
which can act as tumour suppressor genes or as oncogenes. Indeed, Fox proteins can both 
activate and repress gene expression through the recruitment of cofactors or corepressors, 
primarily HDACs. In addition, Fox proteins interact extensively with other factors, such as 
p53 and ER, to modulate gene transcription. A growing body of evidence suggest that Fox 
transcription factors may represent direct targets and/or indirect effectors for cancer 
therapeutic intervention (138).  
Fox factors are regulated by multiple layers of post-transcriptional modifications, 
including phosphorylation, acetylation and ubiquitylation, which determine their cellular 
localization and consequent functional activity. Thus, nuclear Fox proteins act as 
transcriptional regulators, whereas cytoplasmic Fox proteins are inactive and often subject 
to proteossomal degradation. The shuttling of Fox proteins between nuclear and 
cytoplasmatic compartment is driven by interaction with exportin/importin accessory 
proteins (138).  
 In breast cancer, it has been described that essentially FOXO, FOXM, FOXA and FOXC 
proteins assume an important role in crucial tumorigenic signalling pathways, in therapeutic 
responses and as tumour behaviour markers.   Concerning FOXOs, activation of cell survival 
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pathways, such as PI3K/AKT/IKK or Ras/MAPK, are known to phosphorylate these 
transcription factors, leading to their binding to 14-3-3 protein, nuclear exclusion and 
degradation. Consequently, this cytoplasmatic shuttling and FOXO’s inactivation result in 
the suppression of FOXOs transcriptional activity. Perturbation of nuclear FOXOs function 
leads to deregulated cell proliferation and accumulation of DNA damage, since they are 
crucial to maintain cells in check, controlling genes related with apoptosis and cell cycle 
arrest, such as p27kip1, Bim, FasL, GADD45 and cyclin D (139-142) (Figure 7).  
 
Figure 7. Model for the sequential inhibition of FOXO transcription factors in response to growth factors. FOXO factors are 
constantly shuttled between the cytoplasm and the nucleus. (A) In the absence of growth factors, FOXO are mostly 
localized in the nucleus, activating their target genes. (B) Activation of the PI3K–Akt/SGK pathway by growth factors, 
triggers the phosphorylation of FOXO in the nucleus, the binding of the 14-3-3 and the release of FOXO from their DNA-
binding sites, leading to FOXO nuclear export. (C) In the cytoplasm, phosphorylated FOXO is degraded by proteasome-
dependent degradation. [Adapted from Calnan & Brunet, 2008 (143)].  
 
 Growing evidence has demonstrated FOXOs as bona fide tumour suppressor genes. 
Therefore, the inhibition of FOXOs transcriptional activity by kinase pathways is associated 
with cell transformation, tumour progression and angiogenesis (144-147). FOXO3a 
overexpression has been shown to inhibit breast cancer cells growth in vitro and tumour 
size in vivo, and its cytoplasmatic localization correlates with poor patient survival (146). 
Since AKT negatively controls the activity of FOXO3a, inducing its phosphorylation and 
consequently degradation, it has been demonstrated that AKT inhibition leads to 
dephosphorylation and nuclear localization of FOXO3a, resulting in the activation of its 
downstream targets (148). Hence, inhibition of EGFR family members by breast cancer 
clinically used drugs, such as paclitaxel, imatinib, doxorubicin, lapatinib or trastuzumab, 
effectively up-regulates active FOXO3a and its targets, FasL, Bim and p27, by reducing AKT 
activity (139, 149-150). Interestingly, reinforcing the close impact of FOXO3a in breast 
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cancer, there are studies showing that FOXO3a is a key intracellular regulator of ER gene 
transcription and expression (151-152). It was demonstrated that the widely described 
down-regulation of ER induced by the activation of PI3K/AKT pathway (153-155) is 
mediated through the nuclear exportation and consequent inactivation of FOXO3a (151). 
These findings established an important cross-talk between the kinase pathways, the ER 
function and the expression of FOXO3a, showing that the treatment with agents that inhibit 
HER2/PI3K/AKT kinase signalling, enhances FOXO3a activity and elevate the level of ER 
expression in breast cancer cells. Interestingly, using gefitinib-sensitive breast cancer cell 
lines, we showed that gefitinib targets the transcription factor FOXO3a to mediate cell cycle 
arrest predominantly at G0-G1 phase and cell death. This mechanism is associated with 
FOXO3a dephosphorylation at AKT sites and its nuclear translocation (156) (see PAPER III in 
Appendix section). Curiously, it has been suggested that the sensitivity to cytotoxic drugs is 
mediated by some FOXOs, which may differ according to different cellular growth displayed 
by different tissues. In endometrial cancer, for example, we demonstrated that FOXO1, 
another member of FOXO’s family, serves as a tumour suppressor involved in normal 
growth control, maintenance of genomic stability and  limiting proliferation of endometrial 
cancer cells; however, we showed that its induction and activation confers resistance to 
paclitaxel (157) (see PAPER IV in Appendix section).  
In contrast to FOXOs, where tumour development is associated with inactivation by 
phosphorylation, and consequent nuclear export, FOXM factors are activated by 
phosphorylation (158). FOXM1 is ubiquitously expressed in proliferating cells and a key 
regulator of both G1/S and G2/M phases of the cell cycle. This transcription factor is 
localised mainly at the cytoplasm, being phosphorylated and translocated to the nucleus 
upon activation of the Raf/MEK/MAPK, before cells entry in G2/M phase (158-160). 
Consistent with its role in promoting proliferation, elevated expression of FOXM1 has 
recently been reported in human breast cancer (159, 161). FOXM1 down-regulation 
inhibited the growth of breast cancer cell lines and its silencing resulted in the down-
regulation of MMP-2, MMP-9, uPA and VEGF. Interestingly, induced FOXM1 overexpression 
in breast cancer cells expressing low levels of this transcription factor, resulted in increased 
cell proliferation, migration and invasion (162). Very recently, in vitro data have 
demonstrated the FOXM1 protein binding to the ESR1 promoter, thus leading to 
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upregulation of ER mRNA and protein levels, demonstrating that FOXM1 is a physiological 
regulator of ER expression in breast cancer cell lines (160). Based on these findings, 
inhibition of FOXM1 has been seen as a novel therapeutic approach for the treatment of 
aggressive breast cancer (159, 162).  
 Concerning FOXC transcription factors, little is known about these and about its 
downstream targets. However, recent evidence has pointed that the expression of FOXC2 is 
significantly correlated with the highly aggressive basal-like subtype of human breast 
cancers, suggesting a crucial role in promoting invasion and metastasis (163). Moreover, it 
has been shown that FOXC2 is critical for tumour development and for the formation of 
tumour blood vessels (angiogenesis) and with increased metastatic capabilities of breast 
cancer cells (164). Interestingly, FOXC2 specifically promotes mesenchymal differentiation 
during EMT and may serve as a key mediator to orchestrate the mesenchymal component 
of the EMT program (163).  
Deregulation of other FOX proteins may be more associated with specific cancers, 
where they have an important role during development or tissue homeostasis. This is the 
case of FOXA1, where its deregulation is particularly associated with breast cancer due to its 
strong interaction with ER(138). ER binding to chromatin requires co-factors that can 
assist in defining the locations that ER can bind in the genome. FOXA1 (also known as 
HNF3) is a pioneer factor that has been receiving considerable attention, since it interacts 
with cis-regulatory regions of heterochromatin, enhancing the ERα interaction to chromatin, 
which is required for subsequent gene expression (165-167). In fact, FOXA1 can mimic 
histone proteins to enable binding to chromatin, and has been shown to be essential for 
changes in chromatin structure, for example, during oestrogen induction of the cyclin D1 
gene (124). Recently, Carroll and colleagues described several robust data demonstrating 
the requirement of FOXA1 for optimal expression of nearly 50% of ERα-regulated genes and 
oestrogen-induced proliferation (165-166) (Figure 8A). 
 
FOXA1 can bind to the promoters of more than 100 genes associated with metabolic 
processes, regulation of signalling pathways and cell cycle (168-169). Some studies have 
shown that FOXA1 can act either as a growth stimulator/activator or as a repressor. As a 
stimulator, FOXA1 binds to chromatinised DNA and opens the chromatin, enhancing the 
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binding of ERα to its target genes (170), which suggests a growth-promoting role for this 
forkhead protein (166, 170). In breast cancer, however, a growth inhibitory function has 
been attributed to FOXA1, since its overexpression can also block the metastatic progression 
by influencing the expression of the BRCA1-associated cell-cycle inhibitor p27 and 
promoting E-cadherin expression (171-172). Recent studies suggest FOXA1 as a favourable 
prognostic factor and as a predictor of better survival in breast cancer, with potential 
relevance in the subclassification of luminal/ER-positive tumours into two subgroups with 
different biological behaviour and prognosis, the luminal A and the luminal B (86). In breast 
cancers, expression of FOXA1 and ER correlate exceptionally well, and they constitute two 
of the genes that define the luminal breast cancer signature (27, 86). Loss of FOXA1 is 
associated with potential for endocrine independent proliferation and survival, endocrine 
resistance and tumour progression (138). Indeed, the lack of expression of FOXA1 through 
methylation or inactivation of its putative activator, GATA-3, lead with loss of expression of 
ERand formation of mammary tumours (173) (Figure 8B).  
Figure 8. Interaction between FOXA1, GATA-3 and ER and associated co-factors: (A) Pioneer factors, such as FOXA1, 
function to identify where in the chromatin ERbinds. A large number of co-factors can associate with the ER complex to 
either bring in other co-factors, regulate the protein structure of ER or co-factors, or to directly modify the chromatin 
structure. The activity of ER and AIB1 are also regulated by growth-factor-signalling pathways. All of these interactions 
between ER and co-factors determine the transcriptional activity of the target gene. (B) GATA-3 binds to the regulatory 
region (promoter) of the gene encoding FOXA1 and possibly activates its expression. Perturbation of this pathway as a 
result of decreased GATA-3 expression, may contribute to breast tumours. [Adapted from Green K & Carroll J, 2007 (174) 
and Tong Q & Hotamisligil S, 2007 (175)]. 
 
Interestingly, along with FOXA1, GATA3 is also one of the few genes that define ER-
positive luminal breast cancers. Both GATA3 and FOXA1 are oestrogen-regulated genes, and 
both are essential co-factors for oestrogen-mediated cell-cycle progression (174, 176). As 
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FOXA1 may also be a downstream effector of GATA-3, it may be a bridge between GATA-3 
and ER pathways (173), controlling and regulating the biology of luminal mammary cells, 
breast cancer progression and behaviour.  
 
1.5.1.3 - CCAAT/Enhancer-Binding Proteins (C/EBP) 
CCAAT/enhancer binding proteins (C/EBPs) are a family of leucine zipper transcription 
factors, that bind as homodimers and heterodimers to sequence-specific regions in order to 
regulate gene transcription. The C/EBP family members have important roles in the control 
of cellular proliferation, differentiation and apoptosis, metabolism, survival, inflammation 
and transformation, oncogene-induced senescence and tumorigenesis (177-180). These 
transcription factors contain an amino-terminal transactivation domain and a basic DNA-
binding region, immediately adjacent to the highly conserved carboxyl-terminal leucine-rich 
dimerization domain. C/EBPs must dimerize to bind DNA and dimerization can occur within 
a C/EBP family, between different C/EBP family members, between different groups of 
leucine zipper proteins (180), or even with other transcription factors of the AP-1, NFB and 
RB families (181). Therefore, due to this flexibility to form different dimers and also due to 
the type of post-translational modification, the transactivation potential of each C/EBP 
isoform can be quite different, resulting in a myriad of regulatory effects on gene expression 
(182).  
In breast, C/EBPs play a pivotal role in controlling growth and differentiation of the 
mammary gland and, among the six C/EBP genes identified so far C/EBP - - - - -
the encoded intron-less genes C/EBP C/EBP and C/EBP are the most thoroughly 
studied in rodent and human mammary tissue, since they are temporally expressed to 
coordinately control mammary growth, differentiation and programmed cell death (180). In 
terms of function in mammary gland, C/EBP and -protein levels are thought to be more 
related with differentiation and development. Experimental data have shown that 
C/EBPproteins repress proliferation and induce differentiation in epithelial cells (183). 
Moreover, it was found that this protein isoform is expressed in high levels during lactation 
and at lower levels during involution in the rat mammary gland. C/EBP protein expression 
levels are similarly low in the involuted gland, but high expression has been observed during 
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pregnancy and on late lactation (180). In contrast, C/EBP is detected in whole cell extracts 
of the virgin gland and readily detectable throughout lactation and involution, revealing a 
more complex and function-related role in breast, other than differentiation and 
development. In fact, C/EBP can be translated into several distinct protein isoforms, whose 
expression is regulated by the alternative use of several in frame translation start sites. This 
leads with distinct biological and regulatory functions, since it modulates the binding affinity 
to bind to DNA and thus to transactivate gene expression (182). For example, the longer 
C/EBP proteins, which arise from usage of the first two AUG codons (liver-enriched 
transcriptional activating proteins, LAP) support proliferation and repress differentiation of 
many cell types (184); however, the shorter protein product, which arises by usage of the 
third start codon or by post-translational proteolytic cleavage (liver-enriched transcriptional 
inhibitory protein, LIP), lacks the transactivation domain and acts as a dominant-negative 
repressor in experimental systems (185). Nevertheless, LIP isoforms bind to the consensus 
sequences within the DNA, with higher affinity than other C/EBP proteins (184-185). LAP1 
and LAP2, both with N-terminal activation domain, are transcriptional activators and are 
associated with differentiation, being the shorter LAP1 isoform a weaker activator than 
LAP2, which is able to transactivate important genes, such as cyclin D1 promoter (186). 
However, these two isoforms seem to have unique actions and that in specific cellular 
context the LAP1:LAP2 ratio may be important for regulation of gene expression (182). In 
contrast with the LAP isoforms, LIP can function to inhibit the transcriptional activity of 
other C/EBPs, by competing for C/EBP consensus binding sites or by forming inactive 
heterodimers with other C/EBPs, as a dominant negative. However, emerging evidence 
suggest that LIP can act as a transcriptional activator in some cellular contexts; then, the 
mechanism might include the interactions of LIP with other, non-C/EBP transcription 
factors, such as glucocorticoid receptor, NF-B or PgR (182). Unlike C/EBP, C/EBP most 
likely contributes to tumorigenesis through significant elevations in the LIP:LAP ratio, mostly 
observed in ER-negative, aneuploid, highly proliferative and metastatic mammary tumours 
that are associated with a poor prognosis (181). An increase in the LIP:LAP ratio has also 
been linked to a TGF-dependent cytostatic response in metastatic breast cancer cells. 
Interestingly, forced expression of LAP2 in cells expressing elevated LIP, through a 
mechanism which involves the association with FOXOs and consequent repression of Myc, 
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restored the TGF cytostatic response and lead to a significant reduction in the proliferative 
activity of metastatic cells (187). LIP isoform overexpression also leads to a lack of contact 
inhibition, resulting in proliferation and foci formation in epithelial breast cancer cell lines 
(188). Importantly, LIP expression is restricted to the mammary tumours and is not detected 
in preneoplastic lesions, and evaluation of its expression has been suggested as a prognostic 
marker for patients with breast cancer (189-190). The importance of C/EBPs in breast cancer 
is still highlighted by their interaction with receptor tyrosine kinases. In general, EGFR 
signalling leads to increased C/EBP-LIP protein expression, resulting in an increased LIP/LAP 
ratio, which contribute to the mitogenic effects of ErbB signalling by promoting proliferation 
and a more aggressive disease state (191).  
 
1.5.2 - Epigenetics 
Cancer is an epigenetic disease at the same level that it can be considered a genetic 
disease (106). The key mechanisms that underlie target gene activation and repression by 
modulating the accessibility of transcriptional activation complexes to target gene loci are 
the chromatin and nucleossomal remodeling and DNA methylation (173). These epigenetic 
processes, which occur at the chromosomal level in transformed cells, mutually interact 
with each other, in order to modulate the chromatin structure to form euchromatin or 
heterochromatin and, in turn, activate or silence gene expression (192). Alterations in the 
expression of key genes through aberrant epigenetic regulation lead to initiation, promotion 
and maintenance of carcinogenesis, and is even implicated in the generation of drug 
resistance (192-195). Changes in DNA methylation include global hypomethylation and focal 
hypermethylation. Global hypomethylation is linked to genomic instability and activation of 
oncogene expression (196). By contrast, gene-locus-specific hypermethylation can lead to 
the transcriptional silencing of tumour suppressor genes (193-194, 197). In addition to DNA 
methylation, post-translational histone modifications are another epigenetically regulated 
mechanism that can modulate chromatin structure to control gene expression (193, 195, 
198). DNA methylation can, however, be associated with some specific types of histones 
modifications that can cooperatively affect chromatin structure to silence gene expression 
(195, 199) (Figure 9). 
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Figure 9. Epigenetic mechanisms. There are two primary and interconnected epigenetic mechanisms - DNA methylation 
and covalent modification of histones. (A) Schematic of epigenetic modifications. Strands of DNA are wrapped around 
histone octamers, forming nucleosomes, which are organized into chromatin, the building block of the chromosome. 
Reversible and site-specific histone modifications occur at multiple sites through acetylation, methylation and 
phosphorylation. DNA methylation occurs at 5-position of cytosine residues, in a reaction catalyzed by DNA 
methyltransferases (DNMTs). Together, these modifications provide a unique epigenetic signature that regulates 
chromatin organization and gene expression. (B) Schematic of the reversible changes in chromatin organization that 
influence gene expression: genes are expressed (switched on) when the chromatin is open (active), and they are 
inactivated (switched off) when the chromatin is condensed (silent). White circles = unmethylated cytosines; red circles = 
methylated cytosines [Adapted from Collaborative Research Centre, Münster University]. 
 
It was already demonstrated that epigenetic changes are one of the main driving 
mechanisms leading to breast cancer and that both hypermethylation and specific histone 
modifications events are essential in maintaining transcriptionally repressive chromatin by 
forming suppressive complexes at the DNA level (200). Moreover, it was recently described 
significant changes in histone modification levels in the course of tumour progression from 
normal breast epithelium to in situ and invasive ductal carcinoma (201), reinforcing the 
importance of epigenetic mechanisms in breast carcinogenesis. 
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1.5.2.1 – DNA Methylation 
 DNA methylation is a heritable epigenetic change, that alters gene expression and 
results from the activity of a family of DNA methyltransferase (DNMT) enzymes, which 
catalyse the addition of a methyl group to cytosine residues at CpG dinucleotide (adjacent 
cytosine and guanine nucleotides in DNA) (192, 202). The distribution of CpG dinucleotides 
is not random, and some of them cluster together to form CpG-rich DNA regions called CpG 
islands, normally located in the upstream promoter and exon 1 region (203). CpG-island-
containing gene promoters are usually unmethylated in normal cells to maintain 
euchromatic structure, which is the transcriptionally active chromatin conformation, 
allowing gene expression. However, during cancer development, hypermethylation at CpG-
island-containing gene promoters occur in order to inactivate gene transcription, by 
changing open euchromatic structure to compact heterochromatic structure (193, 195, 197, 
199). Hypermethylated genes identified from breast neoplasms form a long list, and their 
biological functions encompass cell cycle regulation (p16INK4A, p14ARF, 14-3-3, cyclin D2, 
p57KIP2), apoptosis (APC, HOXA5), DNA repair (GSTP1, MGMT, BRCA1), hormone receptors 
(ER and PgR), cell adhesion (CDH1, APC, TIMP3), angiogenesis (maspin) and cellular 
growth-inhibitory signalling (RARII, TGFII, SOCS1, WIF1) (192). Besides hypermethylation 
of gene-associated CpG islands, hypomethylation of repetitive genomic DNA has also been 
identified as a specific feature in breast cancers (196, 204). Although less well studied, 
several lines of investigation indicate that the global hypomethylation indentified in cancer 
cells might contribute to structural changes in chromosomes, aberrant activation of proto-
oncogenes expression and increased mutagenesis (197, 204-206). Genomic 
hypomethylation in breast cancer genes has been known to correlate with some clinical 
features, such as disease stage, tumour size and histological grade (207), as it is the case of 
CDH3 gene (208) (see PAPER I in Appendix section). Some proto-oncogenes, implicated in 
proliferation and metastasis (e.g., N-cadherin, ID4, annexin A4, -catenin and WNT11 
genes), have been found to be upregulated in breast cancer through the hypomethylation of 
their promoters (209-210) . 
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1.5.2.2 - Acetylation and Chromatin Remodelling 
The condensation of eukaryotic DNA in arrays of nucleossomes, folded into higher-
order chromatin fibres, influences several aspects of DNA metabolism (211). Knowledge of 
how chromatin structure is organized and maintained is crucial to understand the origins of 
epigenetic alterations in cancer. The basic building block of chromatin - the nucleossome, is 
formed by an octamer of histone proteins, namely H1, H2A, H2B, H3 and H4 (192). Histone 
N-terminal tails, protruding from the nucleossomes, are subject to a variety of covalent 
modifications in a dynamic and reversible manner (212). These modifications include 
acetylation, methylation, phosphorylation, ubiquitylation and sumoylation, which are 
critically implicated in the regulation of chromatin structure and gene expression. Each 
histone modification is a unique mark to show the status of chromatin structure (active or 
repressive), defining the accessibility of the DNA to the transcription machinery (192, 213). 
Acetylation of histone lysines, the best characterized modification of chromatin structure 
(214), has been known to be associated with open chromatin structure and active 
transcription; methylation of these residues is associated with either active or repressive 
states of chromatin architecture and transcription is dependent on the modified site (198, 
215).  Thus, the promoters of transcription-active genes are associated with active histone 
marks, such as acetylation at lysine 9 (K9) of H3 as well as K5, K8, K12 and K16 of H4 and 
methylation at K4 of H3 (H3K4me), which are involved in a loosening of chromatin structure 
(euchromatic state) (195, 215). In contrast, repressive histone marks, including mono-, di- 
and tri-methylation of histone H3 lysine 9 (H3K9), H3K27 and H4K20, that are implicated in 
initiating and maintaining closed chromatin structure (heterochromatic state) (193, 198, 
204). Bidirectional enzymatic machineries modify chromatin and the dynamics of histone 
acetylation is balanced by the action of histone acetyltransferases (HATs) and histone 
deacetylases (HDACs), while histone methylation is done by histone methyltransferases 
(HMTs) and histone demethylases. Some of these histone modification enzymes have been 
recognized as components of nucleossomal remodelling complexes, which work together to 
regulate chromatin structure and gene expression (195, 198, 216-217).  
Acetylation of lysine residues in histone tails by HATs decreases electrostatic 
interactions between the negatively charged DNA and the basic lysine residues, resulting in 
decondensation of chromatin and enhanced transcription, presumably due to the increased 
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accessibility of nucleossomal DNA to transcription factors (214, 218). Importantly, HATs 
cannot bind to target gene promoters directly but are recruited by DNA-bound transcription 
factors (214). Concerning HDACs, their action is to restore a positive charge to lysine 
residues in the amino tail of histones, leading to the compaction of chromatin, which is 
refractory to transcription (219). The 18 human HDACs known are subdivided in classes, 
where the class I HDACs (HDAC-1, -2, -3 and -8) are generally localized in the nucleus and 
associate with various transcriptional corepressors (e.g. NCoR, SMRT or Sin3A) and cofactors 
to form protein complexes (220-221). In addition to histones, many non-histone proteins 
have been identified to be substrates of HDACs, such as proteins involved in transcription 
(p53, E2F1, STAT1, STAT3, GATA1 and NF-B), hormone receptors (AR and ER), cytoskeletal 
structure (-tubulin), WNT signalling (-catenin) and heat shock/chaperon response 
proteins (HSP90) (222-225). In fact, this broad spectrum of HDAC substrates reveal the 
complexity of HDAC functions to regulate gene expression (192). 
But, while histone lysine acetylation alters directly the chromatin structure by charge 
ablation, other histone modifications present binding sites for effector proteins tethering to 
histone marks in a modification and context-specific fashion to generate chromatin changes 
(226). Histone lysine methylation has received lot of interest, as it marks both active and 
inactive chromatin, playing a key role in regulation of transcription. So far, histone 
methylation is the major mark for recruitment of chromatin modifying machineries (212, 
226). The dimethyl- and trimethyl-H3K4 modifications, highly conserved epigenetic marks 
associated with actively transcribed loci and euchromatin (active modification marks) (227), 
have been reported to be catalyzed by the Trithorax group of HMTs (e.g. SET1) (228), a 
know group of effectors that have long been implicated in the transcriptional activation of 
developmental regulatory genes and whose actions are balanced by the opposing effects of 
the Polycomb group (PcG) factors (229). In breast cancer, global histone modification 
analysis has revealed histone modification profiles that have been correlated with 
prognosis. As an example, while H4K16 acetylation is generally reduced or absent, 
suggesting that this alteration may represent an early event of breast cancer, moderate to 
low levels of lysine methylation (H3K4me2 and H3K4me3) has been associated with breast 
carcinomas of poorer prognosis (230).  
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Much of the research efforts to date have concentrated on the identification of 
epigenetic altered genes implicated in breast tumorigenesis. Since ER is a central gene in 
breast development and function, but also in breast carcinogenesis, this gene has been the 
target of multiple studies concerning its regulation and its potential in the epigenetic 
setting. Some of these studies have been shown that abnormal exposure to oestrogen or 
oestrogenic chemicals induces epigenetic alterations in breast progenitor cells, which have 
been previously implicated in breast cancer (192, 231). Although aberrant activation of 
oestrogen signalling can lead to tumour-associated alterations in the epigenome of breast 
progenitor cells, approximately 30% of diagnosed breast cancer cases lack oestrogen 
signalling due to loss or downregulation of ER, also subject to epigenetic silencing (232). 
How ER-negative breast cancer cells acquire more aggressive properties after loss of 
oestrogen signalling is a very important issue in the field of breast cancer research. A robust 
link between ER signalling and acetylation and chromatin remodelling is given by the study 
of Leu et al., where ER signalling abrogation by small-interfering RNA-mediated knock 
down resulted in epigenetic inactivation of ER targets, which initiate by the recruitment of 
PcG repressors and HDACs to their promoters, and then progressively followed by DNA 
methylation (233). Their results suggest that epigenetic regulation of ER target genes is 
required for establishing ER-independent growth and other characteristics of ER-negative 
breast cancer cells. Many other genes, involved in breast carcinogenesis, are targets or 
important actors of chromatin remodelling processes. The breast cancer susceptibility gene 
BRCA1 displayed hypoacetylated and condensed chromatin in its proximal promoter region 
in hereditary breast cancer and chromatin remodelling is a common element for this 
multifunctional protein in processes such as DNA repair, DNA replication and transcription. 
BRCA1 interacts with components of several chromatin remodelling complexes, making this 
gene both a participant in, and a target of, epigenetic regulation in breast cancer (234). Also 
the function of BRCA2 has been linked to the presence of HAT activity (235). In several 
studies, the cyclin-dependent kinase inhibitor p21WAF/CIP is found to be up-regulated after 
treatment of breast cancer cell lines with HDAC inhibitors, resulting from histone 
hyperacetylation specifically associated with Sp1 sites (236-237). Similarly, the actin 
filament-binding protein gelsolin is upregulated by the treatment with HDAC inhibitors and 
this epigenetic induction of p21 and gelsolin lead with reduced proliferation and cell cycle 
1. General Introduction 
39 
arrest and with alterations in cell morphology (238), respectively. Finally, the c-myc 
oncogene, which is amplified and overexpressed in some human breast cancers, is 
transcriptionally regulated by modulation of chromatin structure at its locus (239). 
Recent advances in genome-scale technologies aimed at revealing epigenetic 
alterations in breast cancer, and the current progress in translating this profiling knowledge 
has contributed to diagnosis, prognosis (192) and to new promising anticancer drugs as 
epigenome-modulating agents (214). In fact, several in vitro studies have reported that 
HDAC inhibitors are able to inhibit proliferation of breast cancer cells, regulate ER 
expression and activity, increase the anti-proliferative activity of anti-oestrogens in ER 
breast cancer cell lines and restore this activity in ER-negative or anti-oestrogen resistant 
cells (240-241). 
 
1.6 - CADHERINS 
Epithelial cell-cell junctions provide tissue integrity and promote cell polarity (242). 
The junctional complex comprises tight junctions, adherens junctions and desmossomes 
(243). The adherens junctions play a pivotal role in regulating the activity of the entire 
junctional complex, and the major adhesion molecules in the adherens junctions are the 
cadherins (243-244). The so called classical cadherins, such as E-cadherin, N-cadherin and P-
cadherin, are the best characterized subgroup of adhesion proteins (245). They are the 
transmembrane component of the adherens junction and are composed by three domains: 
1) an extracellular domain responsible for homotypic cadherin-cadherin interaction which 
mediate calcium-dependent cell-cell adhesion, 2) a single pass transmembrane domain, and 
3) a highly conserved cytoplasmatic domain that, through intracellular catenins, is linked to 
actin filaments and thus serves to connect the cell surface to the cytoskeleton (246). The 
cadherin-catenin complexes constitute the main building block of the adherens junctions, 
which are assembled by direct binding between extracellular domains of cadherins (247). 
The cytoplasmatic domain of cadherins interacts with p120-catenin and -catenins, the 
former, playing an important role in the delivery and retention of cadherins at the adherens 
junctions, and the last providing a connection to -catenin, which is required for the actin-
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dependent clustering of cadherin-catenin complexes to form the adherens junctions (248) 
(Figure 10).  
 
 
 
Figure 10. Schematic representation of the classical cadherin-catenin complex. Classical cadherins (blue), which mediate 
calcium-dependent (red) intercellular adhesion, are composed by an extracellular domain, a transmembrane domain and a 
cytoplasmic domain. This last domain comprises a juxtamembrane domain (JMD), which binds p120-catenin (violet), and a 
catenin-binding domain (CBD), which binds β-catenin (green), which in turns binds α-catenin (orange). Both α-catenin, α-
actinin (grey) and vinculin (pink) establish a direct link between the cadherin-catenin complex and the actin cytoskeleton 
(yellow) [Adapted from Paredes J et al., 2007 (249)]. 
 
It has been demonstrated that these cadherin-catenin complexes are not only the 
structural elements stabilizing adhesive contacts, but also the important signalling centres 
that may function as biosensors of the external cellular microenvironment (250). Because of 
the importance of cadherins to cell recognition, adhesion and signalling, disruption of 
cadherin function has significant implications for the development and behaviour of 
tumours (246). In fact, maintenance of normal epithelial cellular architecture is frequently 
altered in tumour progression. In a multistep process, termed EMT, tumour cells 
progressively downregulate their normal cell–cell adhesion epithelial-specific proteins, such 
as E-cadherin, and express de novo mesenchymal adhesion molecules, such as N-cadherin 
(251). This cadherin switch leads to the inhibition of cell–cell contacts and elicits active 
signals, which support tumour cell migration, invasion and metastatic dissemination (252).  
 
1.6.1. CDH3/P-Cadherin in Breast Cancer 
The vast majority of the studies implicating cadherins in tumorigenesis and invasion 
have focused on E-cadherin, since this is the major cadherin involved in epithelial adherent 
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junctions, and most importantly, many epithelium-derived cancer cells have loose E-
cadherin expression. The adherens junctions function to maintain the normal phenotype of 
epithelial cells and is responsible for the strong cell-cell adhesion that promotes epithelial 
polarity and prevents epithelial cells from migrating away from their appropriate location 
(246). During embryogenesis, the critical importance of E-cadherin to normal development 
and tissue function is demonstrated by the lethality of E-cadherin gene knockout in mice in 
the very early stages (253). Extensively studied over the last years, the gene encoding E-
cadherin (CDH1) was one of the first to be considered as an invasion suppressor gene (252, 
254-255) and this notion was strongly supported by immunohistochemical changes in E-
cadherin expression and location in several types of human cancers (256-258). A common 
finding was a positive correlation between disturbance of E-cadherin function/expression 
and decreased differentiation and higher aggressiveness of the tumours (259).  
In normal breast tissue, E-cadherin is expressed by the luminal epithelial cells and is 
found concentrated at cell-cell borders. As is the case of other carcinomas, breast cancer 
cells can exhibit reduced or missing E-cadherin expression or function (246), that could be 
attributed to multiple mechanisms, including complete or partial gene deletion, inactivation 
by promoter methylation, and chromatin rearrangements (260). In diffuse gastric cancers 
and lobular breast cancers, E-cadherin inactivation was associated with somatic point 
mutations of the CDH1 gene, as well as with LOH, promoter hypermethylation or 
overexpression of transcriptional repressors (261-262). However, in some epithelial 
tumours, E-cadherin is not lost, and is expressed concomitantly with other cadherin, such as 
P-cadherin. Interestingly, invasive breast carcinomas co-expressing E- and P-cadherin show a 
worse patient survival when compared to carcinomas with loss of E-cadherin expression 
(263).  
P-cadherin (or placental cadherin) was the third classical cadherin to be indentified 
and its encoding gene is identified as CDH3. Although far less well characterized than is 
CDH1, they share 66% of gene homology. Particularly, the sequence of the upstream 5’ 
region of the P-cadherin gene exhibits structural similarities to the 5’ region of the CDH1 
gene.  CDH3 is currently annotated to chromosome 16q22.1, a region that comprises a 
cluster of several cadherin genes, just 32 kb upstream of the gene encoding the human E-
cadherin (264-266). Briefly characterizing CDH3 gene structure, the TSS of CDH3 is currently 
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annotated to the coordinate 68,678,739 bp on the forward strand and the ATG is found 553 
bp downstream of the TSS. The P-cadherin promoter exhibits no TATA-box, while including a 
CAAT-box, two E-boxes, two putative AP2-binding motifs and a GC-rich region containing 
putative SP1-binding sites. Similarly to CDH1, an AluJb repeat is found ~700 bp upstream of 
the ATG putatively enclosing gene regulation or exonization features (266).  
Mutations in the CDH3 gene have been reported to be responsible for congenital 
hypotrichosis associated with juvenile macular dystrophy, a rare autosomal-recessive 
disorder characterized by abnormal growth of scalp hair, followed by progressive macular 
retinal degeneration that leads to early blindness (267). P-cadherin is transiently expressed 
in various tissues during development and its expression is limited to adult tissues at cell-cell 
boundaries. Unlike E-cadherin, which is broadly distributed in all epithelial tissues, P-
cadherin exhibits a singular pattern of expression, co-localizing partially with E-cadherin and 
being restricted to the basal proliferative cell layer of the majority of stratified epithelia. 
Additionally, it has been proposed that its expression is correlated with undifferentiation 
and proliferation status in these type of tissues (268-270) and that its expression is crucial 
for orderly progression of terminal differentiation of the epidermis (270). In mammary 
gland, P-cadherin-mediated adhesion or signals derived from its cell-cell interaction are 
important determinants of mammary gland growth control (271). Moreover, in normal adult 
non-lactating tissue, spatially selective expression of E-cadherin, which is expressed by both 
luminal and myoepithelial cells, and P-cadherin, restrictedly found in myoepithelial and cap 
cells, appears to be crucial for mammary gland differentiation (272). P-cadherin protein is 
still expressed in the lactating mammary gland tissue, and high levels of an 80kDa soluble P-
cadherin in human milk have been found, raising the suggestion that this protein may be a 
secreted protein rather than an adhesion protein (273). 
P-cadherin mutations are infrequent in human tumours; however, P-cadherin has 
been shown to be overexpressed in several solid tumours, including breast (90-91, 208, 249, 
263, 272, 274-275), ovarian (276), endometrial (277), prostate (278), colon, gastric (279), 
pancreatic and bladder cancer (280). In contrast with what has been observed for E-
cadherin, P-cadherin is frequently upregulated in tumours. Additionally, P-cadherin was 
shown to have a role in promoting cell migration in several cancer models. Taniuchi et al. 
showed that a pancreatic cancer cell line, transfected with wild-type P-cadherin, migrated 
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faster than the cells without this molecule (281). In breast cancer model, we have shown 
that P-cadherin overexpression by breast cancer cells promotes their invasive and migratory 
capacity (249, 282-283) (see PAPERS II and VI in Appendix section). Additionally, the 
expression of this protein induces the secretion of MMPs, which will be responsible by the 
cleavage of its extracellular domain, giving rise to a soluble 80 kDa form of P-cadherin (sP-
cad). Overexpression of exogenous P-cadherin is able to promote single cell motility, 
inducing an increase in the number of moving cells and speed when compared with cells 
with low levels of this protein. We proved that this fragment is a pro-invasive factor, which 
needs to be inhibited in order to render cancer cells non-invasive (283). Moreover, P-
cadherin is able to induce phenotypic changes involving alterations in cell polarity and 
leading edge morphology, formation of membrane protrusions, as well as increase of their 
cytoplasmic area, which usually is characteristic from cells with a motile behavior. Indeed, P-
cadherin-overexpressing cells not only showed increased single cell motility, but also 
increased directional cell migration, as well as, invasion capacity through the matrigel (283) 
(see PAPER VI in Appendix section).  
 
1.6.1.1 - Diagnostic and Prognostic Relevance 
In human breast cancer, P-cadherin has been found to be aberrantly expressed in a 
subset of carcinomas. Based on microarray technology, this molecule is essentially 
expressed in those breast lesions termed basal-like carcinomas (27), which are characterized 
by their negativity for ER, PgR and HER2 (triple-negative) and by their association with poor 
prognosis (284). With the development of P-cadherin monoclonal antibodies, it was 
demonstrated that P-cadherin is expressed in around 30%-50% of invasive ductal 
carcinomas of the breast, being however infrequent in lobular carcinomas, where the loss of 
E-cadherin is the major hallmark (275). We and others have reported that the membranous 
P-cadherin expression is strongly associated with proliferative lesions of high histological 
grade, decreased cell polarity, poor patient survival over short-term follow up and lower 
disease-free survival (249, 272, 274-275, 285-286) (see PAPERS I and II in Appendix section). 
Besides the association of P-cadherin expression with hormonal-negative phenotype of 
breast cancer, the expression of this protein also associates with the expression of EGFR, 
p53 expression, high proliferative rates (MIB-1), high mitotic index and decreased cell 
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differentiation (208, 272, 275, 285); altogether being biological conditions strongly 
associated with malignant behaviour and poor outcome for breast cancer patients. 
However, P-cadherin expression has been shown to be not related with tumour size, lymph 
node metastasis and angiogenesis (208, 272, 275, 287-288). Interestingly, aberrant P-
cadherin expression identifies a subgroup of high-grade ductal carcinoma in situ, which lacks 
ER expression, has high proliferation rates and nuclear pleomorphism (274). Still, by 
immunohistochemistry, we have found that this protein, together with other well described 
basal markers, such as CK5 constitutes one of the most useful adjunctive markers for 
distinguishing the precursor basal-like lesions of DCIS (91). In addition, we still found that P-
cadherin antibody has a high sensitivity to identify invasive basal-like carcinomas, compared 
with the one demonstrated for the “gold-standard” pair CK5/EGFR (see PAPER VII in 
Appendix section). Overall, these findings largely contributed to recognize P-cadherin 
expression as a good indicator of poor prognosis in breast cancer patients (208, 249, 272, 
275, 286).  
 
1.6.2 - CDH3/P-Cadherin Regulation in Breast Cancer  
Signalling pathways or other cellular mechanisms that are involved in the regulation 
of cadherin-mediated adhesion are thought to underlie the dynamics of the adhesive 
interactions between cells (255, 289). Additionally, it is known that the expression of an 
inappropriate cadherin can result from growth factors and hormones stimulation in the 
tumour environment, as well as from changes in the promoter regions of cadherin encoding 
genes (246). However, although P-cadherin associated functions in breast cancer, as well as 
its role in the molecular pathology setting have been extensively studied, little is known 
about the signalling pathways and mechanisms involved in the regulation of P-cadherin 
expression in breast cancer cells.  
 
1.6.2.1 - P-Cadherin Transcriptional and Post-Translational Regulation 
Data concerning the CDH3 promoter regulation by transcription factors is still very 
limited. Recently, it was demonstrated that CDH3 gene is a direct transcriptional target of 
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p63 (290) and this evidence is supported by a study from Carrol et al., where it is suggested 
that p63 play an import role in the regulation of gene expression programs involved in cell 
adhesion (291). In addition, in a study using basal mammary epithelial cells, it was shown 
that -catenin is associated with CDH3 promoter and activates its expression independently 
of LEF/TCF in a cell-type specific-manner. Down-regulation of endogenous -catenin levels, 
by RNA interference technique, inhibited P-cadherin promoter activity. In vivo, in mammary 
gland and skin of mutant mice, activation of -catenin signalling correlates with up-
regulation of P-cadherin expression, suggesting that -catenin-dependent modulation of P-
cadherin expression can contribute to the establishment of the basal phenotype (292).  
In 2004, our group explored the link between ER signalling and the regulation of P-
cadherin expression in breast cancer cell lines, since we found that breast tumours positive 
for P-cadherin expression were essentially ER negative. Taking support in what was 
previously suggested by Gamallo and co-workers for invasive breast cancer, and by Soler 
and colleagues in prostate cancer, we postulated that P-cadherin could, in fact, be related to 
a phenotype that is insensitive to circulating hormones. Indeed, in our study, we showed 
that P-cadherin de novo expression was a result from a lack of ERα signalling, induced by the 
pure anti-oestrogen ICI and counteracted by E2 (282). In fact, cell lines treated with ICI 
showed a two to three-fold increase of P-cadherin mRNA and protein levels in a time and 
dose dependent manner (282). Importantly, these findings established that the lack of ER 
signalling is responsible for the increase in P-cadherin, categorizing CDH3 as a putative 
oestrogen-repressed gene. 
P-cadherin post-translational regulation mechanisms are largely unexplored. However, 
as it has been described for others classical cadherins (293), p120-catenin (p120ctn) has 
demonstrated a key role in P-cadherin control at protein level (294-295). Our group has 
shown that P-cadherin is unable to induce cancer cell invasion when its juxtamembrane 
domain (JMD) is not present or when p120ctn binding-domain is mutated, suggesting an 
important role for this catenin in the P-cadherin function (263). In fact, the JMD binding to 
p120ctn has been already implicated in the stable maintenance of endogenous cadherins 
(294-295). In a pancreatic cell model, Taniuchi et al. demonstrated that overexpression of P-
cadherin was strongly associated with cytoplasmic accumulation of p120ctn and cadherin 
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switching (N-cadherin to P-cadherin) in pancreatic cancer cells (PDAC cells), suggesting that 
alteration of p120ctn cell distribution may be due to its binding strength, conformation or 
different affinity for each classical cadherin. In this model, cytoplasmic p120ctn was able to 
activate Rho-family GTPases, Rac1 and Cdc42, promoting cell migration and motility (281). 
In accordance to this, very recently was confirmed by us that P-cadherin-/E-cadherin+ breast 
carcinomas generally maintain p120ctn expression at the membrane, while tumours 
expressing P-cadherin exhibit cytoplasmic p120ctn immunostaining, especially those also co-
expressing E-cadherin. Thus, the assumption that the P-cadherin-induced invasion is 
achieved as a result of competition for p120ctn, through destabilization of anti-invasive 
cadherin/catenin complexes has been considered (263). Alternatively, P-cadherin could 
simply generate a specific pro-invasive signal via its JMD, possibly with the recruitment of 
other protein binding to P-cadherin, resulting in the activation of pathways that overcome 
the suppressive signals mediated by endogenous cadherins (263). It is interesting to 
highlight, that, in a clinical setting, a poor prognosis in breast cancer patients was found to 
be associated with the cytoplasmic accumulation of p120-catenin and co-expression of P- 
and E-cadherin (263).  
 
1.6.2.2 - CDH3/P-Cadherin Epigenetic Modulation 
Changes in the promoter regions of cadherin encoding genes can trigger abnormal 
expression of these important adhesion molecules, some of them associated with cancer. A 
classic example is the silenced expression of E-cadherin in gastric diffuse cancer and as well 
as in lobular carcinoma of the breast, which in both cases, is due to changes in DNA 
methylation or chromatin acetylation events at CDH1 gene (246).  
The epigenetic deregulation of P-cadherin was recently demonstrated in other cancer 
models. Sato et al. identified CDH3 gene promoter to be aberrantly methylated in 20% of 
pancreatic cancers, but not in normal pancreatic epithelia, which displayed an unmethylated 
promoter pattern (296). Similar results were obtained in prostate cancer cell lines, although 
without finding an association between loss of expression of P-cadherin with promoter 
methylation status of CDH3 in vivo (297). In another study, although conducted restrictedly 
in cell lines, evidences showed that P-cadherin gene seems to be silenced by methylation in 
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melanoma cells (298). CDH3 was also shown to be epigenetically deregulated in colorectal 
cancer; however, in contrast with the pancreatic model, the CDH3 promoter was found 
hypomethylated in colonic aberrant crypt foci, in colorectal cancer, and, occasionally, in the 
normal epithelium adjacent to cancer. This hypomethylation pattern was also associated 
with the induction of P-cadherin expression in the neoplastic colon. Additionally, the 
epigenetic demethylation of the P-cadherin promoter in the human intestine permits its 
ectopic expression very early in the colorectal adenoma-carcinoma sequence and persists 
during invasive cancer (299). Similarly, demethylation of the CDH3 gene was recently 
detected in 25 out of the 36 (69%) primary gastric carcinomas and was significantly 
associated with increasing TNM stage (p=0.0261), suggesting that the aberrant 
demethylation of CDH3 is also a frequent event in gastric carcinomas (300). Very recently, a 
study using in a large series of gastric tumours, showed that there is a correlation between 
P-cadherin expression and CDH3 promoter hypomethylation, and also that in nonneoplastic 
gastric mucosa P-cadherin expression was silenced. Additionally, they also demonstrated 
the existence of a prognostic value for the methylation pattern of CDH3 promoter in gastric 
tumours (301). 
In breast cancer, a complete lack of data concerning CDH3 promoter methylation 
pattern was observed until 2005, when we published a study where we evaluated the P-
cadherin promoter methylation as the putative molecular mechanism underlying the 
overexpression of P-cadherin in a subset of highly aggressive breast carcinomas (208) (see 
PAPER I in Appendix section). As a previous approach, and in order to assess if CDH3 
promoter would be prone to be regulated by methylation, breast cancer cell lines displaying 
low levels of P-cadherin were treated with 5-Aza-2’-deoxycytidine demethylating agent (5-
Aza-dC) and increased P-cadherin mRNA and protein expression levels were observed in 
comparison with the untreated control cells. Additionally, P-cadherin promoter methylation 
was analyzed in five cases of normal breast tissue, from which only epithelial cells were 
microdissected. In these, methylation of P-cadherin gene was found in all the cases 
analyzed, because none of the samples showed the presence of unmethylated alleles. 
Indeed, these results were highly correlated with P-cadherin expression because normal 
breast epithelial cells are negative for this protein. Conversely, in a large series of invasive 
breast carcinoma samples, methylation of P-cadherin gene was found in 58% and when 
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these results were correlated with P-cadherin expression, a statistically significant 
association was found between these variables: 71% of P-cadherin-negative cases were 
methylated, whereas 65% of positive cases were unmethylated. These results established 
for the first time the existence of a significant correlation between P-cadherin 
overexpression and hypomethylation of a specific region of CDH3 gene promoter, 
suggesting an important regulatory role for cytosine methylation in the aberrant expression 
of P-cadherin in breast cancer (208) (see PAPER I in Appendix section).  
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Abstract
Introduction The expression of additional genes, other than
oestrogen receptor (ER), may be important to the hormone-
responsive phenotype of breast cancer. Microarray analyses
have revealed that forkhead box A1 (FOXA1) and GATA binding
protein 3 (GATA-3) are expressed in close association with
ERα, both encoding for transcription factors with a potential
involvement in the ERα-mediated action in breast cancer. The
purpose of this study was to explore if the expression of FOXA1
and GATA-3 may provide an opportunity to stratify subsets of
patients that could have better outcome, among the ERα-
negative/poor prognosis breast cancer group.
Methods We evaluate FOXA1 and GATA-3 expression in 249
breast carcinomas by immunohistochemistry, associating it with
breast cancer molecular markers, clinicopathological features
and patient's survival. The clinicopathological features and
immunohistochemical markers of the tumours were compared
using the chi-square test and ANOVA. Disease-free survival was
analysed through Kaplan–Meier survival curves and Cox
regression.
Results FOXA1 expression was demonstrated in 42% of
invasive carcinomas, while GATA-3 was detected in 48% of the
cases. FOXA1 expression was inversely associated with tumour
size, Nottingham Prognostic Index, histological grade, lymph
vascular invasion, lymph node stage and human epidermal
growth factor receptor-2 (HER-2) overexpression, while GATA-
3 expression showed inverse association with histological grade
and HER-2. Both FOXA1 and GATA-3 were directly associated
with ERα and progesterone receptor. Among FOXA1-positive
tumours, 83.1% are comprised in the luminal A subtype, similar
to GATA-3 where 87.7% of positive tumours were classified
within this molecular subtype. In the subset of ERα-negative
patients, those who were FOXA1-negative had a 3.61-fold
increased risk of breast cancer recurrence when compared with
the FOXA1-positive.
Conclusions FOXA1 was a significant predictor of good
outcome in breast cancer, whereas GATA-3 was an important
luminal marker. The expression of FOXA1 may be used for risk
stratification among ERα-negative patients.
CK: cytokeratin; EGFR: epidermal growth factor receptor; ER: oestrogen receptor; FOXA-1: forkhead box A1; GATA-3: GATA binding protein 3; 
HER-2: human epidermal growth factor receptor 2; PBS: phosphate-buffered saline; P-cadherin: placental cadherin; PR: progesterone receptor.
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Introduction
The expression of oestrogen receptor (ER) is an important
prognostic and predictive factor in breast cancer and has rel-
evant implications for the biology of this type of carcinomas.
Patients with tumours that express ER have a longer disease-
free interval and overall survival than patients with tumours
lacking ER expression [1].
According to international treatment guidelines for early breast
cancer, patients with ERα and/or progesterone receptor (PR)
expression should receive an adjuvant endocrine therapy,
since their expression is associated with higher response rates
to anti-hormonal treatment [2]. However, the association
between ERα expression and hormonal responsiveness is far
from perfect, since approximately 30% of ER-positive tumours
do not respond to hormonal treatment and 5 to 15% of ER-
negative tumours curiously respond to endocrine therapy [3].
In order to overcome and explore this unpredictable breast
tumour behaviour, numerous studies, based on cDNA micro-
arrays, have shown that the gene expression profile in breast
cancer can provide molecular phenotypes that identify distinct
tumour subclasses [4-6], patient survival prediction [5-7], and
differences in tumour biology or clinical features. The molecu-
lar classification of breast cancers distinguishes three major
subtypes: the ER-positive/luminal-like subtype, a gene expres-
sion cluster characteristic of the luminal cells and anchored by
a cluster of transcription factors that include ER; the basal-like
subtype, comprising tumours that express basal cell markers
(namely keratin 5, keratin 14, integrin β4 and laminin); and the
human epidermal growth factor receptor-2 (HER-2)-overex-
pressing subtype, usually associated with gene amplification
of the HER-2 proto-oncogene and high expression of several
genes in the ERBB2 amplicon at 17q22.24 [4,5,8]. These
studies have largely contributed to understanding the complex
behaviour of certain types of breast cancer, including the ones
that respond better to endocrine therapies, regardless of ER
expression.
Oestrogen plays an important role in the regulation of growth,
proliferation and differentiation of mammary epithelium. The
action of oestrogen is mediated through the ER, which func-
tions as an oestrogen-activated transcription factor. The
expression of an additional set of genes that is not part of the
canonical oestradiol-response pathway may also be essential
in clarifying the hormone-responsive phenotype, since intrinsic
differences in the list of transcription factors bound to the ER
gene promoter have been described [9].
Additionally, the distinct behaviour observed between ER-pos-
itive luminal subtypes A and B (a subgroup of tumours with low
to moderate expression of the luminal-specific genes including
the ER cluster) may in part be due to the influence of additional
factors, including transcriptional factors, co-activators and co-
repressors modulating ER activity [10], which can also be
explored towards a therapeutic purpose.
In 2004 Lacroix and Leclercq compiled considerable exten-
sive data describing the strong association and cross-talk
between ERα, forkhead box A1 (FOXA1) and GATA binding
protein 3 (GATA-3) [11]. In most of these studies, GATA-3
and FOXA1 have been highlighted within the ERα pathway in
the luminal A subtype [4-6,12]; FOXA1, a forkhead family tran-
scription factor, has been receiving considerable attention,
since it interacts with cis-regulatory regions of heterochroma-
tin, enhancing the interaction of ERα with DNA [13]. Carroll
and colleagues recently described several robust data demon-
strating the requirement of FOXA1 for optimal expression of
nearly 50% of ERα-regulated genes and oestrogen-induced
proliferation [13,14].
FOXA1 is expressed in the liver, pancreas, bladder, prostate,
colon and lung, as well as in the mammary gland, and can bind
to the promoters of more than 100 genes associated with met-
abolic processes, regulation of signalling pathways and cell
cycle [15-17]. Some studies have shown that FOXA1 can act
either as a growth stimulator/activator or as a repressor. As a
stimulator, FOXA1 binds to chromatinised DNA and opens the
chromatin, enhancing binding of ERα to its target genes [18]
– which suggests a growth-promoting role for this forkhead
protein [14,18]. In breast cancer, however, FOXA1 overex-
pression can also block the metastatic progression by influ-
encing the expression of the BRCA1-associated cell-cycle
inhibitor p27 and promoting E-cadherin expression [19,20].
Recent studies also suggest FOXA1 as a favourable prognos-
tic factor in breast cancer, with potential relevance in the sub-
classification of luminal/ER-positive tumours into two
subgroups with different biological behaviour and prognosis,
the luminal A and the luminal B [5].
FOXA1 and ERα have been explored as potential participants
involved in mammary tumours together with another gene,
GATA-3 [21,22], which regulates the lineage determination
and differentiation of many cells types. In the breast, GATA-3
plays a central role in luminal epithelia differentiation and the
subsequent formation of the ductal tree of differentiated epi-
thelial cells [23], suggesting that this protein might be involved
in breast tumorigenesis [24].
Meta-analysis of four microarray datasets indicated that
GATA-3 was a strong predictor of clinical outcome in breast
tumours and is among the best predictors of ER-positive sta-
tus [4,9,25-27]. Among all of the molecular subgroups of
breast cancer, the luminal A subtype has a relatively favourable
outcome and the highest GATA-3 and ERα expression levels,
compared with luminal B and basal-like breast carcinomas
[24].
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As a result of all of these extensive studies underlying GATA-
3 and ERα in mammary epithelia, it has been clear that GATA-
3 is a crucial regulator of tumour differentiation and suppres-
sor of tumour dissemination [22]. It has been also suggested
that these functions in mammary luminal cells may be linked by
transcriptional regulators, whereas FOXA1 appears as a can-
didate gene, which is necessary for the transcriptional activity
of ERα and its binding to oestrogen-responsive elements in
target gene promoters [13,18]. As FOXA1 may also be a
downstream effector of GATA-3, it may be a bridge between
GATA-3 and ER pathways [22], controlling and regulating the
biology of luminal mammary cells, breast cancer progression
and behaviour.
Based on this intricate and functional complex between
FOXA1 and GATA-3 in breast cancer biology, it is reasonable
to consider that these transcription factors, in addition to ERα,
are important in establishing and clarifying the hormone-
responsive phenotype and prognosis in breast cancer. This
gene set may therefore be used as a diagnostic tool for more
accurate determination of ERα status, in the decision on endo-
crine therapeutic strategies, as well as in the assessment of
breast cancer patient's outcome.
In the present study we provide an immunohistochemical
approach studying FOXA1 and GATA-3 expression, in order
to predict the tumour behaviour of breast cancer patients. In
the whole series, we verified that patients harbouring FOXA1-
positive tumours show a better disease-free survival. Interest-
ingly, and for the first time, we also found the same power of
risk stratification among the ERα-negative breast cancer
patients, demonstrating the clinical importance of this biomar-
ker in breast cancer molecular classification and prognosis.
These results show that FOXA1 and ERα should be used
together in order to subclassify breast carcinomas and to pre-
dict the outcome of breast cancer patients.
Materials and methods
Patient selection
A series of 249 cases of primary operable invasive breast car-
cinomas were retrieved from the files of the Department of
Pathology, Hospital do Divino Espírito Santo, Azores, Portugal
and from the Federal University of Santa Catarina, Florianopo-
lis – SC, Brazil. These samples were obtained from patients
with age ranging from 30 to 89 years. All of the formalin-fixed
paraffin-embedded histological sections were reviewed by
three pathologists (VC, FS and FM) and the diagnoses were
confirmed as follows: 208 invasive ductal carcinomas, seven
invasive lobular carcinomas, three mixed breast carcinomas,
three tubular breast carcinomas, eight medullary breast carci-
nomas and 20 invasive breast carcinomas of other special his-
tological types. These tumours have been fully characterized
for clinical and pathological features – namely, age, tumour
size, histological type, lymph nodes invasion, tumour grade,
Nottingham Prognostic Index, ERα, PR and HER-2 status. The
patients' clinical and pathological characteristics are summa-
rized in Table 1.
Follow-up information was available for 218 cases, ranging
from a minimum of 2 months to a maximum of 129 months
(median 32 months). The disease-free survival data interval
was evaluated and defined as the time from the date of surgery
to the date of breast-cancer-derived relapse/metastasis.
Owing to the short follow-up of the studied series and the con-
sequent limited number of death events, overall survival was
not analysed.
The present study was conducted under the national regula-
tive law for the usage of biological specimens from tumour
banks, where the samples are exclusively available for
research purposes in the case of retrospective studies.
Tissue microarray construction and 
immunohistochemical analysis
Representative areas of different lesions were carefully
selected on haematoxylin and eosin-stained sections and were
marked on individual paraffin blocks. Two tissue cores (2 mm
in diameter) were obtained from each selected specimen and
were precisely deposited into a recipient paraffin block using
a tissue microarray workstation (tissue microarray builder
ab1802; Abcam, Cambridge, UK) as described elsewhere
[28,29]. In each tissue microarray block, non-neoplastic breast
tissue cores were also included as controls.
Immunohistochemistry was performed in 3 μm formalin-fixed,
paraffin-embedded sections. Expression for the most com-
monly used breast cancer markers – namely, HER-2, ER, PR,
P-cadherin, epidermal growth factor receptor (EGFR), vimen-
tin and basal cytokeratins (CK5, CK14) – was assessed. The
immunohistochemistry technique was performed using an
Envision Detection System (DAKO Cytomation Envision Sys-
tem HRP; DAKO Corporation, Carpinteria, CA, USA) or the
classical streptavidin – avidin – biotin complex method
according to the manufacturer's instructions. Imunohisto-
chemistry assay conditions and antibodies specifications were
based on previously published studies from our group [28-30].
Immunoreactivity for ERα, PR, P-cadherin, CK5, CK14, EGFR,
vimentin and HER-2 was classified by estimating the percent-
age of tumour cells showing characteristic staining, in accord-
ance with previous work [28-30].
Expression of FOXA1 was analysed using a mouse mono-
clonal antibody (clone 2F83, ab40868; AbCam), as well as
GATA-3 expression (clone H-63-31, Sc-268; Santa Cruz Bio-
technology Inc., Santa Cruz, CA, USA). Sections were depar-
affinized with xylene and rehydrated in a series of decreasing
concentration of ethanol solutions. Heat-induced epitope
retrieval was carried out in 10 mM citrate buffer (sodium cit-
rate) (pH 6) or in 1 mM ethylenediamine tetraacetic acid buffer
(pH 8) (LabVision Corporation, Fremont, CA, USA), in a 98°C
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Table 1
Patient characteristics and tumour parameters
Variable Data
Age at diagnosis (years)
Mean and standard deviation 57 ± 14.2
Range 59 (minimum 30; maximum 89)
Tumour size (mm)
Mean and standard deviation 32 ± 21 mm
Range 145 (minimum 5; maximum 150)
Lymphovascular invasion
Present 111 (44.6)
Absent 111 (44.6)
Not assessed 27 (10.8)
Lymph node sage
Negative 111 (44.6)
1 to 3 lymph nodes 57 (22.9)
>3 lymph nodes 54 (21.7)
Not assessed 27 (10.8)
Tumour grade
Grade I 51 (20.5)
Grade II 116 (46.6)
Grade III 82 (32.9)
Histology
Invasive ductal carcinoma (not otherwise specified) 208 (83.5)
Invasive lobular carcinoma 7 (2.8)
Mixed 3 (1.2)
Tubular 3 (1.2)
Medullary 8 (3.3)
Other special types 20 (8.0)
Nottingham Prognostic Index
<3.4 46 (18.5)
3.4 to 5.4 106 (42.6)
>5.4 55 (22.0)
Not assessed 42 (16.9)
Oestrogen receptor-α status
Positive 141 (56.6)
Negative 107 (43.0)
Unknown 1 (0.4)
Progesterone receptor status
Positive 89 (35.8)
Negative 154 (61.8)
Unknown 6 (2.4)
Human epidermal growth factor receptor 2 status
Positive 42 (16.9)
Negative 201 (80.7)
Unknown 6 (2.4)
Data presented as n (%) unless stated otherwise.
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water bath, for 14 and 20 minutes for FOXA1 and GATA-3,
respectively. After cooling retrieval solutions for at least 30
minutes at room temperature, the slides were treated for 10
minutes with 3% H2O2 in methanol, in order to block endog-
enous peroxidase. Slides were incubated with monoclonal
antibodies for FOXA1 (1:450) and GATA-3 (1:100) for 2
hours at room temperature and were labelled with the Envision
Detection System from DAKO. Colour reaction product was
developed with 3,3'-diaminobenzidine, tetrahydrochloride
(DAB plus; DAKO Glostrup, Denmark) as a substrate, and
nuclear contrast was achieved with haematoxylin/ammoniacal
water counterstaining. Formalin-fixed, paraffin-embedded sec-
tions from normal breast gland were used as FOXA1 and
GATA-3 positive controls. Negative controls were performed
by replacing the primary antibody with PBS/nonimmune
mouse serum.
The scoring method used for FOXA1 and GATA-3 expression
was based on a semi-quantitative scoring system previously
described by Thorat and colleagues, where the cutoff value for
FOXA1 positivity was validated [31]. In this scoring system,
the percentage of staining was categorized as: 0 = no nuclear
expression; 1 = 1 to 10% positive tumour nuclei; 2 = 11 to
20%; and so on until a maximum score of 10 = 91 to 100%
positive tumour nuclei. The intensity was scored as: 1+ =
weak staining; 2+ = moderate staining; and 3+ = strong stain-
ing. The numeric final score was generated by the multiplica-
tion product of percentage and intensity of nuclear expression
(scoring = percentage × intensity) [10,32]. Based on this
semiquantitative scoring system, scores between 0 and 3
were classified as negative, and scores ≥ 4 to a maximum of
30 were considered positive.
Statistical analysis
Statistical analysis was performed using Stata™, version 9.2
software (StataCorp, College Station, TX, USA). Continuous
variables were presented as the mean ± standard deviation,
and categorical variables were presented as the number (per-
centage). The clinicopathological features and immunohisto-
chemical markers of the tumours were compared across
groups of expression of FOXA1 and GATA-3 using analysis of
variance and the chi-square test, respectively, for continuous
and categorical variables.
Survival curves were estimated by the Kaplan – Meier method
using the log-rank test to assess significant differences for dis-
ease-free patient survival. A maximum cutoff value of 60
months (5 years) was considered, since this is the expected
clinical time for breast cancer recurrence. Cox regression
models were fitted to estimate hazard ratios and the corre-
sponding 95% confidence interval for the classical prognostic
factors, FOXA1 and GATA-3. In all analyses, a significant level
of 5% was considered.
Results
FOXA1 and GATA-3 expression in normal and malignant 
breast tissues
From the total 249 cases, only cases with clear and restricted
nuclear expression for FOXA1 and GATA-3 were selected for
immunohistochemistry classification. Three representative
cases were selected to build a panel, illustrated in Figure 1,
comprising a classical example of the following molecular sub-
types of breast cancer: luminal A subtype (Figure 1, L1 to L7),
basal-like subtype (Figure 1, B1 to B7) and HER-2-overex-
pressing subtype (Figure 1, H1 to H7). Strong immunoexpres-
sion of FOXA1 and GATA-3 in the nuclei of malignant cells, as
well as in some luminal epithelial cells from adjacent normal
ducts, is shown in Figure 1 (L3 and L4). FOXA1 was positive
(score ≥ 4) in the nuclei of 42% (93 out of 224) of the invasive
carcinomas, while GATA-3 was detected in 48% (97 out of
204) of the cases.
Association between FOXA1 and GATA-3 expression 
and clinicopathological features and biological markers
The expression of FOXA1 was inversely associated with
tumour size (P = 0.005), Nottingham Prognostic Index (P =
0.002), histological grade (P = 0.001), vascular invasion (P =
0.012), lymph node stage (P = 0.022) and HER-2 overexpres-
sion (P = 0.017), and was directly associated with ERα
expression (P < 0.0001) and PR expression (P < 0.0001).
GATA-3 expression showed an inverse association with histo-
logical grade (P = 0.013) and HER-2 overexpression (P <
0.0001), and a direct association with ERα expression (P <
0.001) and PR expression (P < 0.001) (Table 2).
When we compared the expression of FOXA1 and GATA-3
with the molecular subtype, we found that 83.1% and 87.7%
of FOXA1 and GATA-3, respectively, were comprised in the
luminal A subtype (P < 0.0001) (Table 3 and Figure 1, L1 to
L7). Basal-like subtype tumours were negative for FOXA1
(Figure 1, B3) and for GATA-3 (Figure 1, B4) in 85.7% and
84.6% of the cases, respectively (Table 3).
The immunohistochemical evaluation of FOXA1 and GATA-3
in breast tumour samples revealed that in 201 of interpretable
cases a very significant direct association between the expres-
sion of FOXA1 and GATA-3 was observed (P < 0.0001)
(Table 3).
On the evaluation of these two transcription factors with other
important immunohistochemical markers in breast cancer, we
found a strong inverse association with basal-like phenotype
markers – namely, CK14 (P = 0.007, P = 0.0002), CK5 (P =
0.027, P < 0.0001), vimentin (P = 0.003, P = 0.0006) and P-
cadherin (P = 0.012, P < 0.0001) for FOXA1 and GATA-3,
respectively. GATA-3, but not FOXA1, showed an interesting
inverse association with EGFR (P = 0.001) (Table 3).
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Survival and patient outcome analysis
Kaplan–Meier survival curves demonstrate that patients with
FOXA1-positive breast carcinomas showed a significant dif-
ference towards the longer disease-free survival time (P <
0.001; Figure 2a). Although these are no statistically signifi-
cant differences in survival according to GATA-3 expression
(P = 0.055; Figure 2b), the positivity for this marker is also
associated with a better outcome for breast cancer patients.
As previously demonstrated in other studies, univariate Cox
proportional hazard analysis showed that the tumour size,
lymph node stage, tumour grade, as well as the expression of
ER, PR and HER-2 were significant predictors for disease-free
Figure 1
Immunohistochemistry panel showing differential expression pattern of FOXA1 and GATA-3. An example of luminal A (L1 to L7), basal-like (B1 to 
B7) and human epidermal growth factor receptor 2 (HER-2)-overexpressing (H1 to H7) invasive breast tumours. Expression of the most commonly 
used breast cancer markers is also illustrated for comparison with the forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA-3) expression. 
(L1, B1, H1) Haematoxylin-eosin stainings from each of the selected core cases. (L3, L4) Strong and restricted nuclear expression of FOXA1 and 
GATA-3 in the normal breast duct (internal control) and in the luminal A invasive tumour (grade II). (B3, B4) Negative expression of FOXA1 and 
GATA-3 in basal subtype tumour (grade III). (H3, H4) HER-2-overexpressing tumour showing negativity for FOXA1 and GATA-3 expression (grade 
III). All microscopy images are at 40× magnification. ER, oestrogen receptor; P-CAD, P-cadherin; CK, cytokeratin.
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Table 2
Association between FOXA1 and GATA3 expression and the clinicopathological features of the infiltrative breast carcinomas
Variable N FOXA1-negative 
(%)
FOXA1-positive 
(%)
P value n GATA3-negative 
(%)
GATA3-positive 
(%)
P value
Tumour size (mm) 209 35.2 ± 24.0 (126) 26.8 ± 15.7 (83) 0.005 191 34.4 ± 25.2 (100) 28.6 ± 16.7 (91) 0.064
Lymphovascular 
invasion
203 185
Present 97 67 (69.1) 30 (30.9) 0.012 92 49 (53.3) 43 (46.7) 0.829
Absent 106 55 (51.9) 51 (48.1) 93 51 (54.8) 42 (45.2)
Lymph node stage 203 185
Negative 106 55 (51.9) 51 (48.1) 0.022 93 51 (54.8) 42 (45.2) 0.166
1 to 3 lymph nodes 49 31 (63.3) 18 (36.7) 46 20 (43.5) 26 (56.5)
>3 lymph nodes 48 36 (75) 12 (25) 46 29 (63) 17 (37)
Grade 224 204
Grade I 44 25 (56.8) 19 (43.2) 0.001 40 24 (60) 16 (40) 0.013
Grade II 105 50 (47.6) 55 (52.4) 96 40 (41.7) 56 (58.3)
Grade III 75 56 (74.7) 19 (25.3) 68 43 (63.2) 25 (36.8)
Histology 224 204
IDC 188 113 (60.1) 75 (39.9) 0.119 171 91 (53.2) 80 (46.8) 0.104
ILC 6 2 (33.3) 4 (66.7) 6 0 (0) 6 (100)
Tubular 1 1 (100) 0 (0) 1 0 (0) 1 (100)
Medullary 7 5 (71.4) 2 (28.6) 7 5 (71.4) 2 (28.6)
Other 19 7 (36.8) 12 (63.2) 16 9 (56.2) 7 (43.8)
Mixed 3 3 (100) 0 (0) 3 2 (66.7) 1 (33.3)
Nottingham 
Prognostic Index
190 172
<3.4 44 18 (40.9) 26 (59.1) 0.002 40 19 (47.5) 21 (52.5) 0.293
3.4 to 5.4 96 59 (61.5) 37 (38.5) 86 44 (51.2) 42 (48.8)
>5.4 50 38 (76) 12 (24) 46 29 (63) 17 (37)
ERα 224 204
Positive 133 60 (45.1) 73 (54.9) <0.0001 122 41 (33.6) 81 (66.4) <0.0001
Negative 91 71 (78) 20 (22) 82 66 (80.9) 16 (19.5)
PR 223 204
Positive 83 33 (39.7) 50 (60.3) <0.0001 74 22 (29.7) 52 (70.3) <0.0001
Negative 140 98 (70) 42 (30) 130 85 (65.4) 45 (34.6)
HER-2 220 201
Positive 35 27 (77.1) 8 (22.9) 0.017 34 29 (85.3) 5 (14.7) <0.0001
Negative 185 103 (55.7) 82 (44.3) 167 77 (46.1) 90 (53.9)
FOXA-1, forkhead box A1; GATA-3, GATA binding protein 3; IDC, invasive ductal carcinoma (not otherwise specified); ILC, invasive lobular 
carcinoma; ERα, oestrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2.
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survival. In accordance with the trend shown by the Kaplan–
Meier curves, the expression of FOXA1 was also a significant
predictor for disease-free survival, showing that negative
cases carry a fourfold increased risk of recurrence (hazard
ratio = 4.25, 95% confidence interval = 1.76 to 10.28) when
compared with the positive ones. In contrast, GATA-3 expres-
sion was revealed not to be important as a predictive marker
for better outcome in this series (hazard ratio = 1.97, 95%
confidence interval = 0.96 to 4.01) (Table 4).
Prognostic significance of FOXA1 and GATA-3 
expression in ER-negative breast cancer
Several studies have shown that FOXA1 and GATA-3 expres-
sion are strong predictors of better clinical outcome in breast
tumours and are among the best predictors of ERα-positive
status [9-12,26,31,33,34]. Since FOXA1 and GATA-3 show
an intrinsic high correlation between themselves and with ERα
status, however, the prognostic and predictive value of these
markers may simply reflect this high expression association. A
cohort of ERα-negative patients was therefore studied in order
to evaluate the predictive importance of FOXA1 and GATA-3
expression in this subset of breast carcinomas.
When the association analysis was performed in the subset of
ERα-negative patients, FOXA1 and GATA-3 failed to show
any significant association with the studied clinicopathological
features. Analysing the association of these transcription fac-
tors with the immunohistochemical biomarkers in breast can-
Table 3
Association between FOXA1 and GATA3 expression and the immunohistochemical markers in infiltrative breast carcinomas
Variable N FOXA1-negative (%) FOXA1-positive (%) P value n GATA3-negative (%) GATA3-positive (%) P value
EGFR 223 203
Positive 13 10 (7.6) 3 (3.3) 0.171 11 11 (10.4) 0 (0) 0.001
Negative 210 121 (92.4) 89 (96.7) 192 95 (89.6) 97 (100)
P-cadherin 220 202
Positive 75 53 (40.8) 22 (24.4) 0.012 71 52 (49.1) 19 (19.8) <0.0001
Negative 145 77 (59.2) 68 (75.6) 131 54 (50.9) 77 (80.2)
Cytokeratin 5 224 204
Positive 50 36 (27.5) 14 (15) 0.027 48 39 (36.4) 9 (9.3) <0.0001
Negative 174 95 (72.5) 79 (85) 156 68 (63.6) 88 (90.7)
Cytokeratin 14 219 201
Positive 14 13 (10.1) 1 (1.5) 0.007 14 14 (13.3) 0 (0) 0.0002
Negative 205 116 (89.9) 89 (98.9) 187 91 (86.7) 96 (100)
Vimentin 203 194
Positive 34 28 (23.1) 6 (7.3) 0.003 32 26 (25) 6 (6.7) 0.0006
Negative 169 93 (76.9) 76 (92.7) 162 78 (75) 84 (93.3)
FOXA1 - - - - 201
Positive - - - 82 16 (15.4) 66 (68) <0.0001
Negative - - - 119 88 (84.6) 31 (32)
GATA-3 201 - - - -
Positive 97 31 (26.1) 66 (80.5) <0.0001 - - -
Negative 104 88 (73.9) 16 (19.5) - - -
Subtype 202 187
Luminal A 125 56 (47) 69 (83.1) <0.0001 114 36 (36.7) 78 (87.7) <0.0001
Luminal B 8 4 (3.4) 4 (4.8) 8 5 (5.1) 3 (3.4)
HER-2 27 23 (19.3) 4 (4.8) 26 24 (24.5) 2 (2.2)
Basal 42 36 (30.3) 6 (7.3) 39 33 (33.7) 6 (6.7)
FOXA-1, forkhead box A1; GATA-3, GATA binding protein 3; EGFR, epidermal growth factor receptor; HER-2, human epidermal growth factor 
receptor 2.
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cer, no significant associations were found concerning
FOXA1 expression. GATA-3 negativity, however, showed sig-
nificant association with P-cadherin and CK14 expression.
Although not statistically significant, we also observed a trend
towards the association of GATA-3 with the other studied
basal-like phenotype markers (namely, EGFR, CK5 and vimen-
tin), where the majority of the negative cases for GATA-3 are
positive for those proteins (Table 5).
In this subset of ERα-negative patients, however, an associa-
tion between loss of FOXA1 expression and worst disease-
free survival was found (P = 0.064), in contrast with GATA-3
expression (P = 0.488) (Figure 2c and 2d, respectively). More-
over, in order to quantify the risk of these survival associations,
univariate analysis was performed for FOXA1 and GATA-3 as
well as for the classical prognostic factors in breast cancer. In
line with the Kaplan–Meier curves, GATA-3 negativity does
not account for an increased risk of recurrence in ERα-nega-
tive tumours. FOXA1 expression, however, is able to stratify
this relative risk among this subset of carcinomas, since its
loss accounts for a 3.61-fold increased risk for breast cancer
recurrence (Table 6). These results suggest a protective role
for this forkhead protein in this poor-outcome breast cancer
subgroup.
Additionally, the multivariate Cox hazard analysis, with models
including tumour size and lymph vascular invasion, demon-
strates the independent value of FOXA1 expression as a pre-
dictor of patient outcome in ERα-negative tumours. FOXA1
negativity is strongly related to breast cancer recurrence, this
association being very close to statistical significance
(FOXA1-negative vs. FOXA1-positive: hazard ratio = 7.02,
95% confidence interval = 0.92 to 53.37; P = 0.060). This
analysis also confirmed that GATA-3 expression is not an
important predictor of breast cancer recurrence in ERα-nega-
tive carcinomas (GATA-3-negative vs. GATA-3-positive
patients: hazard ratio = 1.46, 95% confidence interval = 0.40
to 5.29; P = 0.559).
Discussion
Several studies of global gene expression revealed high levels
of FOXA1 often associated with the expression of ERα
[6,35,36]. In addition, other gene whose expression has been
highly correlated with ERα in breast cancer encodes the tran-
scription factor GATA-3 [6,11,26,27]. Indeed, FOXA1, GATA-
Figure 2
Kaplan–Meier survival curves for disease-free survival. (a) Survival functions for forkhead box A1 (FOXA1) in the whole breast cancer patient series 
(P < 0.001). (b) Survival functions for GATA binding protein 3 (GATA-3) in the whole breast cancer patient series (P = 0.055). (c) Survival functions 
for FOXA1 in the oestrogen receptor α-negative breast cancer patient cohort (P = 0.064). (d) Survival functions for GATA-3 in the oestrogen recep-
tor α-negative breast cancer patient cohort (P = 0.488).
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3 and ERα form a transcriptional circuit required for growth,
differentiation and hormonal dependency of the lineage of
mammary luminal cells [22,37]. Previous work using immuno-
histochemistry has shown that the expression of FOXA1
[10,31,33] and of GATA-3 [9,34,37] is in close association
with ERα expression in breast cancer, highlighting their prog-
nostic and predictive value in this malignancy. In fact, since
these three proteins are components of a transcriptional net-
work that dictates the phenotype of hormonal-dependent
breast cancer [37], the study of their expression would
improve our understanding of the ERα, FOXA1 and GATA-3
relationship in breast cancer patients.
In the present study the staining pattern of FOXA1 and GATA-
3 in normal breast tissue is strikingly similar to that of ERα,
which suggests the same cellular co-localization of these three
cross-functional proteins. In the studied series, the expression
of FOXA1 was inversely associated with clinicopathological
features – namely, with tumour size, tumour grade, Nottingham
Prognostic Index, lymph vascular invasion, lymph node stage
and HER-2 overexpression – while its expression was directly
associated with ERα, PR and the luminal A subtype. Thorat
and colleagues, in a recent published study of 139 cases, did
not demonstrate a significant association with tumour size,
lymph node status or HER-2 [31]. Moreover, these authors
also found an inverse association between FOXA1 and basal-
like phenotype markers (namely, CK5 and CK14). Importantly,
in our study we reinforced this inverse association between
FOXA1 expression and the expression of P-cadherin or vimen-
tin.
The requirement of this forkhead for optimal expression of at
least 50% of ERα-regulated genes and oestrogen-induced
proliferation was recently described [13], and our and other
results may just represent the strong regulatory interdepend-
ency between ERα and FOXA1. Since ERα is one of the cen-
tral genes for the regulation of growth/proliferation of
mammary epithelia, and for the hormone-responsive pheno-
type of breast tumours [9], FOXA1 appears an important bio-
logical-regulatory factor with prognostic consequences in this
setting. In fact, in the present study, FOXA1 expression was
shown to be an important predictor of disease-free survival, in
addition to the robust association with clinicopathological fea-
tures. Interestingly, univariate analysis showed that the evalua-
tion of FOXA1 expression has an important value in the
assessment of the prognostic risk for breast cancer patient
Table 4
Univariate Cox proportional hazard analysis (disease-free survival) in the whole breast cancer series
Variable Evaluation Hazard ratio (95% confidence interval) P value
Tumour size T1 (≤ 2 mm) 1
T2 (2 < T ≤ 5 mm) 1.57 (0.70 to 3.51) 0.265
T3 (>5 mm) 3.12 (1.16 to 8.41) 0.024
Lymph node stage Negative 1
1 to 3 lymph nodes 0.56 (0.20 to 1.56) 0.272
>3 lymph nodes 2.68 (1.30 to 5.49) 0.007
Tumour grade Grade I 1
Grade II 2.60 (0.58 to 11.56) 0.208
Grade III 7.65 (1.80 to 32.48) 0.006
ER expression ER-positive 1
ER-negative 2.94 (1.52 to 5.57) 0.001
PR expression PR-positive 1
PR-negative 2.16 (1.04 to 4.46) 0.038
HER-2/neu expression HER-2/neu-negative 1
HER-2/neu-positive 2.47 (1.19 to 5.09) 0.014
FOXA1 expression FOXA1-positive 1
FOXA1-negative 4.25 (1.76 to 10.28) 0.001
GATA-3 expression GATA-3-positive 1
GATA-3-negative 1.97 (0.96 to 4.01) 0.061
ER, oestrogen receptor; FOXA-1, forkhead box A1; GATA-3, GATA binding protein 3; HER-2, human epidermal growth factor receptor 2; PR, 
progesterone receptor.
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Table 5
Association between FOXA1 and GATA3 expression, clinicopathological features and immunohistochemical markers in ER-
negative cohort
Variable n FOXA1-negative 
(%)
FOXA1-positive (%) P value n GATA3-negative 
(%)
GATA3-positive (%) P value
Tumour size 80 36.7 ± 24.2 (65) 36.6 ± 24.8 (15) 0.987 74 34.46 ± 23.6 (60) 43.4 ± 27.4 (14) 0.229
Lymphovascular 
invasion
83 78
Present 35 29 (82.8) 6 (17.2) 0.391 35 29 (82.8) 6 (17.2) 0.867
Absent 48 36 (75) 12 (25) 43 35 (81.4) 8 (18.6)
Lymph node stage 83 78
Negative 48 36 (75) 12 (25) 0.456 43 35 (81.4) 8 (18.6) 0.609
1 to 3 lymph 
nodes
12 11 (91.7) 1 (8.3) 12 11 (91.7) 1 (8.3)
>3 lymph nodes 23 18 (78.3) 5 (21.7) 23 18 (78.3) 5 (21.7)
Grade 87 80
Grade I 8 6 (75) 2 (25) 0.166 8 8 (100) 0 (0) 0.366
Grade II 33 23 (69.7) 10 (30.3) 28 22 (78.6) 6 (21.4)
Grade III 46 40 (86.9) 6 (13.1) 44 36 (81.8) 8 (18.2)
Nottingham 
Prognostic Index
76 71
<3.4 11 9 (81.8) 2 (18.2) 0.982 10 9 (90) 1 (10) 0.615
3.4 to 5.4 34 27 (79.4) 7 (20.6) 32 26 (81.3) 6 (18.7)
>5.4 31 25 (80.6) 6 (19.4) 29 22 (75.8) 7 (24.2)
HER-2 85 79
Positive 26 23 (88.5) 3 (11.5) 0.254 26 24 (92.3) 2 (7.7) 0.102
Negative 59 46 (77.9) 13 (22.1) 53 41 (77.4) 12 (22.6)
EGFR 86 80
Positive 12 10 (83.3) 2 (16.7) 0.771 11 11 (100) 0 (0) 0.100
Negative 74 59 (79.7) 15 (20.3) 69 55 (79.7) 14 (20.3)
P-cadherin 87 80
Positive 53 45 (84.9) 8 (15.1) 0.107 52 47 (90.4) 5 (9.6) 0.011
Negative 34 24 (70.6) 10 (29.4) 28 19 (67.8) 9 (32.2)
Cytokeratin 5 87 80
Positive 33 28 (84.8) 5 (15.2) 0.318 32 29 (90.6) 3 (9.4) 0.118
Negative 54 41 (75.9) 13 (24.1) 48 37 (77.1) 11 (22.9)
Cytokeratin 14 85 78
Positive 14 13 (92.8) 1 (7.2) 0.188 14 14 (100) 0 (0) 0.053
Negative 71 55 (77.5) 16 (22.5) 64 50 (78.1) 14 (21.9)
Vimentin 82 75
Positive 27 25 (92.6) 2 (7.4) 0.074 25 24 (96) 1 (4) 0.064
Negative 55 42 (76.4) 13 (23.6) 50 40 (80) 10 (20)
FOXA1 - 78
Positive - - - - 15 6 (40) 9 (60) <0.0001
Negative - - - 63 58 (92.1) 5 (7.9)
GATA-3 78 -
Positive 14 5 (35.7) 9 (64.3) <0.0001 - - - -
Negative 64 58 (90.6) 6 (9.4) - - -
ER, oestrogen receptor; EGFR, epidermal growth factor receptor; FOXA-1, forkhead box A1; GATA-3, GATA binding protein 3; HER-2, human 
epidermal growth factor receptor 2.
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recurrence, with a magnitude of association similar to the
observed for the classical prognostic factors, such as tumour
size and lymph node stage, tumour grade, and ER and HER-2
expression. This finding is in line with previously published
works, where both Badve and colleagues and Habashy and
colleagues also demonstrated that FOXA1 expression is able
to significantly predict a better survival for breast cancer
patients [10,33], although the multivariate analysis showed
that it is not an independent prognostic marker, exactly as
shown for ER. These studies still suggest that ERα/FOXA1-
expressing cells, after acquiring tumorigenicity, may promote
selective clonal expansion, resulting in a specific subtype of
breast cancer – the luminal subtype A. Thorat and colleagues
also suggested that FOXA1 immunohistochemistry may be
used as a marker for tumours pertaining to luminal subtype A
breast cancer, which has an exceptionally good prognosis
[31].
In contrast to FOXA1, GATA-3 failed the association with
most of the clinicopathological features – the exception being
an inverse association with HER-2 expression and tumour his-
tological grade, although it was also directly associated with
ERα and PR expression, as well as with tumours from the lumi-
nal A subtype. These results are partially in line with previous
work from Mehra and colleagues, which found that low levels
of GATA-3 expression were associated with higher tumour
histological grade, positive lymph nodes, larger tumour size,
negative ER expression and HER-2 overexpression [24]. In the
present study we could not find an association between
GATA-3 expression and lymph node status, in agreement with
a recent cohort study from Voduc and colleagues comprising
more than 3,000 invasive breast cancers [34]. Regarding the
association between GATA-3 and ERα, 66% of the cases co-
expressed these markers – which is a larger percentage than
those previously described by Mehra and colleagues (46%)
and by Voduc and colleagues (39%) [24,34].
Through the analysis of Kaplan–Meier survival curves it was
not possible to demonstrate a significant association between
GATA-3 expression and disease-free survival in this breast
cancer series, which is in accordance with data from the large
cohort study of Voduc and colleagues [34]. The univariate
analysis confirmed this observation, although there is an asso-
ciation between the positivity for this marker and the better
outcome for breast cancer patients.
Interestingly, the strength of the inverse association that was
observed between GATA-3 and basal-like markers – namely,
CK5, CK14, vimentin, EGFR and P-cadherin – suggests that
GATA-3 can be important for the differentiation state of the
malignant cells, where its presence, together with other differ-
entiation involved partners, may drive the luminal profile of a
malignant cell population within the tumour. Actually, this
growth and differentiation role for GATA-3 in normal mammary
Table 6
Univariate Cox proportional hazard analysis (disease-free survival) in the oestrogen-receptor-negative cohort
Variable Evaluation Hazard ratio (95% confidence interval) P value
Tumour size T1 (≤ 2 mm) 1
T2 (2 < T ≤ 5 mm) 1.45 (0.40 to 5.21) 0.567
T3 (>5 mm) 3.57 (0.88 to 14.4) 0.073
Lymph node stage Negative 1
1 to 3 lymph nodes 0.47 (0.10 to 2.16) 0.338
>3 lymph nodes 2.49 (1.02 to 6.03) 0.044
Tumour grade Grade I a
Grade II 1
Grade III 2.85 (1.05 to 7.57) 0.040
HER-2/neu expression HER-2/neu-negative 1
HER-2/neu-positive 2.04 (0.90 to 4.61) 0.086
FOXA1 expression FOXA1-positive 1
FOXA1-negative 3.61 (0.83 to 15.60) 0.086
GATA-3 expression GATA-3-positive 1
GATA-3-negative 1.53 (0.44 to 5.28) 0.495
FOXA-1, forkhead box A1; GATA-3, GATA binding protein 3; HER-2, human epidermal growth factor receptor 2. aThere were no oestrogen-
receptor-negative cases classified as grade I among the patients with available follow-up information.
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epithelial cells has been already widely described
[9,22,34,38]. Moreover, GATA-3-induced genes were found
in the luminal cluster of gene expression studies, highlighting
its putative ability to maintain a luminal differentiated pheno-
type [34].
In the past, several studies have shown that FOXA1 expres-
sion and GATA-3 expression are among the best predictors of
ERα-positive status [9-12,26,31,33,34]. Additionally, some
reports have proven that FOXA1 expression is able to signifi-
cantly differentiate patients with a better survival within the
luminal A subgroup, or even within the ERα-positive cohort
(including luminal A and luminal B subtypes) [10,31]. These
authors claim that FOXA1 can serve as a clinical marker for the
luminal A subtype, and that its prognostic ability in these low-
risk breast cancers may prove to be useful in clinical treatment
decisions. In contrast, Habashy and colleagues did not find
any clinical relevance in the immunohistochemical assessment
of FOXA1 in breast cancer routine practice [33], since it was
not able to stratify ER-positive (luminal-like) tumours into clini-
cally significant subgroups.
Although never assessed, the difference between these stud-
ies can be possibly due to the endocrine and chemotherapy
administered to the different series of patients, which can
block the ERα-associated pathways and confound interpreta-
tion of the results. Moreover, since ERα, FOXA1 and GATA-3
show an intrinsic high correlation between themselves, the
prognostic and predictive values of these markers may simply
reflect this high expression association and the described bio-
logical interactions.
In order to study whether there was a prognostic value for the
expression of these two transcription factors in the absence of
ERα expression, we therefore decided to perform an explora-
tory subgroup analysis in a cohort of ERα-negative patients.
The aim was to test, for the first time, the possible utility of
FOXA1 and/or GATA-3 as classifiers for breast cancer recur-
rence in this high-risk subset of patients, revealing a stratifica-
tion of ER-negative tumours with different biological
behaviours. Interestingly, only FOXA1-positive expression
showed a clear protective effect for breast cancer relapse in
this cohort of patients with poor prognosis. Patients with loss
of FOXA1 tumour expression showed an increased risk for
breast cancer recurrence compared with the patients that
were positive for this marker. The relative risk estimate was
higher than that calculated for HER-2 positivity, which is a
well-known prognostic factor in hormone-independent breast
carcinomas. Moreover, the multivariate analysis, including the
tumour size and lymph node status, demonstrated the inde-
pendent value of FOXA1 as a predictor of patient outcome in
ERα-negative tumours.
In conclusion, our results confirmed the strong association
between ERα and FOXA1 in breast cancer and confirmed the
role of FOXA1 as a significant breast cancer predictor of good
outcome in univariate analysis, directly associated with luminal
A and inversely associated with basal-like subtype of breast
cancer. GATA-3 was neither a predictor for breast cancer dis-
ease-free survival nor a prognostic marker, but was shown to
be an important and robust luminal differentiation marker, even
stronger than FOXA1. Based on these findings, the expres-
sion assessment of FOXA1 and GATA-3 in breast cancer
patients can provide important clinical information – not only
regarding the favourable prognostic nature and tumour behav-
iour, but the expression can also constitute an important tool
to define and assess the luminal A subtype in breast cancer.
We demonstrated that FOXA1 expression also has an impor-
tant role as breast cancer predictor of good outcome in ER-
negative breast carcinomas.
Based on our results, we can consider that the expression of
FOXA1, as an ER-associated gene, may be important to the
hormone-responsive phenotype of breast cancer, regardless
of the tumour ER status. The absence of FOXA1 in luminal/ER-
positive breast cancer patients may contribute to identify the
30% of ER-positive tumours that are not hormone responsive.
Additionally, because of the known cross-talk and functional
network between FOXA1 and the regulation of ERα and its
downstream targets, the expression of FOXA1 in ER-negative
breast cancer patients may represent the existence of an alter-
native oestradiol-independent response pathway, which may
allow the 5 to 15% of ER-negative tumours to become respon-
sive to endocrine-driven therapies. The clinical implication of
these findings requires a larger prospective cohort, especially
to evaluate the value of FOXA1 in the therapeutic response
setting. Nevertheless, the current study already represents an
important step forward in the overview the ER-negative type of
tumours, with putative future benefit for staging and treatment
of these patients.
Conclusions
Current challenges in oncology include prediction of tumour
behaviour and selection of effective therapy for individual treat-
ment based on molecular targets. In breast cancer, ERα
expression alone has been used to guide systemic therapy
and to estimate patient prognosis. Not all ER-positive carcino-
mas, however, show comparable prognosis or react similarly
to anti-hormonal therapy, and some ER-negative tumours curi-
ously respond to therapy. This clinical evidence demonstrates
that breast carcinomas are extremely heterogeneous, empha-
sizing the need for improving the molecular classification
within tumours to better predict their clinical behaviour and the
patient's response to current therapies.
The identification of transcription factors that control the ERα
pathway provide an opportunity to identify specific subsets of
patients that will have a good prognosis, as well as who will
benefit from endocrine treatment. In the present work, we
studied FOXA1 and GATA-3 expression in order to evaluate
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whether the proteins would predict the recurrence behaviour
of breast cancer patients. We verified that patients harbouring
FOXA1-positive and ER-negative tumours show a better dis-
ease-free survival, demonstrating the clinical importance of
these two biomarkers in breast cancer molecular classification
and prognosis. The analyses showed that FOXA1 and ERα
should be used together in order to subclassify breast carci-
nomas and to predict the outcome of breast cancer patients.
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ICI 182,780 induces P-cadherin overexpression in
breast cancer cells through chromatin remodelling
at the promoter level: a role for C/EBPb in CDH3
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CDH3/P-cadherin is a classical cadherin. Overexpression of which has been associated with proliferative
lesions of high histological grade, decreased cell polarity and poor survival of patients with breast cancer.
In vitro studies showed that it can be up-regulated by ICI 182,780, suggesting that the lack of ERa signalling
is responsible for the aberrant P-cadherin overexpression and for its role in inducing breast cancer cell inva-
sion and migration. However, the mechanism by which ER-signalling inhibition leads to P-cadherin
expression is still unknown. The aim of this study was to explore the molecular mechanism linking the
ERa-signalling and P-cadherin-regulated expression in breast cancer cell lines. This study showed that ICI
182,780 is able to increase CDH3 promoter activity, inducing high levels of the active chromatin mark H3
lysine 4 dimethylation. We also observed, for the first time, that the transcription factor C/EBPb is able to
up-regulate CDH3 promoter activity in breast cancer cells. Moreover, we showed that the expression of P-
cadherin and C/EBPb are highly associated in human breast carcinomas and linked with a worse prognosis
of breast cancer patients. This study demonstrates the existence of an epigenetic regulation by which ICI
182,780 up-regulates P-cadherin expression in MCF-7/AZ breast cancer cells through chromatin remodelling
at CDH3 promoter, bringing forward the growing evidence that ERa signalling-abrogation by anti-oestrogens
is able to induce the expression of ERa-repressed genes which, in the appropriate cell biology context, may
contribute to a breast cancer cell invasion phenotype.
CDH3 GenBank accession no. NT_010498.
INTRODUCTION
Classical cadherins, such as E-, N-, and P-cadherin, are
the major structural components of the adherens junctions
in many tissues (1). This superfamilly of transmembrane
glycoproteins is responsible for calcium-dependent cell–cell
adhesion, mediating specific homophilic protein interactions
through their extracellular domain and being intracellularly
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linked to the actin cytoskeleton (2). Previous studies showed
the involvement of classical cadherins in many biological
processes, such as cell recognition, cell signalling, morpho-
genesis and tumour development (1).
Among these, P-cadherin has extensively been studied by our
and other groups, where it has currently been recognized as an
important biomarker in breast cancer. In human breast carci-
nomas, which represent a heterogeneous group of tumours,
diverse in behaviour, outcome and response to therapy,
P-cadherin was found to be aberrantly expressed in 30–50% of
invasive ductal carcinomas of the breast, being strongly associ-
ated with proliferative lesions of high histological grade,
decreased cell polarity and poor survival of patients over short-
term follow-up (3–7). In addition, the expression of P-cadherin,
together with other well-described basal markers, such as cyto-
keratin (CK)5, constitutes one of the most useful adjunctive
markers to distinguish basal-like carcinomas of the breast (8).
At the in vitro level, our group demonstrated that P-cadherin
plays an important role in cell invasion induction through its
juxtamembrane domain (5), and that its overexpression
induces motility and migration in wild-type E-cadherin breast
cancer cell lines, through the secretion of pro-invasive
factors, such as matrix metalloproteinase (MMP)-1 and
MMP-2. These recent findings revealed the mechanism under-
lying this in vitro invasion behaviour induced by overexpres-
sion of P-cadherin and most likely associated with the poor
prognosis of breast tumours (9,10).
However, although P-cadherin-associated functions in
breast cancer have been extensively studied, the mechanisms
controlling P-cadherin overexpression are still unclear.
It is known that the expression of an inappropriate cadherin
can result from growth factors and hormones stimulation in the
tumour environment, as well as from changes in the promoter
regions of cadherin-encoding genes (11). In non-cancer
models, CDH3 promoter was shown to be genetically regu-
lated through direct binding of transcription factors, such as
p63 (12) and b-catenin (13).
In 2005, we have reported a significant association between
P-cadherin overexpression and the hypomethylation of a specific
region of CDH3 promoter, suggesting an important regulatory
role for CpG DNA methylation in the regulation of P-cadherin
expression in breast cancer. Interestingly, the study of normal
P-cadherin-negative epithelial/luminal cells revealed consistent
hypermethylation at this same promoter region (3). The epige-
netic regulation of CDH3/P-cadherin gene was recently demon-
strated in other cancer models, like pancreatic and colorectal
carcinomas, as well as in melanomas (14–17).
Indeed, one of our current aims is to find upstream regula-
tors and identify the epigenetic mechanisms that are involved
in P-cadherin overexpression in breast cancer cells. In this
study, we explored the link between ER-signalling and
P-cadherin-regulated expression in breast cancer cell lines,
since P-cadherin-positive tumours are essentially ER negative.
In fact, our group found that abnormal P-cadherin expression
results from a lack of ER-a signalling (5), since treatment of
breast cancer cells with the pure anti-oestrogen ICI 182,780
(ICI, Fulvestrant) induced a 2–3-fold increase of P-cadherin
protein and CDH3 mRNA levels in a time- and dose-
dependent manner, being this effect counteracted by
17b-oestradiol (E2) (18). Taken together, these previous
findings suggested that the lack of ER-a signalling was
responsible for the increase of P-cadherin, categorizing
CDH3 as an oestrogen-repressed gene. However, until now,
it remained to be determined whether the induction of the
CDH3 gene was due to an epigenetic effect of the anti-
oestrogens at CDH3 promoter level and/or if it would
require the prior induction of other genes/proteins.
Herein, we describe the epigenetic remodelling induced by
the anti-oestrogen ICI, which leads to higher levels of the
active chromatin mark H3 lysine 4 dimethylation
(H3K4me2) at CDH3 promoter sites. We demonstrated in
this study that when ER-positive breast cancer cells are
treated with ICI, specific transcription sites of the CDH3 pro-
moter become exposed to putative transcription regulators
that, if located nearby, can induce the inappropriate expression
of P-cadherin protein. Moreover, we observed, for the first
time, that expression of the transcription factor C/EBPb is
able to directly activate P-cadherin promoter and its transcrip-
tion in breast cancer cells. We further supported our in vitro
results, showing that the expression of P-cadherin and
C/EBPb are highly associated in human breast carcinomas
and linked with a worse prognosis of breast cancer patients.
RESULTS
ERa signalling pathway inhibition induces the
transcription and up-regulation of the pro-invasive
CDH3/P-cadherin in breast cancer cells
P-cadherin expression is tightly regulated by ERa-signalling
pathway in breast cancer cells (5). In MCF-7/AZ cells,
P-cadherin protein and mRNA expression levels were
up-regulated after the treatment with anti-oestrogen ICI and
down-regulated by oestradiol (Fig. 1A and B). However, until
now, the molecular mechanism leading to increased levels of
P-cadherin by ICI was never determined. In this study, we
tested whether the ICI-induced P-cadherin overexpression was
due to a molecular effect at the CDH3 promoter level, as a
consequence of ERa-signalling pathway deregulation.
To address if ERa-signalling pathway was able to regulate P-
cadherin expression levels through CDH3 promoter activation/
repression, a luciferase reporter gene assay was performed in
ERa-positive MCF-7/AZ breast cancer cells. The full-length
CDH3 gene promoter was cloned at pGL3-basic vector, as
well as PS2/TFF1 promoter, which is a well-known direct
oestrogen-responsive gene, here used as a positive control.
Cells were transiently transfected with the pGL3-basic empty
vector, CDH3 or PS2/TFF1 promoter vector, and treated with
E2 or with the anti-oestrogen ICI. As a negative control, cells
were treated with ethanol (drug vehicle). As expected, PS2/
TFF1 promoter was strongly activated by E2 and inhibited by
the pure anti-oestrogen in the hormonal-dependent MCF-7/
AZ breast cancer cells (Fig. 1C). Concerning P-cadherin, we
found that ICI significantly increased CDH3 promoter activity,
whereas E2 repressed it (Fig. 1C). These effects mediated by
ICI and E2 were detected at mRNA and protein level. Although
these differences were not as evident as the ones observed for
the positive control PS2/TFF1 gene, the results were statisti-
cally significant. pGL3–control (pLUC) containing a modified
coding region for firefly luciferase, optimized for monitoring
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transcriptional activity in transfected eukaryotic cells, was used
as positive luciferase assay control. As expected, pLUC–
control activity was high and similar in all the treatment con-
ditions. pGL3-basic empty vector did not show any activity
with or without treatments.
Similarly, breast cancer cells were transiently transfected
with ERa-siRNA, in order to test if the up-regulation of P-
cadherin expression could be indeed attributed to specific
ERa degradation, or if the ICI-mediated P-cadherin induction
could be due to a secondary effect not related to the ERa-
signalling pathway. As can be seen in Figure 2A and B, the
siRNA for ERa also induced an increased P-cadherin
expression at the mRNA and protein level. Overall, we
showed that the inhibition of ERa-signalling pathway, by ICI
or by ERa-siRNA, induces the transcription and up-regulation
of the pro-invasive CDH3/P-cadherin in breast cancer cells.
The anti-oestrogen ICI 182,780 up-regulated P-cadherin
expression is associated with high levels of the active
chromatin mark H3K4me2 at CDH3 promoter
regulatory regions
On the basis of the above-mentioned results, we also aimed to
understand the molecular mechanism by which ICI is able to
increase the transcription of P-cadherin gene.
Epigenetic mechanisms were already described as induced
by ICI (19), which most probably can affect CDH3 transcrip-
tion. In previous works, we showed that CDH3 promoter is
able to be regulated by methylation (3), but ICI did not
caused any significant change in the methylation pattern of
CDH3 promoter (data not shown). However, it was previously
described that pure anti-oestrogen ICI can induce gene
transcription through releasing HDACs and ERa from Sp1
sites in ERa-repressed genes (19). Varshochi et al. (19)
demonstrated that, in the presence of ICI, ERa and HDACs
are dissociated from Sp1, resulting in an increased histone
acetylation and de-repression of the p21Waf1 promoter and
expression induction. However, for CDH3gene, which promo-
ter is enriched in Sp1 and ERa binding sites, ICI-induced
histone acetylation changes were never studied.
In order to access whetherCDH3 promoter is prone to be regu-
lated by acetylation mechanisms, cells transfected with the full-
length CDH3 gene promoter were treated with increased doses
of Trichostatin A (TSA), a known histone deacetylase (HDAC)
inhibitor. The CDH3 promoter transfected into MCF-7/AZ
breast cancer cells showed a significant dose-dependent acti-
vation after treatment with 0.05 mM TSA and with 0.1 mM TSA
for 12 h, compared with the activation from the cells treated
only with the vehicle [dimethyl sulfoxide (DMSO) (Fig. 3A)].
The increase in CDH3 promoter activation is also reflected at P-
cadherin protein levels (Fig. 3B), indicating that CDH3 promoter
is sensitive to chromatin alterations and that these alterations
affect P-cadherin expression. No alterations in ERa expression
levels were observed after TSA treatment.
In order to address which type of chromatin modifications
could be induced by ICI in CDH3 promoter potentially
Figure 1. Regulation of P-cadherin expression by the anti-oestrogen ICI 182,780 in MCF-7/AZ breast cancer cells. MCF-7/AZ cells were treated with the indi-
cated concentrations of ICI or 17b-estradiol (E2) for 24 h. (A) ERa protein levels of MCF-7/AZ cells treated with E2 or ICI were both decreased, whereas the
P-cadherin protein expression was 3.8-fold increased after ICI treatment, relative to the ethanol control treatment. In contrast, P-cadherin expression was reduced
in 55% when cells were treated with E2. Immunostaining for anti-b-actin was done to control for equal loading. (B) mRNA levels of cells treated with E2 or
ICI showed no alteration concerning ERa expression, but a marked increased in P-cadherin levels is showed after treatment with ICI. A slight reduction of
25% in P-cadherin expression is observed after treatment with E2. GAPDH housekeeping gene amplification was used as a control. (C) Luciferase reporter
assay quantification was done using relative light units—RLU (relative to renilla). ICI significantly induced CDH3 gene promoter activity when cells were
treated with the pure anti-oestrogen (∗P , 0.001), while E2 slightly induced down-regulation of the promoter activity. Oestrogen-responsive PS2/TFF1 gene
promoter vector showed the efficiency and activity of both treatments, namely been activated in the presence of E2 and highly repressed by the presence of
ICI. As a negative control, the pGL3-empty vector showed no activity with any of the treatments.
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leading to increased mRNA and protein overexpression, chro-
matin immunoprecipitation (ChIP) assays were performed
using specific antibodies to identify conventional histone-
activating (H3K4me2, H3K9ac and H3ac) or repressive
marks (H3K27me3 and H4K20me3) within the CDH3 gene
promoter region. We studied two different DNA promoter
regions (a distal Region 1 and a proximal Region 2) that
were selected according to CpG islands enrichment and to
the attributed DNA hypersensitive (DHS) sites within the
CDH3 gene promoter sequence. On the basis of the already
described effect of ICI in ERa-repressed genes, predicted
ERa and Sp1-binding sites were also considered to select
these studied promoter regions (Fig. 4A). No significant altera-
tions in the levels of activating or repressive histones marks
were detected at CDH3 Promoter Region 1 after treatment
with ICI (Fig. 4B). However, anti-oestrogen ICI-treatment
induced a strong enrichment in H3K4me2 levels, a mark for
transcription activation at the proximal CDH3 promoter
Region 2, while neither active H3K9ac and H3ac or repressive
H3K27me3 and H4K20me3 marks showed alterations
(Fig. 4C).
Altogether, it is suggested that the proximal CDH3
Promoter Region 2, which is closer to the transcriptional
start site (TSS) and ATG, is prone to epigenetic regulation
under ICI-treatment, in order to become transcriptionally
active.
The C/EBPb transcription factor activates CDH3
promoter in breast cancer cells
H3K4me2 is an epigenetic mark which is frequently enriched
at regions surrounding known TSSs (20,21). Therefore, we
decided to analyse which transcription factors were better rep-
resented within a sequence region flanking 250 bp up- and
downstream the CDH3 Promoter Region 2, overlapping with
the first nucleotides of the TSS. Combining data from three
transcription factors bioinformatic tools (Genomatix,
TFSearch and TESS), the transcription factor CCAAT/
enhancer-binding protein (C/EBPb) was predominantly
present at this studied region, being this frequency validated
by at least two of the three predictive software resources.
Accordingly, five putative C/EBPb-binding sites were found
around and comprising the CDH3 Promoter Region 2
(Fig. 5A), turning this transcription factor as a putative candi-
date for playing a novel regulatory role on CDH3 promoter
activation in breast cancer cells.
C/EBPb is a well-known transcription factor and a key reg-
ulator of epithelial cell growth, proliferation and differen-
tiation of the mammary gland (22,23). C/EBPb is expressed
in several distinct protein isoforms [liver-enriched transcrip-
tional activating protein (LAP1, LAP2) and liver-enriched
transcriptional inhibitory protein (LIP)] that harbour particular
regulatory functions (24–26). On the basis of this knowledge,
Figure 2. Regulation of P-cadherin expression by the siRNA for ERa in MCF-7/AZ breast cancer cells. (A) Real-time PCR showed that cells transfected with
siRNA for ERa show a significant increase in P-cadherin expression at the mRNA level. P-cadherin high expressing breast cancer cells BT-20 were used as
detection sensitivity control for P-cadherin probe, when P-cadherin is inhibited with a specific siRNA (∗P , 0.005). (B) At the protein level, the up-regulation
of P-cadherin was observed when cells were transfected with an ERa siRNA concentration of 100 nM. The knock-down of ERa expression was observed at both
ERa siRNA concentrations of 50 and 100 nM.
Figure 3. Regulation of CDH3 promoter and P-cadherin expression by epigenetic activating mechanisms. (A) MCF-7/AZ cells transiently transfected with
CDH3 promoter vector were treated with sequential concentrations of TSA during 12 h. An increase of promoter activation was observed when cells were
treated with gradual of TSA concentrations (∗P, 0.0001). (B) The western blot also showed a gradual increased of P-cadherin protein levels without alteration
of ERa protein levels.
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we decided to test the relevance of these different C/EBPb iso-
forms in CDH3 promoter activation, as well as their relevance
in CDH3 expression at mRNA level.
By luciferase gene reporter assay, using the cloned CDH3
promoter, different C/EBPb cDNAs vectors, codifying for a
particular C/EBPb isoform (LAP1, LAP2, or LIP) were inde-
pendently co-transfected in a cDNA amount titration basis
(5, 10 and 20 ng of cDNA) into MCF-7/AZ cells. Luciferase
readouts revealed that CDH3 promoter was gradually activated
by the three isoforms, although the promoter activation induced
by the C/EBPb-LIP isoforms was significantly greater com-
pared with the activation induced by LAP1 and LAP2. CDH3
promoter activation observed with the lowest co-transfected
amount of C/EBPb-LIP (5 ng) was higher when compared
with the highest amount of LAP1 and LAP2 isoforms (20 ng)
co-transfected into MCF-7/AZ cells. Most importantly, promo-
ter activation was raised when titration was done using higher
amounts of C/EBPb-LIP isoform (Fig. 5B). This result shows
that among the three C/EBPb isoforms with known regulatory
functions in breast cancer, in vitro, the LIP isoform is the
most important in CDH3 promoter activation.
In order to test this hypothesis, MCF-7/AZ cells were
co-transfected with CDH3 promoter and with C/EBPb-LIP
vector isoform and treated with ICI/control ethanol (EtOH)
and luciferase activity was measured. This same experiment
was repeated in order to evaluate CDH3 mRNA expression
levels by real-time PCR. The luciferase reporter assay
showed that further than the demonstrated activation of
CDH3 promoter by C/EBPb-LIP isoform, the treatment with
ICI provoked a significant synergistic effect towards the acti-
vation of CDH3 promoter (Fig. 5C). The same trend was also
observed at the mRNA levels, although not statistically signifi-
cant (Fig. 5D). In order to see if the induction of P-cadherin
expression by ICI would coincide with C/EBPb nuclear
accumulation, immunofluorescence for this transcription
factor was performed. Interestingly, we could observe that
C/EBPb is highly expressed at the nuclei of MCF-7/AZ
breast cancer cells, independently if these are treated with
ICI or EtOH (Fig. 5E).
All these results allowed us to conclude that ICI is able to
actively remodel the chromatin at CDH3 promoter, which
permit to expose the C/EBPb-binding sites. Since C/EBPb
is available in the nuclei of these cells, it will promote
P-cadherin transcription and consequent expression.
C/EBPb is associated with P-cadherin expression and with
features of poor prognosis in human breast carcinomas
Similar to what we have previously described for P-cadherin
expression, high levels of C/EBPb have also been associated
with tumour progression and as an indicative of an unfavour-
able prognosis in breast cancer. Most importantly, for the
shorter isoform LIP, correlations with ER-negative and
poorly differentiated phenotype were previously demonstrated
(27,28). Taking into account these results and our in vitro data,
we decided to perform an immunohistochemical characteriz-
ation of C/EBPb expression in a series of 249 invasive
primary breast carcinomas previously characterized for
P-cadherin expression profile.
From the total 249 cases, only the ones with clear nuclear
expression of C/EBPb were selected for immunohistochemis-
try classification. Strong immunoexpression of C/EBPb is
observed in the nuclei of luminal epithelial cells from adjacent
normal ducts, as showed in Figure 6A. In parallel with what is
found for P-cadherin expression in normal epithelial gland
(Fig. 6A), C/EBPb is also expressed in the vast majority of
Figure 4. Chromatin immunoprecipitation (ChIP) analysis of histone modifications at CDH3 promoter after treatment with the pure anti-oestrogen ICI. (A) Rep-
resentation of the CDH3 promoter structure showing epigenetic regulatory regions (CpG islands and DHS—DNAase hypersensitive sites) and putative ERa/Sp1
sites, predicted by bioinformatic tools (Genomatix, TESS and TFSearch). Transcription start site (TSS) and the analysed distal CDH3 Promoter Region 1 and
proximal CDH3 Promoter Region 2 are also illustrated. (B) and (C) ICI-mediated induction of histone activating (H3K4me2, H3K9ac and H3ac) and repressive
(H3K27me3 and H4K20me3) marks in CDH3 Promoter Region 1 and 2, respectively. In promoter Region 1, weak pronounced chromatin alterations were
detected after treatment with ICI. In contrast, significant levels of enrichment for H3K4me2 were observed in promoter Region 2, induced by the anti-oestrogen
treatment (C).
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the myoepithelial/basal cells. In positive tumour samples,
C/EBPb expression was restricted to the nuclei of malignant
cells, while P-cadherin presented its typical membranous
staining (Fig. 6B). C/EBPb was positive (.10% of positive
cells) in the nuclei of 43% (86 of 198) of the invasive carci-
nomas, whereas P-cadherin was present in 33% (64 of 194).
Importantly, C/EBPb was significantly associated with
P-cadherin expression (P ¼ 0.004), with nearly 60% of
co-expression of these two proteins (Table 1). When we
compared the expression of C/EBPb with the molecular
subtype, we found that while 60% of C/EBPb-negative
cases were comprised in the luminal A subtype, basal-like
subtype carcinomas expressed C/EBPb in 74% of the
cases (Table 1). On the basis of these results, we showed
that the expression of C/EBPb strongly associates with aggres-
sive behaviour features as high proliferation rates, poor
differentiation and basal-like phenotype. Furthermore, the
expression of C/EBPb was associated with high histological
Figure 5. Activation of CDH3 promoter and P-cadherin mRNA levels by the transcription factor C/EBPb in MCF-7/AZ cells. (A) Proximal CDH3 promoter
region showing five C/EBPb-binding sites with their predicted sequences based on transcription factors bioinformatic tools. The DNA sequence inside the black
area represents the concordant sequence that was validated by at least two of the three bioinformatic tools used (high score), whereas the grey sequence area
results from the prediction of a single web tool out of the three used (low score). There is one putative C/EBPb-binding site at the CDH3 TSS region and another
two inside the studied promoter region 2. Two high-scored C/EBPb-binding sites are also localized immediately before the limits of the established proximal
CDH3 promoter region. (B) CDH3 luciferase reporter assay where MCF-7/AZ cell were transfected with different amounts (5, 10 and 20 ng) of C/EBPb cDNA
isoforms (LAP1, LAP2 and LIP). Comparative with the pLENTI empty vector, the C/EBPb–LIP isoform significantly activates the CDH3 promoter in a dose-
dependent manner (∗P , 0.001). (C) CDH3 promoter activation by the C/EBPb–LIP isoform in response to ICI treatment in MCF-7/AZ cells, where the anti-
oestrogen induced a synergistic effect with C/EBPb–LIP towards the activation of CDH3 promoter (∗P , 0,001). (D) Real-time PCR analysis of P-cadherin
mRNA expression levels after ICI treatment. P-cadherin mRNA was up-regulated not only by the transfection of C/EBPb–LIP isoform, but also by an ICI-
mediated synergistic effect. (E) MCF-7/AZ cells show nuclear expression of C/EBPb (Alexa 488—green), treated with ethanol or ICI. The DAPI staining
(blue) confirms the nuclei localization of C/EBPb (see the merge image). All the figures show a ×630 magnification. The white line in each picture represents
a 20 mm scale.
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grade (P ¼ 0.002), but no association was found with tumour
size or regional lymph node involvement. We also found a
strong association of C/EBPb with breast cancer markers of
aggressive phenotype, namely CK14 (P ¼ 0.015), vimentin
(P ¼ 0.001), high proliferative index-MIB-1 (P , 0.0001)
and EGFR (P ¼ 0.002), where 90% of the cases that expressed
EGFR were also positive for C/EBPb. Figure 6B shows an
example of a high-grade invasive carcinoma, which was con-
comitantly positive for P-cadherin, C/EBPb, vimentin, EGFR
and MIB-1 expression.
In summary, we demonstrated, for the first time, an associ-
ation of the expression of this transcription factor with the
expression of P-cadherin, a pro-invasive and migration
inducer protein, which also constitutes an important marker
of poor prognosis and aggressive basal-like phenotype in
breast carcinomas.
DISCUSSION
Over the last years, we and others have been describing the
association of P-cadherin expression with malignant behaviour,
poor prognosis and short survival in breast cancer (3,6,7,29,30).
Recent findings have contributed to the elucidation of P-cadherin
function in breast tumour cell biology (10), but the expression
regulation of this protein in breast cancer has poorly been
explored. Previously, we reported a significant association
between P-cadherin overexpression andCDH3hypomethylation,
suggesting an important regulatory role of epigenetic events in
the regulation of P-cadherin expression in breast cancer (3).
Moreover, we demonstrated that the abrogation of ERa-
signalling pathway, caused by the pure anti-oestrogen ICI, was
responsible for the increase of P-cadherin protein and mRNA
expression, pointing CDH3 as an oestrogen-repressed gene (5).
However, the mechanisms by which epigenetic events and ERa-
signalling inhibition leads to P-cadherin expression and to
aggressive tumour behaviour are still unknown.
In the present study, we identified, for the first time, the
existence of an epigenetic regulation by which ICI
up-regulates P-cadherin expression in MCF-7/AZ breast
cancer cells through chromatin remodelling at CDH3 promo-
ter. After treatment of this ERa-positive breast cancer cell
line with the oestrogen antagonist ICI, an important
histone-activating mark (H3K4me2) was enriched at the prox-
imal region of the CDH3/P-cadherin promoter.
Previous studies showed that chromatin structural remodel-
ling and nuclear entropy can be induced by the treatment of
breast cells with anti-oestrogens such as ICI (31). In fact,
and although it was initially believed that anti-oestrogens
function merely by competing with endogenous oestrogens
for receptor binding, recent studies also demonstrated that
ICI and tamoxifen can induce distinct conformational
changes in ER, implying that the ligand-bound ER can
recruit specific co-regulators to modulate different gene pro-
moters, thereby regulating gene expression (32,33).
Figure 6. (A) Immunohistochemistry representation of the expression pattern of C/EBPb and P-cadherin in normal breast tissue. P-cadherin expression is
restricted to myoepithelial cell layer, whereas nuclear expression of C/EBPb is seen in myoepithelial cells of a normal breast duct and in scattered normal
luminal cells (magnification ×400). (B) An immunohistochemical panel of a grade III invasive breast carcinoma (Haematoxylin–eosin staining), showing posi-
tive membrane expression for P-cadherin and EGFR, membranar/cytoplasmic expression for vimentin and nuclear expression for C/EBPb and MIB-1 (magni-
fication ×200).
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A study in 2005 showed that ICI can induce transcription of
the ERa-repressed gene p21Waf1, through the dissociation of
HDACs and ERa from Sp1 sites and therefore, resulting in
increased histone acetylation and de-repression of the
p21Waf1 promoter (19). In fact, the authors not only found
that the proximal Sp1 sites are crucial in mediating the promo-
ter’s response to ICI, but also that HDAC inhibition by TSA
leads to p21Waf1 promoter activity (19). Further than the fact
that most of the proximal promoter regions are generally
important to gene transcription regulation, the studied CDH3
proximal Region 2, which showed an ICI-induced enrichment
for the active histone mark H3K4me2, additionally displays a
CpG island and a DNaseI hypersensitive site (DHS) region,
overlapping with the TSS. As described by the ENCODE
Project Consortium, the aggregate signal of histone modifi-
cations is mainly attributable to active TSS region, in particu-
lar those near CpG islands and DHS, both genomic regions
thought to be enriched for regulatory information (34). Impor-
tantly, after a prediction analysis of the proximal CDH3 pro-
moter, comprising a region from the TSS to the ATG, we
observed that this promoter area was remarkably enriched in
Sp1 sites, having also a significant number of ERa coupled
with those (Fig. 4A). Hence, if a repression complex, mediated
by ERa and HDACs at Sp1 sites, is able to be released by the
treatment with ICI and therefore enhancing the gene transcrip-
tion, the characteristics of the proximal CDH3 promoter,
together with the H3K4me2 enrichment in Region 2, strongly
suggest that this chromatin de-repression mechanism plays an
important role in the ICI-induced promoter transcriptional
activation. Reinforcing this, we also observed an up-regulation
of CDH3 promoter activity and P-cadherin protein expression
in cells treated with TSA, showing that chromatin-activating
modifications are indeed important to the modulation of this
gene.
The most prominent activating mark found within the
CDH3 promoter Region 2 was H3K4me2, which is the
histone modification better correlated with DHS regions and
chromatin accessibility (20,21,34), as well as with active
gene transcription (35).
Herein, we further investigated which transcription factors
were strongly represented within CDH3 promoter Region 2,
TSS and DHS region. We have found that putative C/EBPb-
binding sites were predominantly present within this region.
Furthermore, we tested the ability of C/EBPb to transactivate
P-cadherin protein and mRNA expression, as well asCDH3 pro-
moter, demonstrating, for the first time, that, among the three
different C/EBPb isoforms, C/EBPb-LIP was the most relevant
in a P-cadherin expression activation setting. C/EBPb proteins
are transcription factors which regulate cellular proliferation,
differentiation and apoptosis in mammary gland (24).
However, like P-cadherin, C/EBPb is not mutated in breast
tumours, but its overexpression has widely been described in a
subset of aggressive breast cancer (25). Interestingly, transgenic
and overexpression studies showed that C/EBPb–LIP induces
proliferation in mammary epithelial cells and that a C/EBPb–
LIP-initiated growth cascade may play a role in the development
of breast cancer (24,26). At a clinicopathological level, LIP
isoform correlates with an ER-negative breast cancer phenotype,
high proliferative index and histological grade, aneuploidy and
poor differentiation. These findings are not only suggestive of
the involvement of C/EBPb–LIP in tumour progression and
indicative of an unfavourable patient prognosis (27), but also
show that its expression should be evaluated as a prognostic
marker for breast cancer patients (28). Remarkably, breast carci-
nomas expressing C/EBPb–LIP displays the unfavourable clin-
icopathological features described for the aggressive breast
tumours overexpressing P-cadherin. Additionally, we also
observed an association of C/EBPb with aggressive markers,
namely EGFR, CK14 and vimentin expression, as well with
basal-like molecular phenotype. Thus, based in our results, it
is tempting to consider that, under conditions of ICI-mediated
increased chromatin accessibility, C/EBPb, and most likely
the LIP isoform, can play a role in the activation of CDH3 pro-
moter towards a typical P-cadherin-related aggressive tumour
phenotype.
Our results are also of clinical relevance since there is
growing evidence that selective ER modulators, such as
Table 1. Association of C/EBPb expression with clinicopathological features
and immunohistochemical markers in invasive breast carcinomas
Variables No. C/EBPb negative
(%)
C/EBPb positive
(%)
P-value
Tumour size 187
,15 mm 16 11 (68.7) 5 (31.3) 0.288
≥15 mm 171 94 (55.0) 77 (45.0)
LNI 180
Present 91 55 (60.4) 36 (39.6) 0.138
Absent 89 44 (49.4) 45 (50.6)
Tumour grade 198
GI 42 31 (73.8) 11 (26.2) 0.002
GII 90 54 (60.0) 36 (40.0)
GIII 66 27 (40.9) 39 (59.1)
NPI 169
NPI, 3.4 38 26 (68.4) 12 (31.6) 0.067
3.4 ≤ NPI ≤ 5.4 85 39 (45.9) 46 (54.1)
NPI. 5.4 46 25 (54.3) 21 (45.6)
EGFR 197
Positive 10 1 (10.0) 9 (90.0) 0.002
Negative 187 111 (59.4) 76 (40.6)
P-Cadherin 194
Positive 64 27 (42.2) 37 (57.8) 0.004
Negative 130 83 (63.8) 47 (36.2)
CK5 198
Positive 41 22 (53.7) 19 (46.3) 0.673
Negative 157 90 (57.3) 67 (42.7)
CK14 193
Positive 10 2 (20.0) 8 (80.0) 0.015
Negative 183 107 (58.5) 76 (41.5)
Vimentin 178
Positive 25 7 (28.0) 18 (72.0) 0.001
Negative 153 95 (62.0) 58 (38.0)
MIB-1 197
,10 94 70 (74.5) 24 (25.5) ,0.0001
10–20 20 9 (45.0) 11 (55.0)
.20 83 33 (39.8) 50 (60.2)
Subtype 178
Luminal 122 74 (60.7) 48 (39.3) 0.001
HER-2 22 14 (63.7) 8 (36.3)
Basal 34 9 (26.5) 25 (73.5)
Data presented as n (%) unless stated otherwise.
C/EBPb, CCAAT/enhancer-binding protein beta; LNI, lymph node
involvement; NPI, Nottingham prognostic index; EGFR, epidermal growth
receptor; P-cadherin, placental cadherin; CK, cytokeratin; MIB-1, mindbomb
homolog 1; HER-2, human epidermal growth factor receptor 2.
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tamoxifen or ICI (Fulvestrant), are able to induce expression
of genes which, in the appropriate cell context, may contribute
to adverse cell phenotype, in part by inducing breast cancer
cell invasion (36). Although anti-oestrogens have been the
mainstay of therapy in patients with ERa-positive breast
cancer and have provided significant improvements in survi-
val, their benefits are limited by tumour recurrence in a signifi-
cant proportion of initially drug-responsive breast cancer
patients due to acquired anti-oestrogen resistance (36). There-
fore, it is tempting to assume that one of the important mech-
anisms by which this endocrine resistance occur should be the
inappropriate activation of ER-repressed genes at late stages of
long-course endocrine therapeutic regimens.
To date, mechanistic studies have revealed important roles
for growth factor signalling pathways, such as those regulated
EGFR and HER2, as contributors to endocrine resistance (37–
39). Similarly, in ER-positive breast cancer cells, tamoxifen
has been reported to increase the expression of poor prognosis
markers in breast cancer patients [14-3-3s (40)], as well as of
signalling elements frequently linked to tumour migration and
invasion (MAPK, FAK and Src) (41,42).
The present study highlights that, in ERa-positive breast
cancer cells, the anti-oestrogen ICI is able to induce the
expression of CDH3 gene, leading to P-cadherin overexpres-
sion, which is described as a pro-invasive protein in breast
cancer. These data, together with other studies, contribute to
clarify the ability of selective ER modulators and steroidal
anti-oestrogens, like fulvestrant, to induce expression of
genes normally repressed by oestrogen/ER signalling, and
thus, playing an important role in the capacity of breast
cancer cells to evade their growth inhibitory effects (37,43).
It is important to know which signalling pathways are acti-
vated in anti-oestrogen resistant breast cancer, in order to
find new and effective therapeutic targets to use in this
setting. In the future, it would be interesting to study if P-
cadherin can be a good biomarker in this group of breast
tumour recurrences that occur upon endocrine therapy.
MATERIALS AND METHODS
Antibodies and chemicals
The following primary anti-human antibodies were used for
western blot (WB), immunohistochemistry (IHC) and immu-
nofluorescence (IF) against: P-cadherin [mouse monoclonal,
clone 56; BD Transduction Biosciences, Lexington, KY,
USA; dilutions: 1:250 (WB) and 1:50 (IHC)], C/EBPb
[mouse monoclonal, clone H7, Santa Cruz Biotechnologies,
CA, USA; dilutions: 1:500 (WB) and 1:100 (IHC, IF)],
b-actin [goat monoclonal, I-19; Santa Cruz Biotechnologies;
dilutions: 1:1000 (WB)], ERa [mouse monoclonal,
NCL-L-ER-6F11; Novocastra, Newcastle; dilutions: 1:50
(WB) and 1:200 (IHC)]. Anti-mouse and anti-goat horseradish
peroxidase-conjugated secondary antibodies were also used
for WB [HRP-conjungated, Santa Cruz Biotechnologies;
dilutions: 1:2000]. For chromatin immnunoprecipitation
(ChIP) assays, the following antibodies were used:
anti-acetyl-H3K9 antibody (07–352; Upstate Biotechnology,
Lake Placid, NY, USA), anti-acetyl-H3 antibody (17–615;
Upstate), anti-dimethyl-H3K4 antibody (07–030; Upstate),
anti-trimethyl-H3K27 antibody (07–449; Upstate), anti-
trimethyl-H4K20 antibody (ab9053; Abcam plc, Cambridge,
UK) and rabbit anti-mouse-IgG antiserum (M7023; Sigma-
Aldrich, Bornem, Germany).
ICI 182,780 Imperial Chemical Industries (ICI),
17b-oestradiol (E2) and Trichostatin A (TSA) were all pur-
chased from Sigma. ICI and E2 were dissolved in 100%
ethanol (EtOH) while TSA was dissolved in DMSO.
Cell culture, transfection and treatment conditions
The human breast cancer cell line MCF7/AZ was kindly given
by Prof. Marc Mareel (Laboratory of Experimental Cancerol-
ogy, Ghent University, Belgium), whereas BT-20 breast
cancer cell line was purchased from American Type Culture
Collection—ATCC (Manassas, VA, USA). Cell lines were
cultured in growth media consisting of Dulbecco’s modified
Eagle’s medium [DMEM (Invitrogen Ltd, Paisley, UK)], sup-
plemented with 10% heat inactivated fetal bovine serum (Invi-
trogen), 100 IU/mL penicillin and 100 mg/ml of streptomycin
(Invitrogen), at 378C. MCF/AZ cells were grown at 10% CO2
and BT-20 cells at 5% CO2 controlled atmosphere.
For transient transfections, reagents were used as described
subsequently. For gene reporter assays, MCF-7/AZ cells were
grown in 96-well plates to 60–70% confluence and transfec-
tion was achieved using the liposome-mediated FuGENE 6
transfection reagent (Roche Diagnostic GmbH, Mannheim,
Germany), prepared according to the manufacturer’s instruc-
tions. These transient transfections used a charge ratio
(FuGENE/DNA) of 3:1 where equal amounts (20 ng) of
CDH3 promoter vector, as well as from the expression
vector, were added together with 5 ng of pCMV-Renilla nor-
malization vector. For RNA or protein expression assays,
MCF-7/AZ cells were grown in 6-well plates to 70–80% con-
fluence. Transient transfections of 1 mg of C/EBPb expression
vector were done using Lipofectamine 2000 (Invitrogen),
using a ratio (Lipofectamine/DNA) of 3:1 prepared according
to the manufacture’s instruction.
Whenever not specified, cells treatments with ICI were
carried out for 24 h at a final concentration of 0.1 mM
(1027 M), while treatments with E2 were performed at a
final concentration of 0.01 mM (1028 M) for 24 h. In treatments
with TSA, cell measurements were done after 12 h of incu-
bation at the final concentration of 0.05 mM or 0.1 mM.
Promoter vectors and cDNA constructs
The human pLENTI-C/EBPb expression vectors
(C/EBPb-LAP1, C/EBPb-LAP2 and C/EBPb-LIP) were
kindly provided by Dr. Peter Gott (Institute of Anthropology
and Human Genetics, Tu¨bingen, Germany). To generate the
full-length CDH3-luciferase vector, a 2.1 kb 5′ untranslated
region of human CDH3 gene (GenBank accession no.
NT_010498) was generated by PCR, using a Pfu DNA Poly-
merase (MBI Fermentas, Burlington, Canada), the sense
primer (5′-TGCTAGGCCTGAGAGAGCAAG-3′) and anti-
sense primer (5′-CCTTCCGGGACTCCCTTG-3′). The PCR
product was subcloned into a TOPO Cloning TA vector (Invi-
trogen) and then transferred to a pGL3-luciferase reporter
plasmid (Promega, Corporation, Madison, WI, USA), after
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digestion of both recipient vector and PCR fragment with KpnI
and NcoI restriction enzymes (MBI Fermentas). Ligation was
performed using T4 ligase enzyme (New England Biolabs,
Ipswich, MA, USA), and a pGL3/CDH3-luciferase reporter
full-length vector (positions from 21834 to +1 ATG site),
framed with ATG/firefly luciferase cDNA from the
pGL3-luciferase reporter plasmid, was generated. Direct
sequencing (ABI, Perkin-Elmer, Foster City, CA, USA) was
performed to confirm the cloning frame and integrity of the
promoter.
CDH3-luciferase reporter gene assay
MCF-7/AZ cells were co-transfected with the human full-
length pGL3-CDH3/luc promoter vector and with
pCMV-Renilla luciferase construct (Promega), for normaliza-
tion of transfection efficiency. For promoter analysis, 24 h
after transfection, cells were washed twice in PBS-cold and
then harvested and lysed for firefly/Renilla luciferase assays
using the Luclite Reporter Gene Assay System (Perkin
Elmer, Beaconsfield, UK), according to the manufacturer’s
instructions. Luciferase bioluminescence from Renilla was
measured using native coelenteranzine substrate reagent
(Lux Biotechnology, Edinburgh, UK). Individual transfection
experiments were repeated at least three times and in quadru-
plicate per transfection condition. Empty pGL3-basic vector
(E1751) and pGL3-Control (pLUC) vector (E1741), both
from Promega, were included as controls in all CDH3-reporter
assays. Luminescence was then read using the Wallac/Perkin
Elmer-1450-028 Trilux Microbeta (Perkin Elmer) plate
reader, and the results are shown as mean of relative light
units (RLU).
Protein extraction and WB analysis
Protein lysates were prepared from cultured cells, using
catenin lysis buffer [1% (v/v) Triton X-100 and 1% (v/v)
NP-40 (Sigma) in deionized phosphate-buffered saline
(PBS)] supplemented with 1:7 proteases inhibitors cocktail
(Roche Diagnostics GmbH, Germany). Cells were washed
twice with PBS and were allowed to lyse in 500 ml of
catenin lysis buffer for 10 min, at 48C. Cell lysates were
mixed with a vortex for three times and centrifuged at
20 000g at 48C, during 10 min. Supernatants were collected
and protein concentration was determined using the Bradford
assay (BioRad Protein Assay kit). Proteins were dissolved in
sample buffer [Laemmli with 5% (v/v) 2-b-mercaptoethanol
and 5% (v/v) bromophenol blue] and boiled for 5 min at
958C. Samples were separated by SDS–PAGE, and proteins
were transferred into nitrocellulose membranes [Amersham
Hybond enhanced chemiluminescence (ECL)] at 130 V for
1 h. For immunostaining, membranes were blocked with 5%
(w/v) non-fat dry milk in PBS containing 0.5% (v/v)
Tween-20. These were subsequently incubated with primary
antibodies, during 1–2 h, followed by four 5 min washes
in PBS/Tween-20 (PBS-T). Then the membranes are incu-
bated with horseradish peroxidase-conjugated secondary anti-
bodies, during 45 min. Proteins were detected using ECL
reagent (Amersham), as a substrate, and blots were exposed
to an autoradiographic film. Quantification of WBs was per-
formed using Quantity One software (BioRad), and the ones
selected to show are representative experiments.
Immunofluorescence
Briefly, MCF-7/AZ cells were cultured on glass coverslips,
and fixed with cold methanol for 10 min on ice. After fixation,
cells were permeabilized with 1% Triton X-100 in PBS for
5 min, at room temperature. Non-specific binding was
blocked by cell treatment with PBS containing 3% BSA, for
30 min, at room temperature. Cells were then stained with
the primary antibody for C/EBPb (Santa Cruz), during 1 h,
at 1:100 dilution. After PBS washes, cells were incubated,
for 1 h, with the rabbit polyclonal secondary antibody, conju-
gated with Alexa 488 (Invitrogen), at 1:500 dilution. After a
wash with PBS, each sample was mounted with Vectashield
(Vector Laboratories, Inc., Burlingame, CA, USA) containing
4,6-diamidine-2-phenylindolendihydrochrolide (DAPI). The
C/EBPb and DAPI dual cell staining was observed with a
Zeiss microscope (Imager Z1) with apotome, and images
were acquired using the Axiovision software.
ChIP assay
Exponentially growing MCF-7/AZ cells were treated with ICI
for 24 h and fixed with 1% formaldehyde (378C, 10 min). The
reaction was stopped with addition of glycine to a final con-
centration of 0.125 M. Whole-cell fixed lysed extracts were
prepared for use in ChIP assays as described previously
(44). Briefly, fragmented chromatin to an average size of
300–1000 bp was incubated (48C, 1 h) with 30 ml of
blocked protein-A-agarose beads (Sigma) on a rotating
wheel. Pre-cleared chromatin (150 mg) was immunoprecipi-
tated (48C, overnight) with 10 ml anti-acetyl-H3K9 antibody,
10 ml anti-acetyl-H3 antibody, 5 ml anti-dimethyl-H3K4
antibody, 5 ml anti-trimethyl-H3K27 antibody, 5 ml anti-
trimethyl-H4K20 antibody and 2 ml of a rabbit anti-
mouse-IgG antiserum as a negative control. After elution of
immune complexes, DNA was resuspended in 100 ml of TE
(10 mM Tris, 1 mM EDTA at pH 8.0) solution. Quantification
of precipitated DNA was performed using real-time qPCR
amplification carried out on a Chromo4 DNA engine
(Biorad), using SYBR green jumpstart PCR master mix
(Sigma) and 0.3 mM of the following primers: distal promoter
region 1, forward: 5′-CAGGTTAGCCCTGGAAGGTCAA-3′;
reverse: 5′-TGAGATGGAGTCTCACTGTCGTCC-3′; proxi-
mal promoter region 2, forward 5′-CTGTGAAATGGAAG
AAGCGGTC-3′, reverse 5′-GCTGGTCTTGAACTTCTGGA
CTC-3′. The amount of DNA precipitated by each antibody
was normalized against 1 in 10 of the starting input material.
Gene silencing with small interfering RNAs (siRNAs)
MCF-7/AZ and BT-20 cells in 2 ml of culture medium were
transfected with siRNA for ERa (50 nM and 100 nM
Hs_ESR1, GW Validated siRNA, Qiagen, Cambridge, MA,
USA) or for P-Cadherin (50 nM, Hs_CDH3_6, GW Validated
siRNA, Qiagen). Transfection was carried out at starvation
conditions for 6 h after which appropriated culture, medium
was added to the cells. After 48 h, the cells were harvested
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for RNA isolation or protein extraction for real-time PCR or
WB analysis.
RNA isolation and real-time PCR
RNA was isolated using a Qiagen RNAeasy extraction kit
(Qiagen), according to the protocol provided by the manufac-
turers and concentration was determined in a ND-1000 spec-
trometer (Nanodrop). One microgram of RNA per sample
was used to synthesize cDNA, using reverse-transcriptase
RT (Invitrogen). CDH3 TaqMan probe (HS00354998_m1,
Applied Biosystems, Foster City, CA, USA) was used to
specifically recognize CDH3 fragments, which were amplified
through 40 cycles (Applied Biosystems 7000). Relative CDH3
gene expression was determined by its normalization with
GAPDH expression, using a Human GAPDH endogenous
control (NM_002046.3, Applied Biosystems).
Patient selection
A series of 249 cases of primary operable invasive breast car-
cinomas were retrieved from the files of the Department of
Pathology, Hospital of Divino Espı´rito Santo, Azores, Portugal
and from the Federal University of Santa Catarina,
Floriano´polis-SC, Brazil. These samples were obtained from
patients with age ranging from 30 to 89 years old. All the
formalin-fixed paraffin-embedded histological sections were
reviewed by three pathologists (V.C., F.S. and F.M.) and the
diagnoses were confirmed as follows: 208 invasive ductal car-
cinomas, 7 invasive lobular carcinomas, 3 mixed, 3 tubular,
8 medullary and 20 invasive breast carcinomas of other
special histological types. These tumours have been fully
characterized for the clinical and pathological features,
namely tumour size, lymph nodes invasion, tumour grade,
Nottingham Prognostic Index (NPI) and for the following
breast cancer markers: ERa, PR, HER-2, EGFR, P-cadherin,
CK5, CK14, vimentin and MIB-1, as well as classified for
breast cancer subtype (4,7,8,45,46).
This study was conducted under the national regulative law
for the usage of human biological specimens, where the
samples are delinked from their donor’s identification and
are exclusively available for retrospective research purposes.
Immunohistochemistry analysis
IHC was performed in 3 mm formalin-fixed paraffin-
embedded sections. The IHC technique was performed using
an Envision Detection System (DAKO Cytomation Envision
System HRP, DAKO Corporation, Carpinteria, CA, USA) or
the classical streptavidin–avidin–biotin complex (SABC)
method according with the manufacturer’s instructions.
Expression of C/EBPb was analysed using a mouse mono-
clonal antibody. Sections were deparaffinised with xylene and
rehydrated in a series of decreasing concentrations of ethanol sol-
utions. Heat-induced epitope retrieval was carried out in 10 mM
citrate buffer (sodium citrate) (pH 6) (LabVision Corporation,
Fremont, CA, USA), in a 988C water bath, for 30 min. After
cooling retrieval solutions, for at least 30 min at room tempera-
ture, the slides were treated for 10 min with 3% H2O2 in metha-
nol, in order to block endogenous peroxidase. Slides were
incubated overnight at 48C with monoclonal antibody for C/
EBPb and then labelled with the Envision Detection System
from DAKO. Colour reaction product was developed with
3,3′-diaminobenzidine, tetrahydrochloride (DAB plus, DAKO
Glostrup, Denmark) as a substrate, and nuclear contrast was
achieved with haematoxylin/ammoniacal water counterstaining.
Formalin-fixed paraffin-embedded sections from normal breast
gland, skin or normal gastric mucosa were used as positive con-
trols. Also, negative controls were performed by replacing the
primary antibody with PBS/non-immune mouse serum.
Immunostained slides were reviewed by two pathologists
(F.M. and F.S.) and cases with .10% of nuclei-stained posi-
tive cells for C/EBPb were considered positive.
Statistical analysis
C/EBPb immunoexpression associations were analysed using
StatView, version 5.0 software (SAS Institute, Inc.). Continu-
ous variables were presented as mean+ standard deviation
(SD), and categorical variables were presented as number
(%). The clinicopathological features and immunohistochem-
ical markers of the tumours were compared across groups of
expression of C/EBPb using ANOVA and the chi-square
test, respectively, for continuous and categorical variables.
For luciferase reporter gene analysis, independent quadru-
plicate measurements per each analysed variable were per-
formed and RLU were compared between variables using
Student’s t-test. This same statistical method was also used
to assess the variations in RNA expression.
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4. General Discussion 
 The work presented throughout this thesis addressed two major hot topics in breast 
oncology research. Herein, we highlight the relevance of transcription factors in breast 
cancer as potential tools for prognosis and predictors of patient outcome, as well as, 
markers for therapeutic response and sensitivity. Additionally, we provide innovative data 
concerning CDH3/P-cadherin regulation, pushing the borders of the knowledge about the 
significance of epigenetic regulation in initiating breast carcinogenesis, promoting 
tumorigenic phenotypes, and assisting in the development of drug resistance to anti-
oestrogens. 
 
4.1 - The Broad Relevance of Transcription Factors in Cancer  
 
 Transcription is the key step in the regulation of gene expression and involves 
several distinct dynamic events. The basal transcription machinery and regulatory 
components are recruited to their responsive elements on target genes, and active 
interactions of transcription factors with chromatin – and with each other – play an 
important role in initiation and elongation of this cellular mechanism. The dynamic nature of 
transcription factor-binding event is not only a fundamental property of the transcription 
machinery, but it also emerges as an important modulator of physiological processes, such 
cell differentiation and embryo development (1).  
The human genome encodes approximately 3000 transcription factors, regulating 
23.000 genes spread over 3300Mb of DNA, in contrast with Caenorhabditis elegans which 
encodes just 600 transcription factors, regulating 19.000 genes spread over 100Mb of DNA 
(2-3). However, completion of the human genome sequence revealed just 4000 more genes 
over C. elegans (4), albeit the complexity of Humans. Viewed in this manner, it seems that 
the number of transcription factors relate more closely to complexity than with gene 
number. Reinforcing this, human genome accounts for about 700.000 responsive elements 
for just 3000 transcription factors, establishing a new important issue that is the selective 
binding site sequence recognition (3). Nevertheless, it is the interplay and combinations 
between transcription factors and co-regulators, at specific timings of living cells that govern 
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the differences in the gene expression levels (2). The convergence over recent years 
between the complementary fields of signal transduction and gene regulation has allowed a 
more complete and integrated view concerning the biodiversity of the mechanisms that 
control gene transcription (5-6). Since transcription factors lie at the heart of almost every 
fundamental development and homeostatic organism process – including DNA replication 
and repair, cell growth and division, control of apoptosis and cellular differentiation – it is 
not surprising that inherited or acquired defects in structure and function of these factors 
contribute to human carcinogenesis. Historically, cancer researchers have been elucidating 
the mechanisms that govern gene expression, by analyzing the function of proteins 
commonly overexpressed in transformed and malignant cells. Hence, roles were ascribed to 
several major groups of human transcription factors and a pleiotropic view of the biology of 
transcription factor families has emerged (7).  
There are some transcription factor families that are frequently associated with 
cancer. Nuclear receptors (like ER), the MYC, the p53 and the AP-1 transcription factor 
families are among the most commonly studied in the context of human malignancies (7). 
Many of the well studied proto-oncogenes and tumour suppressor genes are known to 
encode proteins which, alone or in complex with other factors, act as transcriptional 
regulators. Defects in ER, MYC, Rb and p53 contribute to a common growth deregulatory 
mechanism that drives the uncontrolled cellular proliferation underlying breast tumours and 
are known to be transcription factors of clinical importance. Among these, c-MYC and its 
associated proteins activate the expression of a diverse range of genes with important 
relevance for the aggressive and poor-outcome signature of breast cancer (8-10). As a 
transcription factor, recent results suggest that MYC binding is influenced by the chromatin 
package conformation at potential binding sites, and particularly by patterns of histone 
modifications (11). Indeed, MYC was found to bind in regions enriched for several histone 
modifications generally associated with active chromatin such as H3K4me3, which seems to 
pinpoint the accessibility of MYC to gene promoter binding sites (12). At in vitro level, MYC 
ectopic expression attenuates responses to anti-oestrogen treatment, being suggested that 
oestrogen regulates cell growth mainly via MYC (9, 13). Importantly, some studies suggest 
that MYC oncogene activity may be necessary for the translocation of poor-outcome human 
breast tumours to distant sites, since functional inactivation of MYC in human breast cancer 
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cells specifically inhibits distant metastasis in vivo and invasive behaviour in vitro (10). c-
MYC represents, therefore, a classical example of a transcription factor that, not only acts as 
a cell growth regulator, but also as a prognostic and predictive factor in breast cancer. 
However, one of the most revealing examples of how transcription factor function can 
be regulated by multiple players, including binding of proteins, ligand and chromatin-
modifying enzymes, comes from studies on the ER. The kinetics and transcriptional 
signatures of ER under different conditions have been extensively studied, largely owing to 
its vital role in the initiation, progression and therapy of breast cancer (7). In the absence of 
ligand, ER can bind to ERE, as part of large transcriptionally repressive complexes, 
containing corepressor proteins maintaining a locally condensed chromatin structure (14). 
Prior to entry of oestradiol into cells, the epigenome is essentially primed for particular 
responses; combinations of specific histone modifications dictate where pioneer factors and 
transcription factors will bind and thus which genes are activated (15). This equilibrium is 
altered upon ligand addition, through the recruitment of transcription factors and their 
associated chromatin remodelling enzymes, allowing relaxation of the local chromatin and 
binding of further factors (16). In the particular framework where the nuclear receptor ER 
functions as an oestrogen-activated transcription factor, the crucial pioneer factor which 
allows and signalizes its binding to response elements is FOXA1. Studies have shown that 
siRNA mediated knock-down of FOXA1 prevents ER binding to responsive elements and 
alters DNase I sensitivity at the promoters of certain classes of ER target genes. 
Conversely, E2-induced gene expression is significantly inhibited in the absence of FOXA1 
(17-18). FOXA1 binds with high specificity to certain genomic consensus sequences in order 
to define the locations where ER can bind within the chromatin and, similarly with what is 
observed for c-MYC, the occupied sites are significantly enriched in H3K4me1 and H3K4me2 
activation marks (15). Interestingly, knock-down of FOXA1 does not alter the levels of these 
histone modifications, indicating that these are already present in DNA prior to FOXA1 
binding, presumably to localize preferential recruitment of transcription factors (15, 17). 
Carroll et al. recently described several robust data demonstrating the requirement of 
FOXA1 for optimal expression of nearly 50% of ER-regulated genes (19), highlighting the 
importance of this ER pioneer factor as the defining cofactor that determines the subset of 
responsive elements with which ER can associate (20). The identification of FOXA1 as an 
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important transcription factor was originated from experiments showing that it could 
modulate chromatin structure around some genes such as ALB (albumin) (21). However, it is 
actually known that it can bind to the promoters of more than 100 genes associated with 
several cellular mechanisms, such as metabolic processes, regulation of signalling pathways 
and cell cycle (22-24).  
Despite the widely reported relevance of FOXA1 as a transcription factor necessary for 
the transcriptional activity of ER, the expression of this forkhead box protein has been 
shown to be a potential candidate tool in breast cancer molecular pathology. Indeed, recent 
works have been demonstrating that FOXA1 expression is able to significantly predict a 
better survival for breast cancer patients (25-26), and that its assessment may be used as a 
marker for tumours pertaining to luminal A breast cancer, which have an exceptionally good 
prognosis (27). In our study, involving 249 breast cancer patients (see Chapter 2), we have 
found FOXA1 expression as a significant predictor of good outcome in breast cancer, being 
inversely associated with tumour size, Nottingham Prognostic Index, histological grade, 
lymph vascular invasion, lymph node stage and human epidermal growth factor receptor-2 
(HER-2) overexpression. However, because the biological strong regulatory interdependency 
between ER and FOXA1, the prognostic and predictive value of FOXA1 could simply reflect 
the high expression association and the above mentioned biological interplay between 
these two luminal markers. Thus, we further conducted an exploratory subgroup analysis in 
a cohort of ER-negative patients, in order to evaluate whether there was a prognostic 
value for the expression of FOXA1 in the absence of ER. In fact, the presence of ER 
correlates with increased disease-free survival and an overall better prognosis compared to 
breast cancers that lack ER, which are characterized by a more aggressive phenotype and a 
poor prognosis. Importantly, ER-positive breast cancers respond to endocrine therapies, 
like tamoxifen, whereas ER-negative tumours are resistant to endocrine therapies (28). In 
our work, the aim was to test, for the first time, if FOXA1 would be able to stratify the high-
risk subset of ER-negative patients in two different groups of biological behaviour. Herein, 
we showed that patients with loss of FOXA1 tumour expression showed an increased risk for 
breast cancer recurrence and that it constitutes an important and independent predictor of 
patient outcome in ER-negative tumours (see Chapter 2). Based on our results, we 
consider that the expression of FOXA1 is able to stratify the risk of breast cancer recurrence 
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among hormonal-negative patients, demonstrating the clinical importance of this 
transcription factor in breast cancer molecular classification and prognosis. Supporting 
these findings at the biological level, it is very logical to consider that the presence of FOXA1 
in ER-negative breast carcinomas represents an increase in patient disease-free survival, 
since this expression probably confers 1) some biological growth inhibitory potential on 
cancer cells, or 2) increases the response efficiency to breast cancer treatment, therefore, 
delaying the recurrence hit. Analyzing the first assumption, it is important to retain that 
FOXA1 is a transcription factor and, as so, it can bind to the promoters of a myriad of genes 
associated with important signalling pathways, being the ER-signalling pathway one of the 
classical examples. However, this transcription factor has been recently described to be 
important for the activation and expression of the cell cycle inhibitor p27kip1 in breast cancer 
cell models. Importantly, this p27 induction is achieved by interaction of FOXA1 with BRCA1, 
since co-transfection of these two transcription factors resulted in a synergistic activation on 
the p27Kip1 promoter (29). In this interesting study from Williamson et al., it was shown that 
co-transfection of FOXA1 and BRCA1 resulted in a greater amount of each protein, 
compared to transfection of each expression vector alone, and that the half-life of FOXA1 
was increased when co-expressed with BRCA1 (29). Even so, FOXA1 is capable of p27 
activation, either alone or in conjunction with BRCA1 (29). The tumour suppressor BRCA1 is 
probably the best studied gene in breast cancer and its role in regulating the expression of 
many genes implicated in cell cycle regulation (p21, p27, cyclin B1) and DNA repair are well 
established (29-30). Most importantly, a robust study from Liu et al., showed that FOXA1 
also plays an important role in the upregulation of the E-Cadherin gene (CDH1) promoter 
through its binding to the E-cadherin regulatory sequence (31). The activation of these well 
known tumour suppressor genes by FOXA1, in cooperation with p300 and AML1, led to the 
expression of E-cadherin and consequent reduction on motility of ER-negative metastatic 
breast cancer cells. Notably, it was suggested that FOXA1 positively regulates the expression 
of E-cadherin through chromatin modulation at CDH1 promoter level, and thus, allowing the 
coactivators binding to this promoter (31). Overall, it seems plausible that, in ER-negative 
patients harbouring FOXA1 expression, this protein would provide a “compensatory growth-
inhibitory effect”, which is translated by the FOXA1-induced activation of important tumour 
suppressor genes, such as p21, p27 or E-cadherin. This would lead to a reduction, not only 
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on the cell cycle errors and DNA damages associated with tumorigenesis, but also in 
increasing the cellular adhesive potential towards a lessening of the metastatic behaviour.  
Although speculative in the context of our study, it is tempting to suggest that FOXA1, 
as an ER-associated gene, might be important to the hormone-responsive phenotype of 
breast cancer, regardless of the tumour ER status. ER expression alone has been used to 
guide systemic therapy and to estimate breast cancer patient prognosis. However, not all 
ER-positive carcinomas show comparable prognosis or react similarly to anti-hormonal 
therapy (30%), whereas some ER-negative tumours (5-15%) curiously respond to endocrine 
therapy (32). Taking in account the previously described cross-talk and functional network 
between FOXA1 and the regulation of ER and its downstream targets, especially in what 
concerns the chromatin changes produced by FOXA1 as a signal for ER binding, it is likely 
that, in the absence of ER, the chromatin marks associated with FOXA1 would be occupied 
by coregulators complexes which, in an oestradiol-independent response pathway, would 
still activate some ER-target genes. Thus, if this might enlighten a mechanism by which 
those 5 to 15% of ER-negative tumours become responsive to endocrine-driven therapies, 
it also brings up the crucial biological role of FOXA1, as well as other transcription factors 
and coregulators, in a setting of those 30% of ER-positive tumours that are not hormone-
responsive. In other words, although ER is likely to be essential to hormone response, the 
expression of an additional set of genes that are not part of the oestradiol-response 
pathway may be also important in defining the hormone-responsive phenotype in ER-
negative breast cancer or, at least, in delaying the recurrence of the disease. A classical 
example of this hypothesis in breast cancer are the AP2 transcription factors, which control 
a set of genes that are commonly expressed in association with ER and contribute to the 
hormone response via oestrogen-independent signalling pathways (33). Curiously, Doane et 
al. identified an ER/PgR-negative breast cancer subset characterized by a hormonally 
regulated transcriptional program (34). In this very robust study, this subset of hormonal-
negative malignant lesions, which were named as “ER-negative class A” tumours, was 
characterized by a hormonally regulated transcription program and response to androgen. 
More importantly, they display a paradoxical expression of genes known to be either direct 
targets of ER, responsive to oestrogen, or typically expressed in ER+ breast cancer. FOXA1 
was one of these genes identified in this hormonal-responsive ER-negative subset of 
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tumours (34). Interestingly, authors suggested that ER-negative class A breast cancers bear a 
much closer molecular relationship to ER-positive breast cancers than to the basal subtype, 
despite the shared ER-negative phenotype. Moreover, authors ascribe part of this 
hormonally regulated transcriptional program to the presence of androgen receptor (AR) 
within these ER-negative tumours, speculating that this receptor may act in concert with 
other signal transduction pathways, in order to modulate the molecular events associated 
with this special ER-negative subset and contributing to its phenotype (34). In fact, AR 
expression is well known in ER+ breast cancer and has been associated with ER-negative 
breast tumours with apocrine histological features (35-36). 
 Another transcription factor gene, which is not oestradiol-responsive but contributes 
to the ER associated breast cancer phenotype, is GATA-3. In fact, a striking association 
between ER and GATA-3 expression in breast carcinomas has been demonstrated, 
indicating an important functional role of this transcription factor in hormone-responsive 
breast cancers (37). Additionally, GATA-3 has emerged recently as a strong predictor of 
clinical outcome in human luminal breast cancer, and its fundamental role in maintaining 
the differentiation and adhesion of the luminal cells has been extensively explored (38). 
Experimental data showed that induced expression of GATA-3, in GATA-3-negative 
undifferentiated breast cancer cells, is sufficient to induce differentiation and inhibit tumour 
dissemination in a mouse model. In fact, GATA-3 defines a distinct class of cancer genes that 
are differentiation factors, which affect the malignant phenotype by enforcing 
differentiation, rather than conventional tumour suppressor genes (38). As a transcription 
factor, GATA-3 works in a very similar fashion as FOXA1; GATA-3 binds to a consensus DNA 
sequence at gene promoters, to directly activate or repress expression, by recruiting 
chromatin remodelling complexes to remodel gene loci (39-40). Indeed, FOXA1, GATA-3 and 
ER form a transcriptional circuit required for growth, differentiation and hormonal 
dependency of mammary luminal cells, where FOXA1 appears as a downstream target of 
GATA-3 (41). Since this intricate functional complex has been shown to be important for 
breast cancer progression and behaviour, we included GATA-3 in our study, in order to 
assess at which level this transcription factor could be important as a prognostic factor in 
breast cancer (see Chapter 2). Herein, besides the strong association found with the “good 
prognosis signature” of the luminal tumours, GATA-3 expression failed the association with 
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most of the clinicopathological features and did not demonstrate a significant association 
with disease-free survival. Indeed, GATA-3 was neither a predictor for breast cancer survival 
nor a prognostic marker, but was shown to be an important and robust luminal 
differentiation marker, even stronger than FOXA1. Interestingly, a very strong inverse 
association was observed with the basal-like markers, namely, CK5, CK14, vimentin, EGFR 
and P-cadherin (see Chapter 2), suggesting that GATA-3 can be important for the 
differentiation state of the malignant cells, rather than acting as a tumour suppressor gene, 
as actually was recently suggested by other authors (38). Thus, the presence of GATA-3 
expression, together with other differentiation partners, may drive the luminal profile of a 
malignant cell population within the tumour. 
In conclusion, transcription factors are determinants of human complexity and are 
crucial in cancer (1, 7). The majority of oncogenic signalling pathways converge on sets of 
transcription factors, which ultimately control gene expression patterns, resulting in 
tumour-related processes. However, under normal physiological conditions, whole sets of 
genes, with similar functions, are regulated by highly specific, tightly regulated upstream 
transcriptional regulators; in cancer, aberrant activation of these transcription factors lead 
to deregulated expression of multiple gene sets associated with tumour development and 
progression (42). Over the last years, transcription factors have been attracting growing 
attention as new biological tools with clinical, pathological and therapeutic potential. In fact, 
because activation or inactivation of these proteins drive the cellular gene expression 
pattern and consequent cell functions in a tightly regulated manner, they represent not only 
important markers of tumour behaviour with pathological usefulness, but they also 
constitute highly desirable and logical points of therapeutic interference in cancer 
development, progression and in treatment-response prediction.  
 
 
4.2 – P-cadherin Overexpression and its Regulation by Anti-Oestrogens in Breast Cancer 
 
In contrast to E-cadherin, P-cadherin expression is usually related to tumourigenic 
properties, enhancing cell invasion and tumour aggressiveness, and indicating a worse 
prognosis in breast cancer patients (43-45). P-cadherin overexpression is able to identify a 
subgroup of lesions with a more aggressive behaviour (43-49). Indeed, it is possible to see 
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that there is a significant association between P-cadherin overexpression and the increased 
invasion capacity and directional migration of breast cancer cells that maintain the 
expression of wild-type E-cadherin (47, 50). Additionally, using in vitro cell models, we found 
for the first time that overexpression of exogenous P-cadherin is able to promote single cell 
motility, inducing an increase in the number and speed of moving cells, when compared 
with cells with low levels of this protein (50). This behaviour was shown to be directly 
dependent on P-cadherin, as when overexpressing cells were treated with a P-cadherin 
blocking antibody or transfected with a siRNA to inhibit P-cadherin transcripts, there was an 
inhibition of both migration and invasion effects (50). Interestingly, other authors have 
recently identified CDH3 as one of the genes involved in the regulation of breast cell 
migration using a siRNA approach (51). Usually characterized as an hallmark of the cellular 
motile behaviour, P-cadherin is also able to induce phenotypic changes involving alterations 
in cell polarity, leading to edge morphology, formation of membrane protrusions, as well as 
increase of their cytoplasmic area (50). As such, there is an association between P-cadherin 
expression and actin cytoskeleton reorganization, which suggest that P-cadherin has a role 
in the mechanism that integrates localized and transient signalling events and, therefore, 
regulating the cellular architecture changes that are needed to promote cell migration and 
invasion (50). Moreover, P-cadherin induces the secretion of factors that facilitate cell 
invasion of non-invasive MCF-7/AZ cells, that we identified as being active forms of MMP-1 
and MMP-2 (50).  
The in vitro functions assigned by P-cadherin are in agreement with what has been 
described in invasive primary breast tumours. In clinical terms, P-cadherin-overexpressing 
tumours present high proliferative index, high histological grade, decreased cell polarity, 
aggressive behaviour and worse patient survival (43-46), reinforcing the clinical relevance of 
P-cadherin expression in the diagnosis and prognosis of patients with aggressive mammary 
carcinomas, especially those carrying node-negative breast cancers (43, 45, 47, 49). Very 
recently, a large study comprising 4.444 breast tumour samples confirmed the value of P-
cadherin expression as a marker of poor prognosis, associated with high-grade tumour 
subtypes of breast cancer (52). Interestingly, P-cadherin is also a marker for basal-like breast 
cancers, including metaplastic breast carcinomas, and is strongly associated with the 
presence of BRCA1 mutations and lack of ER-signalling (47).  
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Recent works have allowed the clarification of P-cadherin function in breast cancer 
cells. However, the expression regulation of this protein has been poorly elucidated. The 
only mechanism known to be important as having a regulatory role on P-cadherin 
overexpression in breast cancer was described by our group, in a study where we 
demonstrated that hypomethylation of CDH3 promoter was an epigenetic event associated 
with P-cadherin expression (43). Additionally, in a previous work, we reported a connection 
between ER-signalling pathway and overexpression of P-cadherin in breast cancer cells. As 
such, we demonstrated that the abrogation of ER-signalling pathway, caused by the pure 
anti-oestrogen ICI, led to the increase of P-cadherin protein and mRNA expression, pointing 
CDH3 as an oestrogen-repressed gene (49). Since ER is a key regulator of proliferation and 
differentiation in mammary epithelia cells, as well as a crucial prognostic indicator and 
therapeutic target in breast cancer (53), the finding that its blockage/degradation, through 
the usage of anti-oestrogen therapy, was associated with the up-regulation of a pro-invasive 
protein such as P-cadherin, represents a challenging biological and clinical issue.   
Notably, breast cancer research has demonstrated that, although it was initially 
believed that anti-oestrogens would function merely by competing with endogenous 
oestrogens for receptor binding, anti-oestrogens can also interfere with a plethora of crucial 
cellular pathways. Indeed, at the epigenetic level, previous studies showed that chromatin 
structural remodelling and nuclear entropy can be induced by the treatment of breast cells 
with anti-oestrogens, such as ICI (54). The role of ICI in provoking elevated density 
(hyperplastic) of all epithelial structures in mice mammary gland development, as well as 
the finding that it can inhibit BKCa channels in vascular endothelial cells via a mechanism 
unrelated to its anti-oestrogenic activity (55), exemplifies how heterogeneous can be the 
non-ER-related mechanisms mediated by anti-oestrogens in cells (56). Depending of the 
anti-oestrogens type, ER levels can be modulated differently. While tamoxifen increases 
ER levels through its accumulation in the cytoplasm, ICI drastically decreases ER levels 
(57). However, anti-oestrogens are able to modify and modulate other important pathways 
not directly related with ER-signalling within the cell. It has been reported that tamoxifen 
and ICI can induce growth inhibitory effects via the sustained activation/inactivation of 
signalling pathways that regulate cell survival, cell death and differentiation in the absence 
of ER (57). Indeed, levels of protein phosphorylation of the PI3K/Akt, ERK and IGF-1R 
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pathways suggested that the anti-tumour activity of tamoxifen and ICI is unlikely to be 
mediated solely by ER. Particularly in this pathway, antioestrogen treatment modulates 
PI3K/Akt and increased ERK1/2 activation, irrespective of ER expression (57). At the clinical 
level, it is important to highlight that oestrogen is known to up-regulate PI3K/Akt and 
constitutive activation of Akt is associated with resistance to anti-oestrogens both in vitro 
and in vivo (58-60). Noteworthy, in a study where hormone-responsive MCF-7 cells were 
long-term exposed to ICI treatment, insensitivity to the growth-arrest capabilities of ICI, as 
defined by altered growth characteristics and an apparently resistant phenotype, was 
witnessed (61). The most significant observation with this ICI-resistant breast cancer cells 
was that their adaptation to growth in the steroid-deprived environment, and the resultant 
reduction of effective ERE-signalling mechanisms, was reflected on an acquired increased 
expression of a number of components involved in the EGFR/MAPK signalling pathway (61). 
This upregulation of both EGFR protein and mRNA levels in ER-positive breast cancer cells as 
a consequence of effective suppression of ER-mediated signalling after anti-oestrogen 
treatment or ER deprivation has been supported in the literature (62-63). Curiously, and 
unlike wild-type cells, MCF-7 cells treated with ICI are also strongly growth inhibited by 
physiological doses of an EGFR-specific tyrosine kinase inhibitor (61). However, it remains 
probable that components of other signalling pathways in these cells have also been altered 
in response to ICI exposure and that the identified changes in the growth and phenotype of 
these cells may, in part, reflect these changes also (61). 
In a different anti-oestrogen-modulated mechanism type, a study conducted by Lam 
et al., showed that the treatment of MCF-7 cells with anti-oestrogens led to the increase of 
Bcl-2 protein, known by its anti-apoptotic activities (64). Interestingly, this treatment, and 
consequent overexpression of Bcl-2, led to the junction dissociation and redistribution of 
junctional components (E-cadherin and ZO-1) to the cytoplasm in breast cancer cells (57). 
Similarly, a recent study also showed that treatment of ER-positive breast cancer cells with 
ICI led to the activation of the NFkB signalling pathway and up-regulation of Bcl-2. More 
importantly, increasing Bcl-2 levels by exogenous expression or by ICI treatment, decreased 
E-cadherin-mediated adhesion and induced an epithelial-to-mesenchymal-transition (EMT) 
(65). Based on this, it is tempting to consider that the effect of ICI in breast cancer cells is 
able to provoke changes on the membranar cadherins balance, by internalizing and 
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redistributing some cadherins in the cytoplasm and keeping others at their surface. Doing 
this, cells may compromise some adhesion properties with their neighbours and, therefore, 
acquire motile and invasive properties. In fact, our group showed that ICI treatment of MCF-
7/AZ cells lead to an up-regulation of P-cadherin expression, but also to a decrease on cell-
cell adhesion, with associated promotion of in vitro invasion (49). But, while P-cadherin-
induced cells migrate faster than controls in wound healing migration assay, ICI-treated cells 
did not, although inducing invasion. This can be explained by the finding that ICI up-
regulates additional pro-invasive genes, such as MMP-2 and -9 (49). Altogether, these 
findings concerning ICI-mediated upregulation of genes, such Bcl-2, NFkB, ERK1/2, and 
induction of MMPs, represent, in a manner, some genetic alterations that are induced by 
anti-oestrogens treatment in breast cancer cells which, depending of the cell type and its 
molecular background, may induce cell invasion and/or migration.  Supporting this, it has 
been demonstrated that acquired resistance to ICI (commercially known as Fulvestrant) is 
an ER-independent phenomenon, which uses pronounced up-regulation of multiple 
growth-stimulatory pathways to establish autocrine-regulated proliferation (66).  
Exploring the results represented here, together with previous studies conducted by 
us, we identified CDH3/P-cadherin as a highly oestrogen-repressed gene, since ER gene 
silencing by siRNA or treatment with anti-oestrogen ICI, led to overexpression of P-cadherin, 
suggesting a repression abrogation. Indeed, in breast cancer cells, ER is a master regulator 
of transcriptional stimulation and repression. Yet, although the mechanisms by which 
agonistic-bound ER elicits repression are poorly understood (67-68), the roles of ER in 
hormone-induced repression have been attracting growing attention in breast cancer, as 
exemplified by some studies. In MCF-7 cells, the breast cancer and salivary gland expression 
(BASE) gene is repressed by oestrogen in an ER-dependent manner. Similarly with what we 
have found, these authors showed that the cell treatment with ICI induced BASE 
transcription and increased mRNA levels (67). Also in MCF-7 cells, it was recently 
demonstrated that ER was required for gene transcriptional repression of early target 
genes which is released by the treatment with ICI (68). NFAT3, a transcription factor 
involved in breast cancer, was also showed to be repressed at the transcriptional level by 
ER through phosphorylation and dephosphorylation of ER events (69). Using breast 
cancer cell lines, Cvoro et al. demonstrated that ER, in the presence of E2 and recruiting 
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the GRIP co-repressor, acts as a repressor of TNF (70). Interestingly, CD24, a gene which 
has recently generating considerable attention in tumour biology due to its role as a 
potential breast cancer stem cell marker, as well as concerning its function in cell adhesion 
and metastatic tumour spread, was described as an oestrogen-repressed gene. Additionally, 
this repression was a direct transcriptional effect depending of ER and HDACs (71). In fact, 
in this study, and similarly with what demonstrated for CDH3/P-cadherin, treatment of MCF-
7 cells with HDAC inhibitor Trichostatin A (TSA) completely abolished the gene transcription 
repression, reinforcing the existence of a repressive complex ER-HDAC with relevant 
transcriptional inhibitory functions. The same repressive complex was also demonstrated to 
be important in the transcriptional repression of SLUG (one of the genes involved in EMT), 
pointing it as an oestrogen-repressive gene in MCF-7 cells (72). The exposure of MCF-7 cells 
to ICI also induced a significant up-regulation of KAI1 gene transcription, a tumour growth 
suppressor which is inactive in ER-positive breast cancer cells (73). An elegant study, from 
2005, showed that ICI can induce gene transcription through releasing HDACs and ER from 
Sp1 sites in ER-repressed genes. Varshochi and colleagues demonstrated that, in the 
presence of ICI, ER and HDACs are dissociated from Sp1 sites, resulting in an increased 
histone acetylation and de-repression of the p21Waf1 gene promoter, with consequent 
protein expression induction of this cyclin kinase inhibitor (74). Still, the authors found that 
the promoter activation induced by ICI was significantly reduced, when the proximal region 
of the p21Waf1 promoter, containing six putative Sp1 binding sites, was deleted; this 
suggested that the proximal Sp1 sites are crucial in mediating the promoter’s response to 
ICI, probably because these are preferable sites for ER binding. Similarly, when the cells 
were treated with TSA, the induction of p21Waf1 promoter activity was observed, probably 
due to the disruption of the epigenetic repressive system formed by ER and HDAC 
recruitment to Sp1 sites (74). A very similar work was performed, with the aim of 
understanding the mechanism by which cyclin G2 is also repressed by oestrogen in ER-
positive breast cancer cells, leading to its rapidly down-regulation (75). They showed that 
ligand-activated ER is recruited to cyclin G2 regulatory region, which is followed by 
dismissal of RNA polymerase II and recruitment of a complex containing N-CoR and HDACs. 
Additionally, these authors showed that ER-repressive binding occurred in a GC-rich region 
that interact with ER and Sp1 proteins, and also that the half-ERE, as well as the Sp1 sites, 
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are determinants for the recruitment of ER to the cyclin G2 promoter (75). In fact, GC-rich 
regions are known to be involved in ER-mediated gene promoter repression, where 
interplay of ER with members of the Sp1 family of transcriptional factors seems to occur 
(75). Two common molecular features of all the abovementioned repressive mechanisms 
involving HDACs is the presence of Sp1 transcriptions factors, coupled or not with ER 
proteins, as well as the presence of Sp1 sites in regulatory regions of repressed-target 
genes. Actually, the requirement of specific Sp1 sites for histone deacetylase-mediated 
repression and the interaction between Sp1-HDAC complexes with components of the 
cognate transcriptional regulators that bind to DNA, has been showed to be determinant for 
repression of several genes such as, as an example, the TGFII, in pancreatic cells (76-77). 
These Sp1 sites are also important in mediating the transcriptional responsiveness to HDAC 
inhibitors, such as TSA or SAHA, in pancreatic (77) and in MCF-7 breast cancer cells (78), 
respectively.   
In our study, the prediction analysis of the proximal CDH3 promoter, revealed a 
promoter region remarkably enriched in ER sites or half-sites, together with abundant Sp1 
sites localised closer to the former ERs (see Chapter 3). Moreover, and similarly with what 
was observed for the ER-repressive binding in cyclin G2, the CDH3 proximal promoter 
Region 2, which showed an ICI-induced enrichment for active histone mark, also displays a 
GC-rich region, reinforcing this promoter area as preferential for the described repressive 
interactions between ER, Sp1 and HDAC proteins. Hence, in accordance with our suggested 
model, a repression complex, mediated by ER and HDACs at Sp1 sites (Figure 11 A), is able 
to be released by the treatment with ICI, enhancing CDH3 gene transcription through a 
mechanism similar to several other models here described. If so, the characteristics of the 
proximal CDH3 promoter strongly suggests that this chromatin de-repression mechanism, 
driven by the H3K4me2 enrichment in Region 2, plays an important role in the ICI-induced 
promoter transcriptional activation and P-cadherin overexpression (Figure 11 B). Reinforcing 
this, our results are also corroborated by the findings of other studies described above, in 
such a manner that an up-regulation of CDH3 promoter activity and P-cadherin protein 
expression in cells was observed when these were treated with HDAC inhibitors such TSA. In 
our model of ER-mediated repression, we suggest not only that Sp1-HDAC complexes are 
playing a role in mediating the transcriptional responsiveness of CDH3 gene promoter to 
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HDAC inhibitors, but also, that chromatin activating modifications are indeed important to 
the modulation of this gene, in response to ICI treatment (Figure 11).  
 
Figure 11. A proposed model for oestradiol-occupied ER repression of the CDH3 promoter in MCF-7 breast cancer cells. 
(A) Oestrogen receptor alpha, upon binding of E2 (1), is recruited by Sp1 to the half-ERE-containing regions (2) and actively 
represses the CDH3 promoter by recruiting a HDAC-containing co-repressor complex (3), which causes release of RNA 
polymerase II (4). Formation of this complex leads to hypo-acetylation of the N-terminal histone tails, which causes 
stabilization of the nucleossome structure, limiting accessibility to the basal transcriptional machinery and thus suppressing 
CDH3 transcription. This action requires ER binding to DNA and the presence of Sp1 at the promoter site. (B) Upon 
degradation of ER by the pure anti-oestrogen ICI at the cytoplasm compartment (1), ER is no longer able to be shuttled 
to the nucleus and bind to DNA. ICI increases the RNA polymerase II occupancy by inducing an activating chromatin 
remodelling. Histone methyltransferases (HMT) are recruited to the transcriptional machinery inducing histone 
modifications marks, such as H3K4me2 (2), leading to transcriptional de-repression (3) and exposure of binding sites. Sp1 
factors can recruit activators (e.g. AIB1 and p300) forming a transcriptional activating complex at CDH3 promoter, thus 
enabling a permissive chromatin conformation and gene transcription (4). The abundant presence of C/EBP in the nucleus 
of MCF-7 cells enables its binding to exposed C/EBP binding sites, increasing CDH3 promoter activation. 
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Gene expression can be epigenetically regulated at several levels, including the 
position of the gene in the nuclear space or through the conformation of chromatin at the 
genetic locus. Histone modifications are known to be altered in cancer cells and loss of 
selected histone acetylation and methylation marks has recently been shown to predict 
patient outcome in human carcinomas (79-80). These modifications generate a combinatory 
histone code that demarcates chromatin regions for transcription activation or repression 
(81). Although the “epigenetic” code is not fully understood, specific marks are associated 
with transcriptional active gene promoters, whereas others modifications are linked to 
repressed chromatin (81-82). In the present study (see Chapter 3), we identified for the first 
time the existence of a chromatin remodelling at CDH3 promoter level induced by the 
treatment of MCF-7/AZ breast cancer cells with ICI. This epigenetic event was characterised 
by the occurrence of an important histone activating mark (H3K4me2) enrichment at the 
proximal region of the CDH3/P-cadherin promoter. Accordingly with several recent studies, 
histone H3K4 di-methylation is a post-translational modification that is localized to 
punctuate sites near the transcription start sites (83-84), being now well accepted as a 
fingerprint of active euchromatic regions of transcribed genes (82, 85-87). In a very 
interesting study, recently published, frequency of histone modifications were compared 
with clinical profiles in a large series of breast cancer samples. Here, these epigenetic 
alterations were clustered in 3 groups displaying distinct patterns of breast cancer and 
highly significant correlation between histone modification status, tumour biomarker 
phenotypes and clinical outcome were found (80). The histone modification cluster 
comprising the H3K4me2 activation mark was remarkably associated with the poor 
prognostic classes of basal and HER2 breast cancer subtypes, as well as with poorer breast 
cancer specific survival and disease-free survival (80). Notably, the overexpression of P-
cadherin is strongly associated, not only with the basal and HER2 phenotypes, but also with 
poorer survival in breast cancer (43-47, 49, 88). Overall, this study emphasizes the 
importance of studying and understanding histone modification patterns in the context of 
different phenotype classes of invasive breast tumours, in order to better define the 
biological nature and clinical behaviour, and eventually, inform possible therapeutic 
strategies (80).  
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Concerning anti-oestrogen therapies in breast cancer, it has been shown that 
interrupting ER function by anti-oestrogens can result in epigenetic modifications of 
chromatin and altered gene expression, leading to endocrine resistance mechanisms (89-
90). In fact, oestrogenic chemicals induce epigenetic alterations in breast progenitor cells, 
which have been previously implicated in breast cancer (91). Previously studies have found 
distinct gene expression and promoter DNA methylation profiles associated with acquired 
resistance to fulvestrant and tamoxifen. Regarding ICI (or fulvestrant), which constitutes the 
focus of part of the work discussed here, it was shown that a large number of signature 
genes of ER-positive tumours were significantly down-regulated in MCF-7 cells treated 
with ICI, suggesting that acquired fulvestrant resistance is an ER-independent phenomena 
that is coupled with the generation of ER-negative phenotype (66). These interesting 
results were recently reinforced by Borley et al., in a study that highlights the effect of anti-
oestrogens in inducing breast cancer cell invasion and migration (92). This may occur in a 
specific context of absence of good cell-cell contacts, perhaps through a process involving 
activation of Src kinase and loss of E-cadherin (92). More interestingly, activation of growth-
promoting genes, such as EGFR/HER2, Notch or -catenin due to promoter 
hypomethylation, was more frequently observed in anti-oestrogen-resistant cells compared 
with gene inactivation by hypermethylation, revealing an unexpected insight into the 
molecular changes associated with endocrine resistance (66). Curiously, it was also 
demonstrated that cells displaying hypomethylation of ER target genes may be able to 
escape the detrimental effects of anti-oestrogens, establishing that hypomethylation plays a 
role in the development of anti-oestrogen resistance (66). Although not in a context of 
endocrine resistance, in the work presented here, we also provide data that is in line with 
these findings above, since we described that hypomethylation of the ER-repressed CDH3 
promoter was found in high grade invasive tumours expressing high levels of the pro-
invasive P-cadherin. This CDH3 promoter hypomethylated state was associated with poor 
prognosis and decreased breast cancer survival (see PAPER I in Appendix section) (43). 
Additionally, we demonstrated here that histone activation of regulatory regions of 
chromatin at CDH3 promoter level, another form of activate transcription state, is induced 
by antioestrogen treatment, leading with expression of P-cadherin in breast cancer cells (see 
Chapter 3). The action of ICI on CDH3 promoter observed in our study is supported by a 
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robust study published recently, where identification of ER-binding sites in MCF-7 cells, as 
well the effect of tamoxifen and fulvestrant on these ER-binding sites using ChIP-Seq was 
assessed. Interestingly, the authors showed that in E2-repressed genes, while tamoxifen 
acts as an agonist, downregulating these genes, fulvestrant (ICI) antagonizes the E2-induced 
repression and often increases the RNA polymerase II occupancy enabling transcription (93). 
These findings demonstrates that, not only both antagonists act differently on E2-induced 
and E2-repressed genes, but more importantly, they corroborate our findings in a way that 
they showed the ability of ICI to induce ER-mediated de-repression of ER-binding sites 
within ER-repressed genes.  
Another finding described here involves the putative potential of the transcription 
factor, C/EBP, as a novel activator of CDH3 promoter activity and P-cadherin expression in 
breast cancer cells. CDH3 promoter Region 2, where ICI-mediated chromatin remodelling 
was observed, together with the surrounding regions, was identified has containing several 
putative C/EBP binding sites. Notably, besides being identified by several binding sites 
prediction tools, the presence of these C/EBP sites in genomic regions enriched in ERE has 
been supported. As such, in a study from 2009, it was demonstrated that both C/EBP and 
FOXA1 motifs are positively associated with ERE regions (93). In vitro studies confirmed the 
relevance of this transcription factor in CDH3 promoter activation, as well as demonstrated 
its abundant expression in the nucleus of MCF-7 breast cancer cells (see Chapter 3). Based 
on this, we suggest that after ICI-mediated chromatin activation by ER deprivation and 
transcription de-repression, C/EBP binding sites become exposed to the C/EBP 
transcription factors (Figure 11 B) which, being abundantly present in the nucleus, will bind 
to the DNA and activate CDH3 transcription. We also showed that among the three C/EBP 
isoforms, truncated LIP was the most important in a CDH3 promoter activation context. A 
promoter feature that reinforces the hypothesis of interaction of C/EBPLIP with CDH3 
regulatory region is the extremely abundant Sp1 sites within the chromatin activated region. 
Indeed, as demonstrated by some authors, the presence of Sp1 sites within promoters is 
crucial for C/EBPLIP-mediated transcription of several genes (e.g. PLAC1 and prolactin 
receptor gene) in breast cancer cell lines (94-96). In tumours, C/EBPLIP isoform is only 
overexpressed in highly aggressive/proliferative, progesterone/oestrogen-receptor-negative 
breast malignancies, but not in pre-neoplastic or normal breast gland (97-98). This 
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association with poor prognosis and breast cancer aggressive features, such as tumour 
grade, proliferative index and EGFR expression, overlap with the ones found in tumours 
overexpressing P-cadherin. Interestingly, it seems that C/EBP-LIP is an isoform that 
characterize a breast cancer cell malignant status. It has been described that C/EBP-LIP 
isoform, and elevated LIP:LAP ratio, induces potent oncogenes, such as MYC, leading to 
increased malignant transformation in human breast cells, and more importantly, with lack 
of cell contact inhibition (99). Additionally, in a study where the mechanism by which the LIP 
isoform is translationally regulated in mammary epithelial cells was explored, it was showed 
that the transcription factor C/EBP-LIP is a downstream target of EGFR in those cells and 
that this LIP expression is controlled post-transcriptionally (100). Reinforcing this, in our 
study (see Chapter 3), we actually showed a strong association between the expression of 
EGFR and C/EBPin a patients setting. These observations have led to the hypothesis that 
overexpression of the C/EBP-LIP isoform in the mammary gland can result in epithelial cell 
proliferation that may render cells to become more susceptible to additional oncogenic hits, 
resulting in the stochastic formation of breast tumours and, additionally, alter cell fate by 
preventing the transcription of genes that control differentiation (97, 100-101). Another 
interesting involvement of C/EBP-LIP in breast cancer was raised by a study in which it was 
showed that a high level of LIP is linked to a loss of the TGF-dependent cytostatic 
responses in metastatic cells from breast cancer patients. Here, authors also suggested a 
mechanistic link for how high LIP:LAP ratio can contribute to an unfavourable evolution of 
breast cancers (102). Moreover, due to its described association with hormonal-negative 
breast tumours and with its contribution to an increased growth and proliferation rate (97), 
it has been suggested that C/EBP-LIP might indirectly contribute to drug resistance in 
breast cancer (103-104).  
In conclusion, we showed that 1) ICI can facilitate the binding of the transcription 
factor C/EBPLIP to CDH3 promoter, 2) the C/EBP-LIP is able to activate the pro-invasive 
P-cadherin gene and that 3) C/EBP expression is highly associated with the pro-invasive P-
cadherin expression and with basal-phenotype markers in breast tumour samples. Taken 
together, it is tempting to consider that the activation of CDH3 by C/EBPespecially under 
long ICI-treatment regimens, might be one important step for acquired resistance to the 
anti-oestrogen and more importantly, for an increased invasiveness cell capacity. Moreover, 
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in this study, we established that the oestrogen-occupied ER can carry out a program of 
negative regulation which, along with the ability of these oestrogen-occupied ERs to work at 
other genes to enact hormone-induced positive regulation, permits an integrated pattern of 
gene regulation that underlies the ability of this sex-steroid hormone to control important 
genes and cellular activities in breast cancer. Because our studies and those of others 
indicate that repression of gene expression by oestrogen plays a central role (105-107), a 
greater understanding of the mechanisms and proteins involved in ER-mediated regulatory 
functions should provide new and important insights, as well as reveal potential therapeutic 
strategies. This study constitutes a step toward understanding the way in which the 
oestrogen-ER complex can attenuate gene activity, but also, contributes to elucidate how 
anti-oestrogenic drugs can up-regulate gene activity of targets involved in aggressive breast 
cancer cell behaviour.  
Still, several lines of evidence point out the significance of epigenetic regulation in 
initiating breast carcinogenesis, promoting tumourigenic phenotypes, and assisting in the 
development of drug resistance to anti-oestrogens. How breast cancer cells acquire more 
aggressive properties after loss of oestrogen signalling, remains a very important issue in 
the field of breast cancer research. 
 
4.3 – Concluding Remarks 
 
Accumulation of genetic changes is commonly believed to promote cancer 
development. However, if this concept provides the basis of our knowledge of cancer 
progression, it cannot explain the heterogeneity in tumour cell growth, invasion or 
resistance to therapy. The role of transcriptions factors, as key entities for the most 
fundamental cell functions, has becoming studied as important tools to be used in clinical 
pathology. Modulation of transcription factor activity, through genetic or epigenetic 
processes, constitutes the tip of the spear of the cellular gene expression and cellular 
biology. In cancer, where those genetic and epigenetic mechanisms are someway disrupted, 
transcription factors expression naturally represents important markers of tumour 
behaviour with pathological value. Moreover, since they drive the crucial human oncogenic 
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pathways, their usefulness as targets for therapeutic interference in cancer development, 
progression and in treatment-response prediction, has been collecting expressive 
consideration. Some transcription factors, through their interaction with chromatin and as 
pioneer factors for protein binding to DNA, also play an important role in cancer epigenetic 
processes. Indeed, it is the recruitment of distinct remodelling proteins and regulation 
factors to responsive sites within the DNA, which determines normal and deregulated 
expression patterns and makes the linkage between genetic and epigenetic phenomena in 
carcinogenesis. 
Taken together, the study presented here encloses the following major conclusions: 
 There is a strong association between ER, FOXA1 and GATA-3 expression in breast 
cancer. 
 The transcription factor FOXA1 is a significant predictor of good outcome in breast 
cancer and may be used for risk stratification among ER-negative patients. 
 GATA-3 was neither a predictor for breast cancer disease-free survival nor a 
prognostic marker, but was shown to be an important and robust luminal 
differentiation marker, even stronger than FOXA1. 
 The expression assessment of FOXA1 and GATA-3 can provide important clinical 
information – not only regarding the favourable prognostic nature and tumour 
behaviour, but can also constitute an important tool to define and assess the luminal 
A subtype in breast cancer.  
 CDH3 is an ER-repressed gene which is up-regulated by the abrogation of ER-
signalling pathway. 
 A chromatin remodelling event, provoked by the pure anti-oestrogen ICI 182,780, is 
able to increase CDH3 promoter activity and P-cadherin expression in breast cancer 
cells, through the induction of high levels of the active histone mark H3K4me2. 
 The transcription factor C/EBP is able to up-regulate CDH3 promoter activity in 
breast cancer cells. 
 The expression of P-cadherin and C/EBP are highly associated in human breast 
carcinomas and linked with a worse prognosis of breast cancer patients. 
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